

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000295 A2

(51) International Patent Classification⁷: **A61K 47/44**,
9/10, 9/107, 31/4706, 31/44, 31/4196, 31/47, 31/015,
31/41

Franco [US/US]; Pfizer Global Research and Develop-
ment, Eastern Point Road, Groton, CT 06340 (US).

(21) International Application Number: **PCT/IB02/01571**

(74) Agents: **LUMB, J., Trevor et al.**; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(22) International Filing Date: **3 May 2002 (03.05.2002)**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/300,028 **21 June 2001 (21.06.2001)** **US**

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **GUMKOWSKI**,
Michael, Jon [US/US]; Pfizer Global Research and
Development, Eastern Point Road, Groton, CT 06340
(US). **MURDANDE, Sharad, Balasaheb** [IN/US]; Pfizer
Global Research and Development, Eastern Point Road,
Groton, CT 06340 (US). **PERLMAN, Michael, Ellis**
[US/US]; Pfizer Global Research and Development, East-
ern Point Road, Groton, CT 06340 (US). **LOMBARDO**,

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS**

(57) Abstract: CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise 1. a CETP inhibitor; 2. a cosolvent; 3. a surfactant having an HLB of 1 to 8; 4. a surfactant having an HLB of over 8 to 20; and 5. optionally, a digestible oil.

BEST AVAILABLE COPY



WO 03/000295 A2

5

Self-emulsifying Formulations of Cholesteryl Ester
Transfer Protein Inhibitors

Field Of The Invention

10 This invention relates to encapsulated formulations of cholesterol ester transfer protein (CETP) inhibitors for use in mammals, especially humans, which for mulations provide increased concentrations of CETP inhibitors for absorption, hence higher bioavailability.

Background of the Invention

15 CETP inhibitors, as a class, are characterized by high binding activity. Such CETP inhibitors are generally hydrophobic, however, with the consequence that they have extremely low aqueous solubility and have low oral bioavailability. Such compounds have generally proven to be difficult to formulate for oral administration such that high bioavailabilities are achieved.

20 Atherosclerosis and its associated coronary artery disease (CAD) is the leading cause of death in the industrialized world. Despite attempts to modify secondary risk factors (smoking, obesity, lack of exercise) and treatment of dyslipidemia with dietary modification and drug therapy, coronary heart disease (CHD) remains the most common cause of death in the U.S., where cardiovascular
25 disease accounts for 44% of all deaths, with 53% of these associated with atherosclerotic coronary heart disease.

Risk for development of this condition has been shown to be strongly correlated with certain plasma lipid levels. While elevated LDL-cholesterol may be the most recognized form of dyslipidemia, it is by no means the only significant lipid-
30 associated contributor to CHD. Low HDL-cholesterol is also a known risk factor for CHD (Gordon, D.J., et al., "High-density Lipoprotein Cholesterol and Cardiovascular Disease", Circulation, (1989), 79: 8-15).

High LDL-cholesterol and triglyceride levels are positively correlated, while high levels of HDL-cholesterol are negatively correlated, with the risk for developing
35 cardiovascular diseases. Thus, dyslipidemia is not a unitary risk profile for CHD but may be comprised of one or more lipid aberrations.

Among the many factors controlling plasma levels of these disease dependent principles, cholesteryl ester transfer protein (CETP) activity affects all three. The role of this 70,000 dalton plasma glycoprotein found in a number of animal species, including humans, is to transfer cholesteryl ester and triglyceride
5 between lipoprotein particles, including high density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins (VLDL), and chylomicrons. The net result of CETP activity is a lowering of HDL cholesterol and an increase in LDL cholesterol. This effect on lipoprotein profile is believed to be pro-atherogenic, especially in subjects whose lipid profile constitutes an increased risk for CHD.

10 No wholly satisfactory HDL-elevating therapies exist. Niacin can significantly increase HDL, but has serious toleration issues that reduce compliance. Fibrates and the HMG CoA reductase inhibitors raise HDL-cholesterol only modestly (~10-12%). As a result, there is a significant unmet medical need for a well-tolerated agent that can significantly elevate plasma HDL levels, thereby reversing or slowing
15 the progression of atherosclerosis.

CETP inhibitors have been developed that inhibit CETP activity, and thus, if present in the blood, should result in higher HDL cholesterol levels and lower LDL cholesterol levels. To be effective, such CETP inhibitors must be absorbed into the blood. Oral dosing of CETP inhibitors is preferred because to be effective such CETP
20 inhibitors must be taken on a regular basis, such as daily. Accordingly, it is preferred that patients be able to take CETP inhibitors by oral dosing rather than by injection.

However, it has proven to be difficult to formulate CETP inhibitors for oral administration such that therapeutic blood levels are achieved. CETP inhibitors, in general, possess a number of characteristics that render them poorly bioavailable
25 when dosed orally in a conventional manner. CETP inhibitors tend to be quite hydrophobic and extremely water insoluble, with solubility in aqueous solution of usually less than about 10 µg/ml and typically less than 1 µg/ml. Often the aqueous solubility of CETP inhibitors is less than 0.1 µg/ml. Indeed, the solubility of some CETP inhibitors is so low that it is in fact difficult to measure. Accordingly, when
30 CETP inhibitors are dosed orally, concentrations of CETP inhibitor in the aqueous environment of the gastrointestinal tract tend to be extremely low, resulting in poor absorption from the GI tract to blood. The hydrophobicity of CETP inhibitors not only leads to low equilibrium aqueous solubility but also tends to make the drugs poorly wetting and slow to dissolve, further reducing their tendency to dissolve and be

absorbed from the gastrointestinal tract. This combination of characteristics has resulted in the bioavailability for orally dosed conventional crystalline or amorphous forms of CETP inhibitors generally to be quite low, often having absolute bioavailabilities of less than 1%.

5 Various attempts have been made to improve the aqueous concentration of CETP inhibitors, but generally have met with limited success. Conventional methods of formulation do not provide sufficient solubilities and thus poor oral bioavailabilities have been obtained. Pre-dissolving CETP inhibitors in hydrophilic solvents such as acetone or PEG followed by delivery as a solution have failed due to inadequate
10 solubility in the solvent or precipitation upon dilution into the aqueous medium. Suspensions of crystalline drug do not provide sufficient concentrations of drug in solution due to very low aqueous solubilities and therefore yield inadequate blood levels.

One approach that has been disclosed to formulate CETP inhibitors is the
15 formation of CETP solutions in lipids. Solutions in medium chain triglycerides have been of value either as oral solutions or encapsulated in softgels. However, the solubility (65 mg/mL or less) for some of the most potent and useful CETP inhibitors known to the inventors has limited the dose to 30 mg in a reasonable sized softgel. The efficacious dose is expected to be several multiples of this and therefore may
20 require administration of more than 2 softgels per day.

It has also been found that it is necessary to administer triglyceride solutions with food in order to achieve efficacious blood levels of CETP inhibitors. Food effects of 20-30x have been observed in man for some CETP inhibitors, with considerable variability between patients. The food effect is the ratio of plasma AUC values
25 measured for administration of drug with a meal vs. administration in the fasted state. In addition, there is minimal CETP inhibition in the absence of food due to low fasted plasma exposure. As a result, labeling would need to indicate administration with food. This strong dependence of exposure on food could compromise the effectiveness of this medication in the treatment of atherosclerosis if there is a lack of
30 compliance with labeling instructions.

Therefore, there remains a need to develop oral formulations of CETP inhibitors that would reduce the food effect substantially, primarily by improving fasted exposure, thereby minimizing patient-to-patient variability in clinical outcome. An increase in the dose per capsule would also be a desirable improvement.

- Lack of mixing between oil formulations and the aqueous environment of the GI tract is known to lead to variable gastric emptying and thus variable absorption. A frequent means of increasing fasted bioavailability of hydrophobic drugs is to use a surfactant or combination of surfactants to produce an emulsion, which, if of sufficiently small particle size can lead to enhanced absorption of the drug. Lipid solutions containing surfactants that spontaneously form emulsions when mixed with an aqueous medium are referred to in the literature as self-emulsifying drug delivery systems (SEDDS) (S. Charman, et. al., Pharm Res., vol. 9, 87 (1992)). They are isotropic mixtures of oil, typically medium chain triglycerides, and non-ionic emulsifier that yield fine emulsions when gently mixed with aqueous fluid, such as in the stomach and intestine, and have the appropriate polarity for fast drug release (C. W. Pouton, Adv. Drug Deliv. Rev, vol. 25, 47 (1997); P.P. Constantinides, Pharm. Res., vol. 12, 1561 (1995); A. Humberstone and W. Charman, Adv. Drug Del. Rev., vol 25, 103 (1997)). Early SEDDS were defined as forming an emulsion with particle size below 5 microns (S. Charman, et. al., Pharm Res., vol. 9, 87 (1992)) and utilized MIGLYOL[®] and a single surfactant, Tagat TO, which has an HLB (hydrophilic-lipophilic balance) of 10, to form an emulsion with a droplet size of 3 microns. Tagat is not available for human use as are other excipients with the appropriate properties.
- Much of the effort in both the open and patent literature has been invested in formulations of cyclosporin. A formulation of cyclosporin that was found to increase bioavailability by in situ generation of an emulsion utilized long chain triglyceride, a polyglycolized glyceride, and ethanol and was marketed as Sandimmune[®] (Cavanak (Sandoz)). See US 4,388,307 (1983). This had the disadvantage of considerable variability in oral bioavailability and PK profile. Subsequently, a self-microemulsifying system was developed (Meinzer, (Sandoz) WO 93/20833; Ritschel, Clin. Transplant., vol. 10, 364 (1996)) using polyethoxylated hydrogenated castor oil (Cremophor[®] RH40), corn oil mono-, di- and triglycerides, propylene glycol and ethanol. This softgel formulation, marketed as Neoral[®], reduced variability in exposure and also reduced the moderate food effect (Mueller, Pharm. Res. vol 11, 151 (1994)).

Lipophilic solvents have been used in place of ethanol or propylene glycol which will not migrate to the shell and affect shell integrity and/or volatilize and thus impact on the concentration in the fill and on solubility. Triacetin has been used as a

lipophilic cosolvent for cyclosporin microemulsion preconcentrates with a long chain triglyceride and high HLB surfactant (Hong (Chong Kun Dang Corp.) WO 99/000002). It has also been used alone and in a mixture with propylene glycol dicaprylate/dicaprate and a high HLB surfactant for ketoprofen and related anti-inflammatory acids (Shelley and Wei (Scherer) WO 95/31979A).

US 5,993,858 discloses the use of an oil, high HLB surfactant, cosurfactant and triacetin as cosolvent for self-emulsifying formulations of hydrophobic drugs. Propylene carbonate has also been used as a lipophilic solvent for cyclosporin self-emulsifying systems (Woo (Novartis)).

WO 97/48410 and US 5,958,876 (1999)). Use of ethyl lactate as a cosolvent for cyclosporin formulations, including clinical evaluation, has also been reported (WO 00/40219).

Summary Of The Invention

This invention provides pharmaceutical compositions that are liquid solutions, suspensions, and (oil-in-water) emulsions of CETP inhibitors, said solutions being orally administrable. The solutions or dispersions may be administered, for example, as fill in encapsulated dosage forms such as hard or soft gelatin capsules. The CETP inhibitors can be dissolved or dispersed in a variety of lipophilic vehicles, as further described and discussed below, such as digestible oils, solvents and surfactants, including mixtures of any two or more of the aforementioned vehicles.

Reference to a compositional component such as a "digestible oil", to a "surfactant" and so forth, shall be understood as including mixtures of such components such as mixtures of digestible oils and surfactants.

In a first embodiment, the CETP inhibitor is dissolved or dispersed in a digestible oil such as a medium chain triglyceride oil or a mixture of digestible oils.

In a second embodiment, the CETP inhibitor is dissolved or dispersed in a digestible oil with one or more high HLB surfactants. The aforementioned solution or dispersion containing a high HLB surfactant or surfactant mixture may optionally contain one or more low HLB surfactants.

In a third embodiment, the CETP inhibitor is dissolved in a pharmaceutically acceptable lipophilic solvent optionally containing a digestible oil or digestible oil mixture. The CETP inhibitor solvent solution or dispersion or solvent/digestible oil solution or dispersion may optionally contain one or more high HLB surfactants and/or

one or more low HLB surfactants.

The presence of one or more surfactants can, upon contacting the pharmaceutical composition with water, yield an emulsion that is either preformed by mixing with an aqueous phase or that is generated in vivo by contacting the aqueous fluids of the gastrointestinal tract. Formation of an emulsion can improve fasted bioavailability and thus reduce the food effect in man (i.e., the effect of food upon absorption and/or bioavailability of a drug). It can also allow the oil to be consumed as a beverage in addition to being administered in capsules. Use of surfactants to provide an emulsion can also be of value for increasing exposures in toxicology species. Combination of a digestible oil with a cosolvent can have the advantage of higher solubility and thus a higher dose in a given volume of formulation than is obtainable with the digestible oil alone. It is advantageous for bioavailability to have the entire dose dissolved. The presence of a third component in any of the above embodiments may also improve miscibility between the first two components.

Thus, in a first embodiment, the invention provides an orally administrable pharmaceutical composition comprising a CETP inhibitor and a lipophilic vehicle selected from a digestible oil, a lipophilic solvent (also referred to herein as a "cosolvent", whether or not another solvent is in fact present), a lipophilic surfactant, and mixtures of any two or more thereof. Preferred embodiments include a CETP inhibitor and: (1) the combination of a pharmaceutically acceptable digestible oil and a surfactant; (2) the combination of a pharmaceutically acceptable digestible oil and a lipophilic solvent which is miscible therewith; and (3) the combination of a pharmaceutically acceptable digestible oil, a lipophilic solvent, and a surfactant.

In a particularly preferred embodiment, the invention provides a composition of matter for increasing the oral bioavailability of a CETP inhibitor. The composition comprises:

1. a CETP inhibitor;
2. a cosolvent;
3. a surfactant having an HLB of from 1 to not more than 8;
4. a surfactant having an HLB of over 8 up to 20; and
5. optionally, a digestible oil.

-7-

In such formulations, all of the excipients are pharmaceutically acceptable. The above composition is sometimes referred to herein as a "pre-concentrate", in reference to its function of forming a stable emulsion when gently
5 mixed with water or other aqueous medium, usually gastrointestinal fluids. It is also referred to herein as a "fill", referring to its utility as a fill for a softgel capsule.

Reference herein is frequently made to a softgel as a preferred dosage form for use with this invention, "softgel" being an abbreviation for soft gelatin capsules. It is understood that when reference is made to the term "softgel" alone, it shall be
10 understood that the invention applies equally to all types of gelatin and non-gelatin capsules, regardless of hardness, softness, and so forth.

A cosolvent means a solvent in which the CETP inhibitor of interest is highly soluble, having, for any given CETP inhibitor, a solubility of at least 150 mg/mL.

As noted above, and as discussed further below, a digestible oil can form a part
15 of the pre-concentrate. If no other component of the pre-concentrate is capable of functioning as an emulsifiable oily phase, a digestible oil can be included as the oil which acts as a solvent for the CETP inhibitor and which disperses to form the (emulsifiable) oil droplet phase once the pre-concentrate has been added to water. Some surfactants can serve a dual function, however, i.e., that of acting as a
20 surfactant and also as a solvent and an oily vehicle for forming an oil-in-water emulsion. In the event such a surfactant is employed, and, depending on the amount used, a digestible oil may be required in less of an amount, or not required at all.

The pre-concentrate can be self-emulsifying or self-microemulsifying.

The term "self-emulsifying" refers to a formulation which, when diluted by a
25 factor of at least 100 by water or other aqueous medium and gently mixed, yields an opaque, stable oil/water emulsion with a mean droplet diameter less than about 5 microns, but greater than 100 nm, and which is generally polydisperse. Such an emulsion is stable for at least several (i.e., for at least 6) hours, meaning there is no visibly detectable phase separation and that there is no visibly detectable
30 crystallization of CETP inhibitor.

The term "self-microemulsifying" refers to a pre-concentrate which, upon at least 100 x dilution with an aqueous medium and gentle mixing, yields a non-opaque, stable oil/water emulsion with an average droplet size of about 1 micron or less, said average particle size preferably being less than 100 nm. The particle size is primarily

unimodal. Most preferably the emulsion is transparent and has a unimodal particle size distribution with a mean diameter less than 50 nm as determined, for example, by dynamic light scattering. The microemulsion is thermodynamically stable and without any indication of crystallization of CETP inhibitor.

5 "Gentle mixing" as used above is understood in the art to refer to the formation of an emulsion by gentle hand (or machine) mixing, such as by repeated inversions on a standard laboratory mixing machine. High shear mixing is not required to form the emulsion. Such pre-concentrates generally emulsify nearly spontaneously when introduced into the human (or other animal) gastrointestinal tract.

10 The term "CETP inhibitor" implies any such compound that is sparingly or poorly water soluble. Generally, and as mentioned above, such compounds exhibit an aqueous solubility (e.g., in water) of less than about 10 µg/mL measured at about 22°C and at a physiologically relevant pH of from 1 through 8.

 Combinations of 2 surfactants, one being a low HLB surfactant with an HLB of
15 1 to 8, the other being a high HLB surfactant with a higher HLB of over 8 to 20, preferably 9 to 20, can be employed to create the right conditions for efficient emulsification. The HLB, an acronym for "hydrophobic-lipophilic balance", is a rating scale which can range from 1-20 for non-ionic surfactants. The higher the HLB, the more hydrophilic the surfactant. Hydrophilic surfactants (HLB ca. 8 -20), when used
20 alone, provide fine emulsions which are, advantageously, more likely to empty uniformly from the stomach and provide a much higher surface area for absorption. Disadvantageously, however, limited miscibility of such high HLB surfactants with oils can limit their effectiveness, and thus a low HLB, lipophilic surfactant (HLB ca. 1-8) is also included. This combination of surfactants can also provide superior
25 emulsification. A combination of a medium chain triglyceride (such as Miglyol® 812), Polysorbate 80 (HLB 15) and medium chain mono/diglycerides (Capmul® MCM, HLB =6) was found to be as efficient as Miglyol® 812 and a surfactant with an HLB of 10 (Labrafac® CM). N.H. Shah et al. Int. J. Pharm., vol 106, 15 (1994). The advantages of using combinations of high and low HLB surfactants for self-emulsifying systems,
30 including promotion of lipolysis, have been demonstrated by Lacy, US 6,096,338.

Detailed Description

Suitable digestible oils, which can be used alone as the vehicle or in a vehicle which includes a digestible oil as part of a mixture, include medium chain triglycerides (MCT, C6-C12) and long chain triglycerides (LCT, C14-C20) and mixtures of mono-, di-, and triglycerides, or lipophilic derivatives of fatty acids such as esters with alkyl alcohols. Examples of preferred MCT's include fractionated coconut oils, such as Miglyol® 812 which is a 56% caprylic (C8) and 36% capric (C10) triglyceride, Miglyol® 810 (68% C8 and 28% C10), Neobee® M5, Captex® 300, Captex® 355, and Crodamol® GTCC. The Miglyols are supplied by Condea Vista Inc. (Huls), Neobee® by Stepan Europe, Voreppe, France, Captex® by Abitec Corp., and Crodamol® by Croda Corp. Examples of LCTs include vegetable oils such as soybean, safflower, corn, olive, cottonseed, arachis, sunflowerseed, palm, or rapeseed. Examples of fatty acid esters of alkyl alcohols include ethyl oleate and glyceryl monooleate. Of the digestible oils MCT's are preferred, and Miglyol® 812 is most preferred.

The vehicle may also be a pharmaceutically acceptable solvent, for use alone, or as a cosolvent in a mixture. Suitable solvents include any solvent that is used to increase solubility of the CETP inhibitor in the formulation in order to allow delivery of the desired dose per dosing unit. It is not generally possible to predict the solubility of CETP inhibitors in the individual solvents, but such can be easily determined by "trial runs". Suitable solvents include triacetin (1,2,3-propanetriyl triacetate or glyceryl triacetate available from Eastman Chemical Corp.) or other polyol esters of fatty acids, trialkyl citrate esters, propylene carbonate, dimethylisobornide, ethyl lactate, N-methyl pyrrolidones, transcitol, glycofurol, peppermint oil, 1,2- propylene glycol, ethanol, and polyethylene glycols. Preferred as solvents are triacetin, propylene carbonate (Huntsman Corp.), transcitol (Gattefosse), ethyl lactate (Purac, Lincolnshire, NE) and dimethylisobornide (sold under the registered trademark ARLASOLVE DMI, ICI Americas). A hydrophilic solvent is more likely to migrate to the capsule shell and soften the shell, and, if volatile, its concentration in the composition can be reduced, but with a potential negative impact on active component (CETP inhibitor) solubility. More preferred are the lipophilic solvents triacetin, ethyl lactate and propylene carbonate. Most preferred is triacetin.

Hydrophilic surfactants having an HLB of 8-20, preferably having an HLB greater than 10, are particularly effective at reducing emulsion droplet particle size. Suitable choices include nonionic surfactants such as polyoxyethylene 20 sorbitan

monooleate, polysorbate 80, sold under the trademark TWEEN 80, available commercially from ICI; polyoxyethylene 20 sorbitan monolaurate (Polysorbate 20, TWEEN 20); polyethylene (40 or 60) hydrogenated castor oil (available under the registered trademarks CREMOPHOR® RH40 and RH60 from BASF); polyoxyethylene (35) castor oil (CREMOPHOR® EL); polyethylene (60) hydrogenated castor oil (Nikkol® HCO-60); alpha tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS); glyceryl PEG 8 caprylate/caprates (available commercially under the registered trademark LABRASOL® from Gattefosse); PEG 32 glyceryl laurate (sold commercially under the registered trademark GELUCIRE® 44/14 by Gattefosse), polyoxyethylene fatty acid esters (available commercially under the registered trademark MYRJ from ICI), polyoxyethylene fatty acid ethers (available commercially under the registered trademark BRIJ from ICI). Preferred are Polysorbate 80, CREMOPHOR® RH40 (BASF), and Vitamin E TPGS (Eastman). Most preferred are Polysorbate 80 and CREMOPHOR® RH40.

Lipophilic surfactants having an HLB of less than 8 are useful for achieving a balance of polarity to provide a stable emulsion, and have also been used to reverse the lipolysis inhibitory effect of hydrophilic surfactants. Suitable lipophilic surfactants include mono and diglycerides of capric and caprylic acid under the following registered trademarks: Capmul® MCM, MCM 8, and MCM 10, available commercially from Abitec; and Imwitor® 988, 742 or 308, available commercially from Condea Vista; polyoxyethylene 6 apricot kernel oil, available under the registered trademark Labrafil® M 1944 CS from Gattefosse; polyoxyethylene corn oil, available commercially as Labrafil® M 2125; propylene glycol monolaurate, available commercially as Lauroglycol from Gattefosse; propylene glycol dicaprylate/caprates available commercially as Captex® 200 from Abitec or Miglyol® 840 from Condea Vista, polyglyceryl oleate available commercially as Plurol oleique from Gattefosse, sorbitan esters of fatty acids (e.g. Span® 20, Crill® 1, Crill® 4, available commercially from ICI and Croda), and glyceryl monooleate (Maisine, Peceol). Preferred from this class are Capmul® MCM (Abitec Corp.) and Labrafil® M1944 CS (Gattefosse). Most preferred is Capmul® MCM.

In addition to the main liquid formulation ingredients previously noted, other stabilizing additives, as conventionally known in the art of softgel formulation, can be introduced to the fill as needed, usually in relatively small quantities, such as antioxidants (BHA, BHT, tocopherol, propyl gallate, etc.) and other preservatives such

-11-

as benzyl alcohol or parabens.

The composition can be formulated as a fill encapsulated in a soft gelatin capsule, a hard gelatin capsule with an appropriate seal, a non-gelatin capsule such as a hydroxypropyl methylcellulose capsule or an oral liquid or emulsion by methods commonly employed in the art. The fill is prepared by mixing the excipients and CETP inhibitor with heating if required.

The ratio of CETP inhibitor, digestible oil, cosolvent, and surfactants depends upon the efficiency of emulsification and the solubility, and the solubility depends on the dose per capsule that is desired. A self-emulsifying formulation is generally useful if the primary goals are to deliver a high dose per softgel (at least 60 mg) with, generally, a much lower food effect than with an oil solution alone. In general, softgel preconcentrates having solubilities of CETP inhibitor of at least 140 mg/mL in the preconcentrate, and thus requiring higher amounts of cosolvent and lower levels of surfactants and oil, are preferred.

In general, the following ranges, in weight percent, of the components for a self-emulsifying formulation of CETP inhibitors are:

- 1 - 50 % CETP inhibitor
- 5 - 60 % cosolvent
- 5 - 75 % high HLB surfactant
- 5 - 75 % low HLB surfactant

Preferred ranges which have advantageously low food effects include those stated immediately below:

- 1 - 33 % CETP inhibitor
- 0 - 30 % digestible oil
- 15 - 55 % cosolvent
- 5 - 40 % high HLB surfactant
- 10 - 50 % low HLB surfactant

More preferred ranges include

- 1 - 25 % CETP inhibitor
- 10 - 25 % digestible oil
- 20 - 35 % cosolvent

-12-

10 - 30 % high HLB surfactant

15 - 35 % low HLB surfactant

If a specific goal is a minimal food effect, then a self-microemulsifying
 5 formulation is advantageous. Such formulations generally require relatively high
 levels of surfactants and a reduced amount of cosolvent. These formulations can,
 however, result in lower solubilities and, accordingly, a lower dose per capsule.
 These formulations have been found to increase fasted exposure.

General ranges, in weight percent, for the components for a self-
 10 microemulsifying formulation of CETP inhibitors are

1 - 40% CETP inhibitor

5 - 65 % digestible oil

5 - 60 % cosolvent

10 - 75 % high HLB surfactant

15 5 - 75 % low HLB surfactant

Preferred ranges include those which follow

1- 20 % CETP inhibitor

5 - 30 % digestible oil

5 - 45 % cosolvent

20 30 - 55%, high HLB surfactant

10 - 40 %, low HLB surfactant

Specific examples of preferred formulations include:

A composition comprising

25 a compound which is [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-
 methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-
 carboxylic acid ethyl ester; or a compound which is [2R,4S] 4-[acetyl-(3,5-bis-
 trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-
 carboxylic acid isopropyl ester; or a compound which is [2R, 4S] 4-[(3,5-Bis-
 30 trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-
 dihydro-2H-quinoline-1-carboxylic acid isopropyl ester

a cosolvent;

a high HLB surfactant;

a low HLB surfactant; and

-13-

optionally, a digestible oil.

A more preferred composition is that noted immediately above, wherein

said cosolvent is triacetin or ethyl lactate;

said high HLB surfactant comprises polysorbate 80 or a polyethylene

5 hydrogenated castor oil;

said low HLB surfactant comprises a mixture of mono- and diglycerides of capric and caprylic acids;

said digestible oil comprises a medium chain triglyceride, wherein each of the three hydrocarbon chains therein is predominantly C6-C12.

10

A more specific preferred composition is that noted immediately above, which comprises, by weight:

5 -25% of said CETP inhibitor;

10-25% of said digestible oil;

15 20-35% of said cosolvent:

10-35% of said high HLB surfactant; and

10-35% of said low HLB surfactant;

A still more specific preferred embodiment is that noted immediately above which

20 comprises, by weight:

8-12% of [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester

10-20% of said digestible oil;

25-35% of said cosolvent which comprises triacetin:

25 10-30% of said high HLB surfactant which comprises polysorbate 80; and

15-35% of said low HLB surfactant which comprises a mixture of medium chain mono- and di-glycerides.

Another still more specific preferred embodiment is one, which comprises, by weight:

30 8-12% of [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

10-20% of said digestible oil;

25-35% of said cosolvent which comprises triacetin;

10-30% of said high HLB surfactant which comprises a polyethylene (40) hydrogenated castor oil;

15-35% of said low HLB surfactant, which comprises a mixture of medium chain mono- and di-glycerides.

5

Another still more specific preferred embodiment is one which comprises, by weight

8-25% of [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

10-25% of digestible oil;

10

20-35% of said cosolvent which comprises triacetin;

10-30% of said high HLB surfactant which comprises polysorbate 80; and

15-35% of said low HLB surfactant which comprises a mixture of medium chain mono- and di-glycerides.

As indicated by the broadest range above, the digestible oil may be optionally omitted in order to further increase the amount of cosolvent and, therefore, solubility of the CETP inhibitor in the pre-concentrate.

In addition to the main softgel capsule ingredients previously noted, other stabilizing additives, as conventionally known in the art of softgel formulation, can be introduced to the fill as needed, usually in relatively small quantities, such as antioxidants (BHA, BHT, tocopherol, propyl gallate, etc.) and other preservatives such as benzyl alcohol or parabens.

The composition can be formulated as a fill encapsulated in a soft gelatin capsule, a hard gelatin capsule with an appropriate seal, a non-gelatin capsule such as a hydroxypropyl methylcellulose capsule or an oral liquid or emulsion by methods commonly employed in the art. The fill is prepared by mixing the excipients and CETP inhibitor with heating if required.

Preferred embodiments comprise a CETP inhibitor with:

30

(a) solubility less than 10 $\mu\text{g/ml}$;

(b) $\log P$ greater than 5; and/or

(c) dose greater than 10 mg, preferably at least 30 mg.

The invention is not limited by any particular structure or group of CETP inhibitors. Rather, the invention has general applicability to CETP inhibitors as a class, the class tending to be composed of compounds having low solubility. Compounds which may be the subject of the invention may be found in a number of patents and published applications, including DE 19741400 A1; DE 19741399 A1; WO 9914215 A1; WO 9914174; DE 19709125 A1; DE 19704244 A1; DE 19704243 A1; EP 818448 A1; WO 9804528 A2; DE 19627431 A1; DE 19627430 A1; DE 19627419 A1; EP 796846 A1; DE 19832159; DE 818197; DE 19741051; WO 9941237 A1; WO 9914204 A1; WO 9835937 A1; JP 11049743; WO 200018721; WO 200018723; WO 200018724; WO 200017164; WO 200017165; WO 200017166; EP 992496; and EP 987251; all of which are hereby incorporated by reference in their entirety.


Oral delivery of many CETP inhibitors is particularly difficult because their aqueous solubility is usually extremely low, typically being less than 2 $\mu\text{g/ml}$, often being less than 0.1 $\mu\text{g/ml}$. Such low solubilities are a direct consequence of the particular structural characteristics of species that bind to CETP and thus act as CETP inhibitors. This low solubility is primarily due to the hydrophobic nature of CETP inhibitors. Log P, defined as the base 10 logarithm of the ratio of the drug concentration in octanol to the drug concentration in water in a partitioning experiment, is a widely accepted measure of hydrophobicity. In general, Log P values for CETP inhibitors are greater than 4 and are often greater than 5 to 7. This property may also be calculated from the structure of the molecule and is designated "cLog P." The calculation of cLog P values from chemical structures is given in Leo, A.J.; "Calculating log P from structures", Chem. Rev. 1993, 93, 1281. Thus, the hydrophobic and insoluble nature of CETP inhibitors as a class pose a particular challenge for oral delivery. Achieving therapeutic drug levels in the blood by oral dosing of practical quantities of drug generally requires a large enhancement in drug concentrations in the gastrointestinal fluid and a resulting large enhancement in bioavailability.

The formulations of this invention will be administered in such an amount that an effective dose of the CETP inhibitor of interest is administered to the patient. The amount of CETP inhibitor will generally be known or determined by the attending physician. Thus the amount or volume of preconcentrate administered will be determined by the amount of CETP inhibitor prescribed and/or otherwise desired as a

-16-

dose and the solubility of the CETP in the preconcentrate. In general, an effective dose for most CETP inhibitors is in the range of from 5 to 500 mg, preferably 10-300 mg, more preferably 10-200 mg per day, in single or divided doses. The compositions of the invention are pre-concentrates for emulsification which are generally administered orally, in soft or hard gelatin capsules, gelatin encapsulation technology being well known to the pharmaceutical arts. Such pre-concentrates can also be administered in aqueous oral emulsions by adding the pre-concentrate to water or other aqueous liquid (e.g., soda). They can be mixed with an aqueous liquid and sold as pre-formed emulsions, or added to food such as ice cream.

- 10 Turning now to the chemical structures of specific CETP inhibitors, one class of CETP inhibitors that finds utility with the present invention consists of oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines having the Formula I



15

Formula I

and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds;

wherein R_{1-1} is hydrogen, Y_1 , W_1-X_1 , W_1-Y_1 ;

- 20 wherein W_1 is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

X_1 is $-O-Y_1$, $-S-Y_1$, $-N(H)-Y_1$ or $-N(Y_1)_2$;

wherein Y_1 for each occurrence is independently Z_1 or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be

- 25 replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo,

said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_i ;

wherein Z_i is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_i substituent is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxyl, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxyl, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

R_{4-3} is hydrogen or Q_i ;

wherein Q_i is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_i ;

wherein V_i is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V_i substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carbamoyl, mono-N- or di-N,N- (C_1-C_6)

wherein Q_{1-1} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with

wherein V_{1-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

20 wherein said V_{1-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

25 wherein either R_{i-3} must contain V_i or R_{i-4} must contain V_{i-1} ; and

SPDOCID: <WQ 03000295A2 | >

wherein T_1 is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken
5 independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said T_1 substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-
10 N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines.

15 Compounds of Formula I are disclosed in commonly assigned pending U.S. Patent Application Serial No. 09/390,731, the complete disclosure of which is herein incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula I:

20

[2R,4S] 4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

25

[2R,4S] 4-[(3,5-dinitro-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

30

[2R,4S] 4-[(2,6-dichloro-pyridin-4-ylmethyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

35


[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

40

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-methoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,
[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-ethoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- 5 [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2,2,2-trifluoro-ethylester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;
- 10 [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethoxy-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,
- 15 [2R,4S] (3,5-bis-trifluoromethyl-benzyl)-(1-butyl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
- [2R,4S] (3,5-bis-trifluoromethyl-benzyl)-(1-butyl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
- 20 [2R,4S] (3,5-bis-trifluoromethyl-benzyl)-[1-(2-ethyl-butyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester, hydrochloride

- 25 Another class of CETP inhibitors that finds utility with the present invention consists of 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines, having the Formula II



- 30 Formula II

and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds;

wherein R_{II-1} is hydrogen, Y_{II} , $W_{II}-X_{II}$, $W_{II}-Y_{II}$;

wherein W_{II} is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

- 35 X_{II} is $-O-Y_{II}$, $-S-Y_{II}$, $-N(H)-Y_{II}$ or $-N-(Y_{II})_2$;

wherein Y_{ii} for each occurrence is independently Z_{ii} or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_{ii} ;

Z_{ii} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_{ii} substituent is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl is also optionally substituted with from one to nine fluorines;

R_{i1-3} is hydrogen or Q_{ii} ;

wherein Q_{ii} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{ii} ;

wherein V_{ii} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected

-22-

independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

- 5 wherein said V_{II} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N- (C_1-C_6) alkylcarboxamoyl, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally
- 10 mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino or said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituents are optionally substituted with from one to nine fluorines;

R_{II-4} is Q_{II-1} or V_{II-1}

- 15 wherein Q_{II-1} a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said
- 20 carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{II-1} ;

- wherein V_{II-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently
- 25 from oxygen, sulfur and nitrogen;

- wherein said V_{II-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent is
- 30 optionally substituted with from one to nine fluorines;

 wherein either R_{II-3} must contain V_{II} or R_{II-4} must contain V_{II-1} ; and

R_{II-5} , R_{II-6} , R_{II-7} and R_{II-8} are each independently hydrogen, a bond, nitro or halo wherein said bond is substituted with T_{II} or a partially saturated, fully saturated or fully unsaturated (C_1-C_{12}) straight or branched carbon chain wherein carbon may optionally

be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-
5 substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon is optionally mono-substituted with T_{II};

wherein T_{II} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two
10 fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said T_{II} substituent is optionally mono-, di- or tri-substituted independently with halo, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, hydroxy, (C₁-C₆)alkoxy, (C₁-
15 C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl substituent is also optionally substituted with from one to nine
20 fluorines;

provided that at least one of substituents R_{II-5}, R_{II-6}, R_{II-7} and R_{II-8} is not hydrogen and is not linked to the quinoline moiety through oxy.

Compounds of Formula II are disclosed in commonly assigned pending U.S. Patent 6,147,090 the complete disclosure of which is herein incorporated by reference.

25 In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula II:

30 [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-7-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

35 [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2,6,7-trimethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester

[2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-diethyl-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;


5 [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-ethyl-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester.

10

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.

Another class of CETP inhibitors that finds utility with the present invention
15 consists of annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines, having the Formula III



20

Formula III

and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds;

wherein R_{III-1} is hydrogen, Y_{III} , $W_{III}-X_{III}$, $W_{III}-Y_{III}$;

wherein W_{III} is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

25 X_{III} is $-O-Y_{III}$, $-S-Y_{III}$, $-N(H)-Y_{III}$ or $-N-(Y_{III})_2$;

Y_{III} for each occurrence is independently Z_{III} or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and
30 nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo,

said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_{III};

wherein Z_{III} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected

5 independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_{III} substituent is optionally mono-, di- or tri-substituted

10 independently with halo, (C₂-C₆)alkenyl, (C₁-C₆) alkyl, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-
15 C₆)alkylamino, said (C₁-C₆)alkyl optionally substituted with from one to nine fluorines; R_{III-3} is hydrogen or Q_{III};

wherein Q_{III} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from
20 oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{III};

25 wherein V_{III} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected
30 independently from nitrogen, sulfur and oxygen;

wherein said V_{III} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N-(C₁-C₆)alkylcarboxamoyl, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-

C_6)alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino or said (C_1-C_6) alkyl or (C_2-C_6) alkenyl are optionally substituted with from one to nine fluorines;

R_{III-4} is Q_{III-1} or V_{III-1} ;

wherein Q_{III-1} a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with

V_{III-1} ;

wherein V_{III-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V_{III-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent optionally having from one to nine fluorines;

wherein either R_{III-3} must contain V_{III} or R_{III-4} must contain V_{III-1} ; and R_{III-5} and R_{III-6} , or R_{III-6} and R_{III-7} , and/or R_{III-7} and R_{III-8} are taken together and form at least one four to eight membered ring that is partially saturated or fully unsaturated optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring or rings formed by R_{III-5} and R_{III-6} , or R_{III-6} and R_{III-7} , and/or R_{III-7} and R_{III-8} are optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_4) alkylsulfonyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro,

-27-

cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl substituent optionally having from one to nine fluorines;

provided that the R_{III-5}, R_{III-6}, R_{III-7} and/or R_{III-8}, as the case may be, that do not form at least one ring are each independently hydrogen, halo, (C₁-C₆)alkoxy or (C₁-

5 C₆)alkyl, said (C₁-C₆)alkyl optionally having from one to nine fluorines.

Compounds of Formula III are disclosed in commonly assigned pending U.S. Patent 6,147,089 the complete disclosure of which is herein incorporated by reference.

10 In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula III:

[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-2,3,4,6,7,8-hexahydro-cyclopenta[g]quinoline-1-carboxylic acid ethyl ester;

15 [6R, 8S] 8-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methyl-3,6,7,8-tetrahydro-1H-2-thia-5-aza-cyclopenta[b]naphthalene-5-carboxylic acid ethylester;

20 [6R, 8S] 8-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methyl-3,6,7,8-tetrahydro-2H-furo[2,3-g]quinoline-5-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-3,4,6,8-tetrahydro-2H-furo[3,4-g]quinoline-1-carboxylic acid ethyl ester;


25 [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-3,4,6,7,8,9-hexahydro-2H-benzo[g]quinoline-1-carboxylic acid propyl ester;

[7R,9S] 9-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-methyl-1,2,3,7,8,9-hexahydro-6-aza-cyclopenta[a]naphthalene-6-carboxylic acid ethyl ester; and

30 [6S,8R] 6-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-8-methyl-1,2,3,6,7,8-hexahydro-9-aza-cyclopenta[a]naphthalene-9-carboxylic acid ethyl ester.

35 Another class of CETP inhibitors that finds utility with the present invention consists of 4-carboxyamino-2-substituted-1,2,3,4,-tetrahydroquinolines, having the Formula IV

-28-



Formula IV

and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds;

wherein R_{IV-1} is hydrogen, Y_{IV} , $W_{IV}-X_{IV}$ or $W_{IV}-Y_{IV}$;

wherein W_{IV} is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

X_{IV} is $-O-Y_{IV}$, $-S-Y_{IV}$, $-N(H)-Y_{IV}$ or $-N(Y_{IV})_2$;

wherein Y_{IV} for each occurrence is independently Z_{IV} or a fully saturated,

- 10 partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is
- 15 optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_{IV} ;

wherein Z_{IV} is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently

20 from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_{IV} substituent is optionally mono-, di- or tri-substituted

- 25 independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino,

nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl substituent is also optionally substituted with from one to nine fluorines;

- 5 R_{IV,2} is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, 10 said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R_{IV,2} is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said R_{IV,2} ring is optionally attached through (C₁-C₄)alkyl;
- 15 wherein said R_{IV,2} ring is optionally mono-, di- or tri-substituted independently with halo, (C₂-C₆)alkenyl, (C₁-C₆) alkyl, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, oxo or 20 (C₁-C₆)alkyloxycarbonyl;

with the proviso that R_{IV,2} is not methyl;

R_{IV,3} is hydrogen or Q_{IV};

- wherein Q_{IV} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons other than the 25 connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and 30 said carbon chain is optionally mono-substituted with V_{IV};

wherein V_{IV} is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken

independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V_{IV} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N- (C_1-C_6) alkylcarboxamoyl, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituents are also optionally substituted with from one to nine fluorines;

R_{IV-4} is Q_{IV-1} or V_{IV-1} ;

wherein Q_{IV-1} a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{IV-1} ;

wherein V_{IV-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V_{IV-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

wherein either R_{IV-3} must contain V_{IV} or R_{IV-4} must contain V_{IV-1} ;

R_{IV-5} , R_{IV-6} , R_{IV-7} and R_{IV-8} are each independently hydrogen, a bond, nitro or halo wherein said bond is substituted with T_{IV} or a partially saturated, fully saturated or fully unsaturated (C_1-C_{12}) straight or branched carbon chain wherein carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur

and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and
5 said carbon is optionally mono-substituted with T_{IV} ;

wherein T_{IV} is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken
10 independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said T_{IV} substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-
15 N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines; and

20 wherein R_{IV-5} and R_{IV-6} , or R_{IV-6} and R_{IV-7} , and/or R_{IV-7} and R_{IV-8} may also be taken together and can form at least one four to eight membered ring that is partially saturated or fully unsaturated optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring or rings formed by R_{IV-5} and R_{IV-6} , or R_{IV-6} and R_{IV-7} , and/or
25 R_{IV-7} and R_{IV-8} are optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_4) alkylsulfonyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro,
30 cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;


with the proviso that when R_{IV-2} is carboxyl or (C_1-C_4) alkylcarboxyl, then R_{IV-1} is not hydrogen.

Compounds of Formula IV are disclosed in commonly assigned pending U.S. Patent 6,197,786 the complete disclosure of which is herein incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula IV:

- 5 [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-isopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-cyclopropyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- 10 [2S,4S] 2-cyclopropyl-4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;
- 15 [2R,4R] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- 20 [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- 25 [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- 30 [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxy-ethyl ester;
- 35 [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- 40 [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester; and
- 45 [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester.

Another class of CETP inhibitors that finds utility with the present invention consists of 4-amino substituted-2-substituted-1,2,3,4,-tetrahydroquinolines, having the Formula V



Formula V

and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds;

10 wherein R_{V-1} is Y_V , W_V-X_V or W_V-Y_V ;

wherein W_V is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

X_V is $-O-Y_V$, $-S-Y_V$, $-N(H)-Y_V$ or $-N-(Y_V)_2$;

wherein Y_V for each occurrence is independently Z_V or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_V ;

wherein Z_V is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_V substituent is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, $(C_1-$

- C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl substituent is also optionally substituted with from one to nine fluorines;

- R_{V,2} is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R_{V,2} is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said R_{V,2} ring is optionally attached through (C₁-C₄)alkyl;

- wherein said R_{V,2} ring is optionally mono-, di- or tri-substituted independently with halo, (C₂-C₆)alkenyl, (C₁-C₆)alkyl, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, oxo or (C₁-C₆)alkyloxycarbonyl;

- R_{V,3} is hydrogen or Q_V;
- wherein Q_V is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_V;

wherein V_V is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently

from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

- 5 wherein said V_V substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N- (C_1-C_6) alkylcarboxamoyl, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally
- 10 mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituents are also optionally substituted with from one to nine fluorines;
- $R_{V,4}$ is cyano, formyl, $W_{V,1}Q_{V,1}$, $W_{V,1}V_{V,1}$, (C_1-C_4) alkylene $V_{V,1}$ or $V_{V,2}$;

- 15 wherein $W_{V,1}$ is carbonyl, thiocarbonyl, SO or SO_2 ,
- wherein $Q_{V,1}$ a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is
- 20 optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with $V_{V,1}$;

- wherein $V_{V,1}$ is a partially saturated, fully saturated or fully unsaturated three to
- 25 six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

- 30 wherein said $V_{V,1}$ substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, hydroxy, oxo, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

wherein $V_{V,2}$ is a partially saturated, fully saturated or fully unsaturated five to seven membered ring containing one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said $V_{V,2}$ substituent is optionally mono-, di- or tri-substituted
5 independently with halo, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, hydroxy, or oxo wherein said (C_1-C_2) alkyl optionally has from one to five fluorines; and

wherein $R_{V,4}$ does not include oxycarbonyl linked directly to the C^4 nitrogen;

wherein either $R_{V,3}$ must contain V_V or $R_{V,4}$ must contain $V_{V,1}$;

$R_{V,5}$, $R_{V,6}$, $R_{V,7}$ and $R_{V,8}$ are independently hydrogen, a bond, nitro or halo
10 wherein said bond is substituted with T_V or a partially saturated, fully saturated or fully unsaturated (C_1-C_{12}) straight or branched carbon chain wherein carbon may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said
15 carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with T_V ;

wherein T_V is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected
20 independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said T_V substituent is optionally mono-, di- or tri-substituted
25 independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino,
30 said (C_1-C_6) alkyl substituent also optionally has from one to nine fluorines;

wherein $R_{V,5}$ and $R_{V,6}$, or $R_{V,6}$ and $R_{V,7}$, and/or $R_{V,7}$ and $R_{V,8}$ may also be taken together and can form at least one ring that is a partially saturated or fully unsaturated four to eight membered ring optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;

-37-

wherein said rings formed by R_{V-5} and R_{V-6} , or R_{V-6} and R_{V-7} , and/or R_{V-7} and R_{V-8} are optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_4) alkylsulfonyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- $(C_1-$

- 5 $C_6)$ alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent also optionally has from one to nine fluorines.

- Compounds of Formula V are disclosed in commonly assigned pending
10 U.S. Patent 6,140,343 the complete disclosure of which is herein incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula V:

- 15 [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester,
[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester,
20 [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester,
[2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester,
25 [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,
[2S,4S] 4-[1-(3,5-bis-trifluoromethyl-benzyl)-ureido]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester,
30 [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,
[2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester,
35 [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester,
40 [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,
[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester,
45

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester:

5 [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;


[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

10 [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester:

15 [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; and

[2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.

Another class of CETP inhibitors that finds utility with the present invention consists of cycloalkano-pyridines having the Formula VI



Formula VI

25 and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds:


in which

A_{V1} denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with up to five identical or different substituents in the form of a halogen, nitro, hydroxyl, trifluoromethyl, trifluoromethoxy or a straight-chain or branched alkyl, acyl, hydroxyalkyl or alkoxy containing up to 7 carbon atoms each, or in the form of a group according to the formula $-BNR_{V1.3}R_{V1.4}$, wherein

R_{VI-3} and R_{VI-4} are identical or different and denote a hydrogen, phenyl or a straight-chain or branched alkyl containing up to 6 carbon atoms,

35 D_V denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with a phenyl, nitro, halogen, trifluoromethyl or trifluoromethoxy, or a radical according to the formula $R_{VL5-LVR}$.

-39-




or $R_{VI-9}-T_{VI}-V_{VI}-X_{VI}$, wherein

- 5 R_{VI-5} , R_{VI-6} and R_{VI-9} denote, independently from one another, a cycloalkyl containing 3 to 6 carbon atoms, or an aryl containing 6 to 10 carbon atom or a 5- to 7-membered, optionally benzo-condensed, saturated or unsaturated, mono-, bi- or tricyclic heterocycle containing up to 4 heteroatoms from the series of S, N and/or O, wherein the rings are optionally substituted, in the case of the nitrogen-containing rings also via the N function, with up to five identical or different substituents in the form of a
- 10 halogen, trifluoromethyl, nitro, hydroxyl, cyano, carboxyl, trifluoromethoxy, a straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl containing up to 6 carbon atoms each, an aryl or trifluoromethyl-substituted aryl containing 6 to 10 carbon atoms each, or an optionally benzo-condensed, aromatic 5- to 7-membered
- 15 heterocycle containing up to 3 heteroatoms from the series of S, N and/or O, and/or in the form of a group according to the formula BOR_{VI-10} , $-SR_{VI-11}$, $-SO_2R_{VI-12}$ or $BNR_{VI-13}R_{VI-14}$, wherein

- R_{VI-10} , R_{VI-11} and R_{VI-12} denote, independently from one another, an aryl containing 6 to 10 carbon atoms, which is in turn substituted with up to two identical or
- 20 different substituents in the form of a phenyl, halogen or a straight-chain or branched alkyl containing up to 6 carbon atoms,

R_{VI-13} and R_{VI-14} are identical or different and have the meaning of R_{VI-3} and R_{VI-4} given above, or

R_{VI-5} and/or R_{VI-6} denote a radical according to the formula



25

R_{VI-7} denotes a hydrogen or halogen, and

R_{VI-8} denotes a hydrogen, halogen, azido, trifluoromethyl, hydroxyl, trifluoromethoxy, a straight-chain or branched alkoxy or alkyl containing up to 6 carbon atoms each, or a radical according to the formula

30



wherein

R_{VI-15} and R_{VI-16} are identical or different and have the meaning of R_{VI-3} and R_{VI-4} given above, or

R_{VI-7} and R_{VI-8} together form a radical according to the formula $=O$ or $=NR_{VI-17}$,

5 wherein

R_{VI-17} denotes a hydrogen or a straight-chain or branched alkyl, alkoxy or acyl containing up to 6 carbon atoms each,

L_{VI} denotes a straight-chain or branched alkylene or alkenylene chain containing up to 8 carbon atoms each, which are optionally substituted with up to two hydroxyl groups,

T_{VI} and X_{VI} are identical or different and denote a straight-chain or branched alkylene chain containing up to 8 carbon atoms, or


T_{VI} or X_{VI} denotes a bond,

V_{VI} denotes an oxygen or sulfur atom or an BNR_{VI-18} group, wherein

15 R_{VI-18} denotes a hydrogen or a straight-chain or branched alkyl containing up to 6 carbon atoms or a phenyl,

E_{VI} denotes a cycloalkyl containing 3 to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a cycloalkyl containing 3 to 8 carbon atoms or a hydroxyl, or a phenyl, which is optionally substituted with a halogen or trifluoromethyl,

R_{VI-1} and R_{VI-2} together form a straight-chain or branched alkylene chain containing up to 7 carbon atoms, which must be substituted with a carbonyl group and/or a radical according to the formula



25 wherein

a and b are identical or different and denote a number equaling 1, 2 or 3,

R_{VI-19} denotes a hydrogen atom, a cycloalkyl containing 3 to 7 carbon atoms, a straight-chain or branched silylalkyl containing up to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a hydroxyl, a straight-chain or a branched alkoxy containing up to 6 carbon atoms or a phenyl, which may in turn be substituted with a halogen, nitro,

30



trifluoromethyl, trifluoromethoxy or phenyl or tetrazole-substituted phenyl, and an alkyl that is optionally substituted with a group according to the formula $\text{BOR}_{\text{VI-22}}$, wherein

$\text{R}_{\text{VI-22}}$ denotes a straight-chain or branched acyl containing up to 4 carbon atoms or benzyl, or

- 5 $\text{R}_{\text{VI-19}}$ denotes a straight-chain or branched acyl containing up to 20 carbon atoms or benzoyl, which is optionally substituted with a halogen, trifluoromethyl, nitro or trifluoromethoxy, or a straight-chain or branched fluoroacyl containing up to 8 carbon atoms,

- $\text{R}_{\text{VI-20}}$ and $\text{R}_{\text{VI-21}}$ are identical or different and denote a hydrogen, phenyl or a
10 straight-chain or branched alkyl containing up to 6 carbon atoms, or

- $\text{R}_{\text{VI-20}}$ and $\text{R}_{\text{VI-21}}$ together form a 3- to 6-membered carbocyclic ring, and the carbocyclic rings formed are optionally substituted, optionally also geminally, with up to six identical or different substituents in the form of trifluoromethyl, hydroxyl, nitrile, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy containing 3 to 7
15 carbon atoms each, a straight-chain or branched alkoxycarbonyl, alkoxy or alkylthio containing up to 6 carbon atoms each, or a straight-chain or branched alkyl containing up to 6 carbon atoms, which is in turn substituted with up to two identical or different substituents in the form of a hydroxyl, benzyloxy, trifluoromethyl, benzoyl, a straight-chain or branched alkoxy, oxyacyl or carboxyl containing up to 4 carbon atoms each
20 and/or a phenyl, which may in turn be substituted with a halogen, trifluoromethyl or trifluoromethoxy, and/or the carbocyclic rings formed are optionally substituted, also geminally, with up to five identical or different substituents in the form of a phenyl, benzoyl, thiophenyl or sulfonylbenzyl, which in turn are optionally substituted with a halogen, trifluoromethyl, trifluoromethoxy or nitro, and/or optionally in the form of a
25 radical according to the formula




wherein

- c is a number equaling 1, 2, 3 or 4,
30 d is a number equaling 0 or 1,


$\text{R}_{\text{VI-23}}$ and $\text{R}_{\text{VI-24}}$ are identical or different and denote a hydrogen, cycloalkyl containing 3 to 6 carbon atoms, a straight-chain or branched alkyl containing up to 6 carbon atoms, benzyl or phenyl, which is optionally substituted with up to two identical or different substituents in the form of halogen, trifluoromethyl, cyano, phenyl or nitro,

and/or the carbocyclic rings formed are optionally substituted with a spiro-linked radical according to the formula



wherein

- 5 W_{VI} denotes either an oxygen atom or a sulfur atom,
 Y_{VI} and $Y=_{VI}$ together form a 2- to 6-membered straight-chain or branched alkylene chain,
 e is a number equaling 1, 2, 3, 4, 5, 6 or 7,
 f is a number equaling 1 or 2,
- 10 R_{VI-25} , R_{VI-26} , R_{VI-27} , R_{VI-28} , R_{VI-29} , R_{VI-30} and R_{VI-31} are identical or different and denote a hydrogen, trifluoromethyl, phenyl, halogen or a straight-chain or branched alkyl or alkoxy containing up to 6 carbon atoms each, or
 R_{VI-25} and R_{VI-26} or R_{VI-27} and R_{VI-28} each together denote a straight-chain or branched alkyl chain containing up to 6 carbon atoms or
- 15 R_{VI-25} and R_{VI-26} or R_{VI-27} and R_{VI-28} each together form a radical according to the formula



wherein


- W_{VI} has the meaning given above,
- 20 g is a number equaling 1, 2, 3, 4, 5, 6 or 7,
 R_{VI-32} and R_{VI-33} together form a 3- to 7-membered heterocycle, which contains an oxygen or sulfur atom or a group according to the formula SO , SO_2 or BNR_{VI-34} ,
 wherein
 R_{VI-34} denotes a hydrogen atom, a phenyl, benzyl, or a straight-chain or
 25 branched alkyl containing up to 4 carbon atoms, and salts and N oxides thereof, with the exception of 5(6H)-quinolones, 3-benzoyl-7,8-dihydro-2,7,7-trimethyl-4-phenyl.

Compounds of Formula VI are disclosed in European Patent Application No. EP 818448 A1, U.S. Patent 6,207,671 and U.S. Patent 6,064,148 the complete disclosures of which are herein incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula VI:

- 2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-3-(4-trifluoromethylbenzoyl)-4,6,7,8-tetrahydro-1H-quinolin-5-one;
- 2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-3-(4-trifluoromethylbenzoyl)-7,8-dihydro-6H-quinolin-5-one;
- [2-cyclopentyl-4-(4-fluorophenyl)-5-hydroxy-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanone;
- [5-(t-butyl dimethylsilyloxy)-2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanone;
- [5-(t-butyl dimethylsilyloxy)-2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanol;
- 5-(t-butyl dimethylsilyloxy)-2-cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-(4-trifluoromethylphenyl)-methyl]-7,7-dimethyl-5,6,7,8-tetrahydroquinoline;
- 2-cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-(4-trifluoromethylphenyl)-methyl]-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

Another class of CETP inhibitors that finds utility with the present invention consists of substituted-pyridines having the Formula VII




Formula VII

or a pharmaceutically acceptable salt or tautomer thereof, wherein

R_{VII-2} and R_{VII-6} are independently selected from the group consisting of hydrogen, hydroxy, alkyl, fluorinated alkyl, fluorinated aralkyl, chlorofluorinated alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, alkoxyalkyl, and alkoxy carbonyl; provided that at least one of R_{VII-2} and R_{VII-6} is fluorinated alkyl, chlorofluorinated alkyl or alkoxyalkyl;

R_{VII-3} is selected from the group consisting of hydroxy, amido, aryl carbonyl, heteroaryl carbonyl, hydroxymethyl -CHO,

-CO₂R_{VII-7}, wherein R_{VII-7} is selected from the group consisting of hydrogen, alkyl and cyanoalkyl; and




wherein $R_{VII-15a}$ is selected from the group consisting of hydroxy, hydrogen, halogen, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy and heterocyclyloxy, and

$R_{VII-16a}$ is selected from the group consisting of alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, and heterocyclyl, arylalkoxy, trialkylsilyloxy,

10 R_{VII-4} is selected from the group consisting of hydrogen, hydroxy, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkylalkyl, cycloalkenylalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkylalkenyl, cycloalkenylalkenyl, aralkenyl, heteroarylalkenyl, heterocyclylalkenyl, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, 15 heterocycliloxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloxyloxy, heteroaryloxy, heterocycliloxyloxy, alkoxycarbonyl, alkenoxycarbonyl, alkynoxycarbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, heterocycliloxy carbonyl, thio, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalkenylthio, alkylthioalkyl, alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, 20 heteroarylthioalkyl, heterocyclylthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl, arylthioalkenyl, heteroarylthioalkenyl, heterocyclylthioalkenyl, alkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, heterocyclylamino, arylalkylamino, diarylamino, diheteroarylamino, alkylaryl amino, alkylheteroaryl amino, arylheteroaryl amino, trialkylsilyl, trialkenylsilyl, triarylsilyl, 25 $-CO(O)N(R_{VII-9a}R_{VII-9b})$, wherein R_{VII-9a} and R_{VII-9b} are independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, $-SO_2R_{VII-9}$, wherein R_{VII-9} is selected from the group consisting of hydroxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, $-OP(O)(OR_{VII-10a})(OR_{VII-10b})$, wherein $R_{VII-10a}$ and $R_{VII-10b}$ are independently selected from the group consisting of hydrogen, hydroxy, alkyl, 30 alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, and $-OP(S)(OR_{VII-11a})(OR_{VII-11b})$, wherein $R_{VII-11a}$ and $R_{VII-11b}$ are independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;


-45-

- R_{VII-5} is selected from the group consisting of hydrogen, hydroxy, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, alkylcarbonyloxyalkyl, alkenylcarbonyloxyalkyl, alkynylcarbonyloxyalkyl, arylcarbonyloxyalkyl, heteroarylcarbonyloxyalkyl, heterocyclylcarbonyloxyalkyl, cycloalkylalkyl, cycloalkenylalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkylalkenyl, cycloalkenylalkenyl, aralkenyl, heteroarylalkenyl, heterocyclylalkenyl, alkylthioalkyl, cycloalkylthioalkyl, alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, heteroarylthioalkyl, heterocyclylthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl, arylthioalkenyl, heteroarylthioalkenyl, heterocyclylthioalkenyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkenyl, alkenoxyalkenyl, alkynoxyalkenyl, aryloxyalkenyl, heteroaryloxyalkenyl, heterocyclyloxyalkenyl, cyano, hydroxymethyl, $-CO_2R_{VII-14}$, wherein R_{VII-14} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;




- wherein $R_{VII-15b}$ is selected from the group consisting of hydroxy, hydrogen, halogen, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryloxy, and alkylsulfonyloxy, and

$R_{VII-16b}$ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, arylalkoxy, and trialkylsilyloxy;



- wherein R_{VII-17} and R_{VII-18} are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;



wherein R_{VII-19} is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycdyl, -SR_{VII-20}, -OR_{VII-21}, and BR_{VII-22}CO₂R_{VII-23}, wherein


R_{VII-20} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aminoaryl,

5 aminoheteroaryl, aminoheterocyclyl, alkylheteroarylamino, arylheteroarylamino,


R_{VII-21} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl,

R_{VII-22} is selected from the group consisting of alkylene or arylene, and


R_{VII-23} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;






wherein R_{VII-24} is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, aralkyl, aralkenyl, and aralkynyl;




wherein R_{VII-25} is heterocyclidenyl;




wherein R_{VII-26} and R_{VII-27} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;





wherein R_{VII-28} and R_{VII-29} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;



wherein R_{VII-30} and R_{VII-31} are independently alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, and heterocyclyloxy; and




10 wherein R_{VII-32} and R_{VII-33} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;




wherein R_{VII-36} is selected from the group consisting of alkyl, alkenyl, aryl, heteroaryl and heterocyclyl;

-48-



wherein $\text{R}_{\text{VII-37}}$ and $\text{R}_{\text{VII-38}}$ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;




- 5 wherein $\text{R}_{\text{VII-39}}$ is selected from the group consisting of hydrogen, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio and heterocyclylthio, and

$\text{R}_{\text{VII-40}}$ is selected from the group consisting of haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, haloheterocyclyl, cycloalkyl, cycloalkenyl,

- 10 heterocyclalkoxy, heterocyclalkenoxo, heterocyclalkynoxo, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio and heterocyclthio;




wherein $\text{R}_{\text{VII-41}}$ is heterocyclidenyl;




- 15 wherein $\text{R}_{\text{VII-42}}$ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycl, and

$\text{R}_{\text{VII-43}}$ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, and haloheterocycl;



20

wherein $\text{R}_{\text{VII-44}}$ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocycl;



25



-49-


- N₃;- SR_{VII-45}

- wherein R_{VII-45} is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, haloheterocyclyl, heterocyclyl, cycloalkylalkyl, cycloalkenylalkyl, aralkyl, heteroarylalkyl, heterocyclalkyl, cycloalkylalkenyl, cycloalkenylalkenyl, aralkenyl, heteroarylalkenyl, heterocyclalkenyl, alkylthioalkyl, alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, heteroarylthioalkyl, heterocyclthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl, arylthioalkenyl, heteroarylthioalkenyl, heterocyclthioalkenyl, aminocarbonylalkyl, aminocarbonylalkenyl, aminocarbonylalkynyl, aminocarbonylaryl, aminocarbonylheteroaryl, and aminocarbonylheterocyclyl,

-SR_{VII-46}, and -CH₂R_{VII-47},


- wherein R_{VII-46} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl; and

R_{VII-47} is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl; and




- wherein R_{VII-48} is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl; and

R_{VII-49} is selected from the group consisting of alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocycloxy, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl and haloheterocyclyl;




- wherein R_{VII-50} is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy and heterocycloxy;

-50-



wherein R_{VII-51} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl and haloheterocyclyl; and



wherein R_{VII-53} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;

provided that when R_{VII-5} is selected from the group consisting of

heterocyclalkyl and heterocyclalkenyl, the heterocycl radical of the corresponding heterocyclalkyl or heterocyclalkenyl is other than δ -lactone; and


provided that when R_{VII-4} is aryl, heteroaryl or heterocyclyl, and one of R_{VII-2} and R_{VII-6} is trifluoromethyl, then the other of R_{VII-2} and R_{VII-6} is difluoromethyl.

Compounds of Formula VII are disclosed in WO 9941237-A1, the complete disclosure of which is incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula VII:

Dimethyl 5,5-dithiobis[2-difluoromethyl-4-(2-methylpropyl)-6-(trifluoromethyl)-3-pyridine-carboxylate].

Another class of CETP inhibitors that finds utility with the present invention consists of substituted pyridines having the Formula VIII



Formula VIII

or a pharmaceutically acceptable salt, enantiomers, or stereoisomers thereof,
in which

-51-

A_{VIII} stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula

5 -NR_{VIII-1}R_{VIII-2}, wherein

R_{VIII-1} and R_{VIII-2} are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms,

D_{VIII} stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is substituted by hydroxy,

10 E_{VIII} and L_{VIII} are either identical or different and stand for straight-chain or branched alkyl with up to 8 carbon atoms, which is optionally substituted by cycloalkyl with 3 to 8 carbon atoms, or stands for cycloalkyl with 3 to 8 carbon atoms, or

E_{VIII} has the above-mentioned meaning and

15 L_{VIII} in this case stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula

-NR_{VIII-3}R_{VIII-4}, wherein

20 R_{VIII-3} and R_{VIII-4} are identical or different and have the meaning given above for R_{VIII-1} and R_{VIII-2}, or


E_{VIII} stands for straight-chain or branched alkyl with up to 8 carbon atoms, or stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula

-NR_{VIII-5}R_{VIII-6}, wherein

R_{VIII-5} and R_{VIII-6} are identical or different and have the meaning given above for R_{VIII-1} and R_{VIII-2}, and

30 L_{VIII} in this case stands for straight-chain or branched alkoxy with up to 8 carbon atoms or for cycloalkyloxy with 3 to 8 carbon atoms,

T_{VIII} stands for a radical of the formula



R_{VIII-7} and R_{VIII-8} are identical or different and denote cycloalkyl with 3 to 8 carbon atoms, or aryl with 6 to 10 carbon atoms, or denote a 5- to 7-member aromatic, optionally benzo-condensed, heterocyclic compound with up to 3 heteroatoms from the series S, N and/or O, which are optionally substituted up to 3 times in an identical manner or differently by trifluoromethyl, trifluoromethoxy, halogen, hydroxy, carboxyl, by straight-chain or branched alkyl, acyl, alkoxy, or alkoxycarbonyl with up to 6 carbon atoms each, or by phenyl, phenoxy, or thiophenyl, which can in turn be substituted by halogen, trifluoromethyl, or trifluoromethoxy, and/or the rings are substituted by a group of the formula

10 $-NR_{VIII-11}R_{VIII-12}$, wherein

$R_{VIII-11}$ and $R_{VIII-12}$ are identical or different and have the meaning given above for R_{VII-1} and R_{VII-2} ,

X_{VIII} denotes a straight or branched alkyl chain or alkenyl chain with 2 to 10 carbon atoms each, which are optionally substituted up to 2 times by hydroxy,

15 R_{VIII-9} denotes hydrogen, and

$R_{VIII-10}$ denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, mercapto, trifluoromethoxy, straight-chain or branched alkoxy with up to 5 carbon atoms, or a radical of the formula


$-NR_{VIII-13}R_{VIII-14}$, wherein

20 $R_{VIII-13}$ and $R_{VIII-14}$ are identical or different and have the meaning given above for R_{VII-1} and R_{VII-2} , or

R_{VIII-9} and $R_{VIII-10}$ form a carbonyl group together with the carbon atom.

Compounds of Formula VIII are disclosed in WO 9804528, the complete disclosure of which is incorporated by reference.

25 Another class of CETP inhibitors that finds utility with the present invention consists of substituted 1,2,4-triazoles having the Formula IX



Formula IX

or a pharmaceutically acceptable salt or tautomer thereof;

wherein R_{IX-1} is selected from higher alkyl, higher alkenyl, higher alkynyl, aryl, 30 aralkyl, aryloxyalkyl, alkoxyalkyl, alkylthioalkyl, arylthioalkyl, and cycloalkylalkyl;

wherein R_{IX-2} is selected from aryl, heteroaryl, cycloalkyl, and cycloalkenyl,

wherein

R_{IX-2} is optionally substituted at a substitutable position with one or more radicals independently selected from alkyl, haloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, 5 alkoxy, halo, aryloxy, aralkyloxy, aryl, aralkyl, aminosulfonyl, amino, monoalkylamino and dialkylamino; and

wherein R_{IX-3} is selected from hydrido, -SH and halo;

provided R_{IX-2} cannot be phenyl or 4-methylphenyl when R_{IX-1} is higher alkyl and when R_{IX-3} is BSH.

10 Compounds of Formula IX are disclosed in WO 9914204, the complete disclosure of which is incorporated by reference.


In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula IX:

- 15 2,4-dihydro-4-(3-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(2-fluorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(2-methylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 20 2,4-dihydro-4-(3-chlorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2, 4-dihydro-4-(2-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(3-methylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 25 4-cyclohexyl-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(3-pyridyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 30 2,4-dihydro-4-(2-ethoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(2,6-dimethylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(4-phenoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 35 4-(1,3-benzodioxol-5-yl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 4-(2-chlorophenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 40 2,4-dihydro-4-(4-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-5-tridecyl-4-(3-trifluoromethylphenyl)-3H-1,2,4-triazole-3-thione;
- 45 2,4-dihydro-5-tridecyl-4-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione;

-54-

- 4-(3-chloro-4-methylphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-4-(2-methylthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 5 4-(4-benzoyloxyphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-4-(2-naphthyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-5-tridecyl-4-(4-trifluoromethylphenyl)-3H-1,2,4-triazole-3-thione;
 10 2,4-dihydro-4-(1-naphthyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-4-(3-methylthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 15 2,4-dihydro-4-(4-methylthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-4-(3,4-dimethoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-4-(2,5-dimethoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 20 2,4-dihydro-4-(2-methoxy-5-chlorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
 4-(4-aminosulfonylphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;
 25 2,4-dihydro-5-dodecyl-4-(3-methoxyphenyl)-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-4-(3-methoxyphenyl)-5-tetradecyl-3H-1,2,4-triazole-3-thione;
 2,4-dihydro-4-(3-methoxyphenyl)-5-undecyl-3H-1,2,4-triazole-3-thione; and
 30 2,4-dihydro-(4-methoxyphenyl)-5-pentadecyl-3H-1,2,4-triazole-3-thione.

Another class of CETP inhibitors that finds utility with the present invention consists of hetero-tetrahydroquinolines having the Formula X



Formula X

and pharmaceutically acceptable salts, enantiomers, or stereoisomers or N-oxides of said compounds;
 in which


A_x represents cycloalkyl with 3 to 8 carbon atoms or a 5 to 7-membered, saturated, partially saturated or unsaturated, optionally benzo-condensed heterocyclic ring containing up to 3 heteroatoms from the series comprising S, N and/or O, that in case of a saturated heterocyclic ring is bonded to a nitrogen function, optionally
 5 bridged over it, and in which the aromatic systems mentioned above are optionally substituted up to 5-times in an identical or different substituents in the form of halogen, nitro, hydroxy, trifluoromethyl, trifluoromethoxy or by a straight-chain or branched alkyl, acyl, hydroxyalkyl or alkoxy each having up to 7 carbon atoms or by a group of the formula $BNR_{x-3}R_{x-4}$,

10 in which



R_{x-3} and R_{x-4} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms,
 or

15


A_x represents a radical of the formula



D_x represents an aryl having 6 to 10 carbon atoms, that is optionally
 20 substituted by phenyl, nitro, halogen, trifluoromethyl or trifluoromethoxy, or it represents a radical of the formula



or



in which

R_{x-5} , R_{x-6} and R_{x-9} independently of one another denote cycloalkyl having 3 to 6
 25 carbon atoms, or an aryl having 6 to 10 carbon atoms or a 5- to 7-membered aromatic, optionally benzo-condensed saturated or unsaturated, mono-, bi-, or tricyclic



heterocyclic ring from the series consisting of S, N and/or O, in which the rings are substituted, optionally, in case of the nitrogen containing aromatic rings via the N function, with up to 5 identical or different substituents in the form of halogen, trifluoromethyl, nitro, hydroxy, cyano, carbonyl, trifluoromethoxy, straight straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy, or alkoxy carbonyl each having up to 6 carbon atoms, by aryl or trifluoromethyl-substituted aryl each having 6 to 10 carbon atoms or by an, optionally benzo-condensed, aromatic 5- to 7-membered heterocyclic ring having up to 3 heteroatoms from the series consisting of S, N, and/or O, and/or substituted by a group of the formula $\text{BOR}_{\text{X-10}}$, $-\text{SR}_{\text{X-11}}$, $\text{SO}_2\text{R}_{\text{X-12}}$ or $\text{BNR}_{\text{X-13}}$, $^{13}\text{R}_{\text{X-14}}$, in which

R_{X-10} , R_{X-11} and R_{X-12} independently from each other denote aryl having 6 to 10 carbon atoms, which is in turn substituted with up to 2 identical or different substituents in the form of phenyl, halogen or a straight-chain or branched alkyl having up to 6 carbon atoms,

R_{x-13} and R_{x-14} are identical or different and have the meaning of R_{x-3} and R_{x-4} indicated above.

or

R_{X-5} and/or R_{X-6} denote a radical of the formula



20

or

R_{X-7} denotes hydrogen or halogen, and

25 R_{x-3} denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy or alkyl having up to 6 carbon atoms or a radical of the formula

BNR_{X-15}R_{X-16}.

in which

R_{x-15} and R_{x-16} are identical or different and have the meaning of R_{x-3} and R_{x-4} indicated above.

30 or

-57-

R_{X-7} and R_{X-8} together form a radical of the formula $=O$ or $=NR_{X-17}$,

in which

R_{X-17} denotes hydrogen or straight chain or branched alkyl, alkoxy or acyl having up to 6 carbon atoms,

5 L_X denotes a straight chain or branched alkylene or alkenylene chain having up to 8 carbon atoms, that are optionally substituted with up to 2 hydroxy groups,

T_X and X_X are identical or different and denote a straight chain or branched alkylene chain with up to 8 carbon atoms

or


10 T_X or X_X denotes a bond,

V_X represents an oxygen or sulfur atom or an BNR_{X-18} -group, in which

R_{X-18} denotes hydrogen or straight chain or branched alkyl with up to 6 carbon atoms or phenyl,

15 E_X represents cycloalkyl with 3 to 8 carbon atoms, or straight chain or branched alkyl with up to 8 carbon atoms, that is optionally substituted by cycloalkyl with 3 to 8 carbon atoms or hydroxy, or represents a phenyl, that is optionally substituted by halogen or trifluoromethyl,

20 R_{X-1} and R_{X-2} together form a straight-chain or branched alkylene chain with up to 7 carbon atoms, that must be substituted by carbonyl group and/or by a radical with the formula



in which a and b are identical or different and denote a number equaling 1,2, or 3,

25 R_{X-19} denotes hydrogen, cycloalkyl with 3 up to 7 carbon atoms, straight chain or branched silylalkyl with up to 8 carbon atoms or straight chain or branched alkyl with up to 8 carbon atoms, that are optionally substituted by hydroxyl, straight chain or branched alkoxy with up to 6 carbon atoms or by phenyl, which in turn might be substituted by halogen, nitro, trifluoromethyl, trifluoromethoxy or by phenyl or by tetrazole-substituted phenyl, and alkyl, optionally be substituted by a group with the formula BOR_{X-22} ,

30 in which

R_{X-22} denotes a straight chain or branched acyl with up to 4 carbon atoms or benzyl,


or

R_{X-19} denotes straight chain or branched acyl with up to 20 carbon atoms or benzoyl, that is optionally substituted by halogen, trifluoromethyl, nitro or trifluoromethoxy, or it denotes straight chain or branched fluoroacyl with up to 8 carbon atoms and 9 fluorine atoms,

R_{X-20} and R_{X-21} are identical or different and denote hydrogen, phenyl or straight chain or branched alkyl with up to 6 carbon atoms,

or

R_{X-20} and R_{X-21} together form a 3- to 6- membered carbocyclic ring, and the carbocyclic rings formed are optionally substituted, optionally also geminally, with up to six identical or different substituents in the form of trifluoromethyl, hydroxy, nitrile, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy with 3 to 7 carbon atoms each, by straight chain or branched alkoxy carbonyl, alkoxy or alkylthio with up to 6 carbon atoms each or by straight chain or branched alkyl with up to 6 carbon atoms, which in turn is substituted with up to 2 identically or differently by hydroxyl, benzyloxy, trifluoromethyl, benzoyl, straight chain or branched alkoxy, oxyacyl or carbonyl with up to 4 carbon atoms each and/or phenyl, which may in turn be substituted with a halogen, trifluoromethyl or trifluoromethoxy, and/or the formed carbocyclic rings are optionally substituted, also geminally, with up to 5 identical or different substituents in the form of phenyl, benzoyl, thiophenyl or sulfonylbenzyl, which in turn are optionally substituted by halogen, trifluoromethyl, trifluoromethoxy or nitro, and/or optionally are substituted by a radical with the formula




in which

c denotes a number equaling 1, 2, 3, or 4,

d denotes a number equaling 0 or 1,

R_{X-23} and R_{X-24} are identical or different and denote hydrogen, cycloalkyl with 3 to 6 carbon atoms, straight chain or branched alkyl with up to 6 carbon atoms, benzyl or phenyl, that is optionally substituted with up to 2 identically or differently by halogen, trifluoromethyl, cyano, phenyl or nitro, and/or the formed carbocyclic rings are substituted optionally by a spiro-linked radical with the formula

-59-



in which

W_x denotes either an oxygen or a sulfur atom

5 Y_x and Y'_x together form a 2 to 6 membered straight chain or branched alkylene chain,

e denotes a number equaling 1, 2, 3, 4, 5, 6, or 7,

f denotes a number equaling 1 or 2,


10 R_{x-25} , R_{x-26} , R_{x-27} , R_{x-28} , R_{x-29} , R_{x-30} and R_{x-31} are identical or different and denote hydrogen, trifluoromethyl, phenyl, halogen or straight chain or branched alkyl or alkoxy with up to 6 carbon atoms each,

or

R_{x-25} and R_{x-26} or R_{x-27} and R_{x-28} respectively form together a straight chain or branched alkyl chain with up to 6 carbon atoms,

15 or

R_{x-25} and R_{x-26} or R_{x-27} and R_{x-28} each together form a radical with the formula



in which

W_x has the meaning given above,

20 g denotes a number equaling 1, 2, 3, 4, 5, 6, or 7,

R_{x-32} and R_{x-33} form together a 3- to 7- membered heterocycle, which contains an oxygen or sulfur atom or a group with the formula SO , SO_2 or

$-NR_{x-34}$,

in which

25 R_{x-34} denotes hydrogen, phenyl, benzyl or straight or branched alkyl with up to 4 carbon atoms.

Compounds of Formula X are disclosed in WO 9914215, the complete disclosure of which is incorporated by reference.


In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula X:

2-cyclopentyl-5-hydroxy-7,7-dimethyl-4-(3-thienyl)-3-(4-trifluoromethylbenzoyl)-5,6,7,8-tetrahydroquinoline;

2-cyclopentyl-3-[fluoro-(4-trifluoromethylphenyl)methyl]-5-hydroxy-7,7-dimethyl-4-(3-thienyl)-5,6,7,8-tetrahydroquinoline; and

2-cyclopentyl-5-hydroxy-7,7-dimethyl-4-(3-thienyl)-3-(trifluoromethylbenzyl)-5,6,7,8-tetrahydroquinoline.

Another class of CETP inhibitors that finds utility with the present invention consists of substituted tetrahydro naphthalines and analogous compound having the Formula XI



Formula XI

and stereoisomers, stereoisomer mixtures, and salts thereof, in which

A_{XI} stands for cycloalkyl with 3 to 8 carbon atoms, or stands for aryl with 6 to 10 carbon atoms, or stands for a 5- to 7-membered, saturated, partially unsaturated or unsaturated, possibly benzocondensated, heterocycle with up to 4 heteroatoms from the series S, N and/or O, where aryl and the heterocyclic ring systems mentioned above are substituted up to 5-fold, identical or different, by cyano, halogen, nitro, carboxyl, hydroxy, trifluoromethyl, trifluoro- methoxy, or by straight-chain or branched alkyl, acyl, hydroxyalkyl, alkylthio, alkoxycarbonyl, oxyalkoxycarbonyl or alkoxy each with up to 7 carbon atoms, or by a group of the formula


-NR_{XI-3}R_{XI-4},

in which

R_{XI-3} and R_{XI-4} are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms

D_{XI} stands for a radical of the formula

-61-



in which

- R_{X1-5} , R_{X1-6} and R_{X1-9} , independent of each other, denote cycloalkyl with 3 to 6 carbon atoms, or denote aryl with 6 to 10 carbon atoms, or denote a 5- to 7-membered, possibly benzocondensated, saturated or unsaturated, mono-, bi- or tricyclic heterocycle with up to 4 heteroatoms of the series S, N and/or O, where the cycles are possibly substituted in the case of the nitrogen-containing rings also via the N-function up to 5-fold, identical or different, by halogen, trifluoromethyl, nitro, hydroxy, cyano, carboxyl, trifluoromethoxy, straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl with up to 6 carbon atoms each, by aryl or trifluoromethyl substituted aryl with 6 to 10 carbon atoms each, or by a possibly benzocondensated aromatic 5- to 7-membered heterocycle with up to 3 heteroatoms of the series S, N and/or O, and/or are substituted by a group of the formula $-OR_{X1-10}$, $-SR_{X1-11}$, $-SO_2R_{X1-12}$ or $-NR_{X1-13}R_{X1-14}$,


in which

R_{X1-10} , R_{X1-11} and R_{X1-12} , independent of each other, denote aryl with 6 to 10 carbon atoms, which itself is substituted up to 2-fold, identical or different, by phenyl, halogen, or by straight-chain or branched alkyl with up to 6 carbon atoms,

R_{X1-13} and R_{X1-14} are identical or different and have the meaning given above for R_{X1-3} and R_{X1-4} ,

or

R_{X1-5} and/or R_{X1-6} denote a radical of the formula



R_{X1-7} denotes hydrogen, halogen or methyl,

and

R_{X1-8} denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy or alkyl with up to 6 carbon atoms each, or a radical of the formula $-NR_{X1-15}R_{X1-16}$,

in which

R_{X1-15} and R_{X1-16} are identical or different and have the meaning given above for R_{X1-3} and R_{X1-4} ,

or

- 5 R_{X1-7} and R_{X1-8} together form a radical of the formula $=O$ or $=NR_{X1-17}$, in which R_{X1-17} denotes hydrogen or straight-chain or branched alkyl, alkoxy or acyl with up to 6 carbon atoms each,

L_{X1} denotes a straight-chain or branched alkylene- or alkenylene chain with up to 8 carbon atoms each, which is possibly substituted up to 2-fold by hydroxy,

- 10 T_{X1} and X_{X1} are identical or different and denote a straight-chain or branched alkylene chain with up to 8 carbon atoms,

or

T_{X1} and X_{X1} denotes a bond,


V_{X1} stands for an oxygen- or sulfur atom or for an $-NR_{X1-18}$ group,

in which

- 15 R_{X1-18} denotes hydrogen or straight-chain or branched alkyl with up to 6 carbon atoms, or phenyl,

- 20 E_{X1} stands for cycloalkyl with 3 to 8 carbon atoms, or stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by cycloalkyl with 3 to 8 carbon atoms or hydroxy, or stands for phenyl, which is possibly substituted by halogen or trifluoromethyl,

R_{X1-1} and R_{X1-2} together form a straight-chain or branched alkylene chain with up to 7 carbon atoms, which must be substituted by a carbonyl group and/or by a radical of the formula



- 25 in which

a and b are identical or different and denote a number 1, 2 or 3

- 30 R_{X1-19} denotes hydrogen, cycloalkyl with 3 to 7 carbon atoms, straight-chain or branched silylalkyl with up to 8 carbon atoms, or straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by hydroxy, straight-chain or branched alkoxy with up to 6 carbon atoms, or by phenyl, which itself can be substituted by halogen, nitro, trifluoromethyl, trifluoromethoxy or by phenyl substituted

by phenyl or tetrazol, and alkyl is possibly substituted by a group of the formula $-OR_{X1}$.

22.

in which

5 R_{X1-22} denotes straight-chain or branched acyl with up to 4 carbon atoms, or benzyl, or


10 R_{X1-19} denotes straight-chain or branched acyl with up to 20 carbon atoms or benzoyl, which is possibly substituted by halogen, trifluoromethyl, nitro or trifluoromethoxy, or denotes straight-chain or branched fluoroacyl with up to 8 carbon atoms and 9 fluorine atoms,

R_{X1-20} and R_{X1-21} are identical or different, denoting hydrogen, phenyl or straight-chain or branched alkyl with up to 6 carbon atoms, or

15 R_{X1-20} and R_{X1-21} together form a 3- to 6-membered carbocycle, and, possibly also geminally, the alkylene chain formed by R_{X1-1} and R_{X1-2} , is possibly substituted up to 6-fold, identical or different, by trifluoromethyl, hydroxy, nitrile, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy with 3 to 7 carbon atoms each, by straight-chain or branched alkoxy carbonyl, alkoxy or alkoxythio with up to 6 carbon atoms each, or by straight-chain or branched alkyl with up to 6 carbon atoms, which

20 itself is substituted up to 2-fold, identical or different, by hydroxyl, benzyloxy, trifluoromethyl, benzoyl, straight-chain or branched alkoxy, oxyacyl or carboxyl with up to 4 carbon atoms each, and/or phenyl- which itself can be substituted by halogen, trifluoromethyl or trifluoromethoxy, and/or the alkylene chain formed by R_{X1-1} and R_{X1-2} is substituted, also geminally,

25 possibly up to 5-fold, identical or different, by phenyl, benzoyl, thiophenyl or sulfobenzyl -which themselves are possibly substituted by halogen, trifluoromethyl, trifluoromethoxy or nitro, and/or the alkylene chain formed by R_{X1-1} and R_{X1-2} is possibly substituted by a radical of the formula




in which

c denotes a number 1, 2, 3 or 4,


d denotes a number 0 or 1,

- R_{X1-23} and R_{X1-24} are identical or different and denote hydrogen, cycloalkyl with 3 to 6 carbon atoms, straight-chain or branched alkyl with up to 6 carbon atoms, benzyl or phenyl, which is possibly substituted up to 2-fold, identical or different, by halogen, trifluoromethyl, cyano, phenyl or nitro, and/or the alkylene chain formed by R_{X1-1} and R_{X1-2} is possibly substituted by a spiro-jointed radical of the formula



in which

- W_{X1} denotes either an oxygen or a sulfur atom,
- Y_{X1} and Y'_{X1} together form a 2- to 6-membered straight-chain or branched alkylene chain,
- e is a number 1, 2, 3, 4, 5, 6 or 7,
- f denotes a number 1 or 2,
- R_{X1-25} , R_{X1-26} , R_{X1-27} , R_{X1-28} , R_{X1-29} , R_{X1-30} and R_{X1-31} are identical or different and denote hydrogen, trifluoromethyl, phenyl, halogen, or straight-chain or branched alkyl or alkoxy with up to 6 carbon atoms each,
- or
- R_{X1-25} and R_{X1-26} or R_{X1-27} and R_{X1-28} together form a straight-chain or branched alkyl chain with up to 6 carbon atoms,
- or
- R_{X1-25} and R_{X1-26} or R_{X1-27} and R_{X1-28} together form a radical of the formula




in which

- W_{X1} has the meaning given above,
- g is a number 1, 2, 3, 4, 5, 6 or 7,
- R_{X1-32} and R_{X1-33} together form a 3- to 7-membered heterocycle that contains an oxygen- or sulfur atom or a group of the formula SO, SO₂ or -NR_{X1-34},
- in which

R_{XI-34} denotes hydrogen, phenyl, benzyl, or straight-chain or branched alkyl with up to 4 carbon atoms.

Compounds of Formula XI are disclosed in WO 9914174, the complete disclosure of which is incorporated by reference.

- 5 Another class of CETP inhibitors that finds utility with the present invention consists of 2-aryl-substituted pyridines having the Formula (XII)



Formula XII

- 10 or pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds,
in which


- A_{XII} and E_{XII} are identical or different and stand for aryl with 6 to 10 carbon atoms which is possibly substituted, up to 5-fold identical or different, by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, nitro or by straight-chain or branched alkyl, acyl, hydroxy alkyl or alkoxy with up to 7 carbon atoms each, or by a group of the formula $-NR_{XII-1}R_{XII-2}$,
15 where

R_{XII-1} and R_{XII-2} are identical or different and are meant to be hydrogen, phenyl or straight-chain or branched alkyl with up to 6 carbon atoms,

- 20 D_{XII} stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is substituted by hydroxy,

L_{XII} stands for cycloalkyl with 3 to 8 carbon atoms or for straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by cycloalkyl with 3 to 8 carbon atoms, or by hydroxy,

- 25 T_{XII} stands for a radical of the formula $R_{XII-3}-X_{XII}$ or



where

R_{XII-3} and R_{XII-4} are identical or different and are meant to be cycloalkyl with 3 to

8 carbon atoms, or aryl with 6 to 10 carbon atoms, or a 5- to 7-membered aromatic, possibly benzocondensated heterocycle with up to 3 heteroatoms from the series S, N and/or O, which are possibly substituted. up to 3-fold identical or different, by trifluoromethyl, trifluoromethoxy, halogen, hydroxy, carboxyl, nitro, by straight-chain or
 5 branched alkyl, acyl, alkoxy or alkoxycarbonyl with up to 6 carbon atoms each. or by phenyl, phenoxy or phenylthio which in turn can be substituted by halogen. trifluoromethyl or trifluoromethoxy, and/or where the cycles are possibly substituted by a group of the formula $-NR_{XII-7}R_{XII-8}$,
 where

10 R_{XII-7} and R_{XII-8} are identical or different and have the meaning of R_{XII-1} and R_{XII-2} given above,

X_{XII} is a straight-chain or branched alkyl or alkenyl with 2 to 10 carbon atoms each, possibly substituted up to 2-fold by hydroxy or halogen,

R_{XII-5} stands for hydrogen,

15 and

R_{XII-6} means to be hydrogen, halogen, mercapto, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy with up to 5 carbon atoms, or a radical of the formula $BNR_{XII-9}R_{XII-10}$,

where

20 R_{XII-9} and R_{XII-10} are identical or different and have the meaning of R_{XII-1} and R_{XII-2} given above,

or


R_{XII-5} and R_{XII-6} , together with the carbon atom, form a carbonyl group.

Compounds of Formula XII are disclosed in EP 796846-A1, U.S. Patent
 25 6,127,383 and U.S. Patent 5,925,645 the complete disclosures of which are incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XII:

- 30 4,6-bis-(p-fluorophenyl)-2-isopropyl-3-[(p-trifluoromethylphenyl)-(fluoro)-methyl]-5-(1-hydroxyethyl)pyridine;
- 2,4-bis-(4-fluorophenyl)-6-isopropyl-5-[4-(trifluoromethylphenyl)-fluoromethyl]-3-hydroxymethylpyridine; and
- 35 2,4-bis-(4-fluorophenyl)-6-isopropyl-5-[2-(3-trifluoromethylphenyl)vinyl]-3-hydroxymethylpyridine.

Another class of CETP inhibitors that finds utility with the present invention consists of compounds having the Formula (XIII)



Formula XIII

or pharmaceutically acceptable salts, enantiomers, stereoisomers, hydrates, or solvates of said compounds, in which

- 10 R_{XIII} is a straight chain or branched C_{1-10} alkyl; straight chain or branched C_{2-10} alkenyl; halogenated C_{1-4} lower alkyl; C_{3-10} cycloalkyl that may be substituted; C_{5-8} cycloalkenyl that may be substituted; C_{3-10} cycloalkyl C_{1-10} alkyl that may be substituted; aryl that may be substituted; aralkyl that may be substituted; or a 5- or 6-membered heterocyclic group having 1 to 3 nitrogen atoms, oxygen atoms or sulfur
- 15 atoms that may be substituted,

X_{XIII-1} , X_{XIII-2} , X_{XIII-3} , X_{XIII-4} may be the same or different and are a hydrogen atom; halogen atom; C_{1-4} lower alkyl; halogenated C_{1-4} lower alkyl; C_{1-4} lower alkoxy; cyano group; nitro group; acyl; or aryl, respectively;

Y_{XIII} is $-CO-$; or BSO_2- ; and

- 20 Z_{XIII} is a hydrogen atom; or mercapto protective group.

Compounds of Formula XIII are disclosed in WO 98/35937, the complete disclosure of which is incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XIII:


25

N,N'-(dithiodi-2,1-phenylene)bis[2,2-dimethyl-propanamide];

N,N'-(dithiodi-2,1-phenylene)bis[1-methyl-cyclohexanecarboxamide];

- N,N'-(dithiodi-2,1-phenylene)bis[1-(3-methylbutyl)-cyclopentanecarboxamide];
- N,N'-(dithiodi-2,1-phenylene)bis[1-(3-methylbutyl)-cyclohexanecarboxamide];
- 5 N,N'-(dithiodi-2,1-phenylene)bis[1-(2-ethylbutyl)-cyclohexanecarboxamide];
- N,N'-(dithiodi-2,1-phenylene)bis-tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide;
- 10 propanethioic acid, 2-methyl-, S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] ester;
- propanethioic acid, 2,2-dimethyl-, S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] ester; and
- 15 ethanethioic acid, S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] ester.

- Another class of CETP inhibitors that finds utility with the present invention
- 20 consists of polycyclic aryl and heteroaryl tertiary-heteroalkylamines having the Formula XIV



Formula XIV

and pharmaceutically acceptable forms thereof, wherein:

n_{XIV} is an integer selected from 0 through 5;

5 R_{XIV-1} is selected from the group consisting of haloalkyl, haloalkenyl, haloalkoxyalkyl, and haloalkenyloxyalkyl;

X_{XIV} is selected from the group consisting of O, H, F, S, S(O), NH, N(OH), N(alkyl), and N(alkoxy);

10 R_{XIV-16} is selected from the group consisting of hydrido, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, aralkoxyalkyl, heteroaralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, monocarboalkoxyalkyl, monocarboalkoxy, dicarboalkoxyalkyl, monocarboxamido, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, dialkoxylphosphonoalkyl, trialkylsilyl, and a spacer selected from the group consisting of a covalent single bond and a linear spacer moiety having from 1 through 4 contiguous atoms linked to the point of bonding of an aromatic substituent selected from the group consisting of R_{XIV-4} , R_{XIV-8} , R_{XIV-9} , and R_{XIV-13} to form a heterocycl ring having from 5 through 10 contiguous members with the provisos that said spacer moiety is other than a covalent single bond when R_{XIV-2} is alkyl and there is no R_{XIV-16} wherein X is H or F;

25 D_{XIV-1} , D_{XIV-2} , J_{XIV-1} , J_{XIV-2} and K_{XIV-1} are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one of D_{XIV-1} , D_{XIV-2} , J_{XIV-1} , J_{XIV-2} and K_{XIV-1} is a covalent bond, no more than one of D_{XIV-1} , D_{XIV-2} , J_{XIV-1} , J_{XIV-2} and K_{XIV-1} is O, no more than one of D_{XIV-1} , D_{XIV-2} , J_{XIV-1} , J_{XIV-2} and K_{XIV-1} is S, one of D_{XIV-1} , D_{XIV-2} , J_{XIV-1} , J_{XIV-2} and K_{XIV-1} must be a covalent bond when two of D_{XIV-1} , D_{XIV-2} , J_{XIV-1} , J_{XIV-2} and K_{XIV-1} are O and S, and no more than four of D_{XIV-1} , D_{XIV-2} , J_{XIV-1} , J_{XIV-2} and K_{XIV-1} are N;

D_{XIV-3} , D_{XIV-4} , J_{XIV-3} , J_{XIV-4} and K_{XIV-2} are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one

-70-

of D_{XIV-3} , D_{XIV-4} , J_{XIV-3} , J_{XIV-4} and K_{XIV-2} is a covalent bond, no more than one of D_{XIV-3} , D_{XIV-4} , J_{XIV-3} , J_{XIV-4} and K_{XIV-2} is O, no more than one of D_{XIV-3} , D_{XIV-4} , J_{XIV-3} , J_{XIV-4} and K_{XIV-2} is S, one of D_{XIV-3} , D_{XIV-4} , J_{XIV-3} , J_{XIV-4} and K_{XIV-2} must be a covalent bond when two of D_{XIV-3} , D_{XIV-4} , J_{XIV-3} , J_{XIV-4} and K_{XIV-2} are O and S, and no more than four of D_{XIV-3} , D_{XIV-4} , J_{XIV-3} , J_{XIV-4} and K_{XIV-2} are N;

- 5 R_{XIV-2} is independently selected from the group consisting of hydrido, hydroxy, hydroxyalkyl, amino, aminoalkyl, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkoxyalkyl, aryloxyalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, aralkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, 10 cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, alkoalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocynoalkyl, 15 dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, 20 aralkylsulfonylalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyposphono, diaralkoxyposphono, dialkoxyposphonoalkyl, and diaralkoxyposphonoalkyl;

- R_{XIV-2} and R_{XIV-3} are taken together to form a linear spacer moiety selected from the group consisting of a covalent single bond and a moiety having from 1 through 6 25 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl having from 3 through 8 contiguous members, a cycloalkenyl having from 5 through 8 contiguous members, and a heterocyclyl having from 4 through 8 contiguous members;

- R_{XIV-3} is selected from the group consisting of hydrido, hydroxy, halo, cyano, 30 aryloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, acyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyl, heteroarylthio, aralkylthio, aralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, aroyl, heteroaroyl, aralkylthioalkyl,

- heteroaralkylthioalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy,
- 5 halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, aralkylsulfinyl, aralkylsulfonyl,
- 10 cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsulfonylalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyposphono, diaralkoxyposphono, dialkoxyposphonoalkyl, and diaralkoxyposphonoalkyl;
- 15 Y_{XIV} is selected from a group consisting of a covalent single bond, $(C(R_{XIV-14})_2)_{q_{XIV}}$ wherein q_{XIV} is an integer selected from 1 and 2 and $(CH(R_{XIV-14}))_{p_{XIV}}-W_{XIV}$ wherein p_{XIV} and q_{XIV} are integers independently selected from 0 and 1; R_{XIV-14} is independently selected from the group consisting of hydrido, hydroxy, halo, cyano, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, acyl, aryl,
- 20 heteroaroyl, heteroaryloxyalkyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkylalkoxy, alkylsulfinylalkyl, alkylsulfonylalkyl, aralkylthioalkyl, heteroaralkoxythioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl,
- 25 halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl,
- 30 aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsulfonylalkyl,

carboxy, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyphosphono, diaralkoxyphosphono, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, a spacer selected from a moiety having a chain length of 3 to 6 atoms connected to the point of bonding selected from the group consisting of R_{XIV-9} and R_{XIV-13} to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members and a heterocyclyl ring having from 5 through 8 contiguous members and a spacer selected from a moiety having a chain length of 2 to 5 atoms connected to the point of bonding selected from the group consisting of R_{XIV-4} and R_{XIV-8} to form a heterocyclyl having from 5 through 8 contiguous members with the proviso that, when Y_{XIV} is a covalent bond, an R_{XIV-14} substituent is not attached to Y_{XIV} ;

R_{XIV-14} and R_{XIV-14} , when bonded to the different atoms, are taken together to form a group selected from the group consisting of a covalent bond, alkylene, haloalkylene, and a spacer selected from a group consisting of a moiety having a chain length of 2 to 5 atoms connected to form a ring selected from the group of a saturated cycloalkyl having from 5 through 8 contiguous members, a cycloalkenyl having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;

R_{XIV-14} and R_{XIV-14} , when bonded to the same atom are taken together to form a group selected from the group consisting of oxo, thiono, alkylene, haloalkylene, and a spacer selected from the group consisting of a moiety having a chain length of 3 to 7 atoms connected to form a ring selected from the group consisting of a cycloalkyl having from 4 through 8 contiguous members, a cycloalkenyl having from 4 through 8 contiguous members, and a heterocyclyl having from 4 through 8 contiguous members;

W_{XIV} is selected from the group consisting of O, C(O), C(S), C(O)N(R_{XIV-14}), C(S)N(R_{XIV-14}), (R_{XIV-14})NC(O), (R_{XIV-14})NC(S), S, S(O), S(O)₂, S(O)₂N(R_{XIV-14}), (R_{XIV-14})NS(O)₂, and N(R_{XIV-14}) with the proviso that R_{XIV-14} is selected from other than halo and cyano;

Z_{XIV} is independently selected from a group consisting of a covalent single bond, (C(R_{XIV-15})₂)_{q_{XIV-2}} wherein q_{XIV-2} is an integer selected from 1 and 2, (CH(R_{XIV-15}))_{j_{XIV}}-W-(CH(R_{XIV-15}))_{k_{XIV}} wherein j_{XIV} and k_{XIV} are integers independently selected from 0 and 1 with the proviso that, when Z_{XIV} is a covalent single bond, an R_{XIV-15} substituent is not attached to Z_{XIV} ;

- R_{XIV-15} is independently selected, when Z_{XIV} is $(C(R_{XIV-15})_2)_{q_{XIV}}$ wherein q_{XIV} is an integer selected from 1 and 2, from the group consisting of hydrido, hydroxy, halo, cyano, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsulfonylalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyposphono, diaralkoxyposphono, dialkoxyposphonoalkyl, diaralkoxyposphonoalkyl, a spacer selected from a moiety having a chain length of 3 to 6 atoms connected to the point of bonding selected from the group consisting of R_{XIV-4} and R_{XIV-8} to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members and a heterocyclyl ring having from 5 through 8 contiguous members, and a spacer selected from a moiety having a chain length of 2 to 5 atoms connected to the point of bonding selected from the group consisting of R_{XIV-9} and R_{XIV-13} to form a heterocyclyl having from 5 through 8 contiguous members;

R_{XIV-15} and R_{XIV-15} , when bonded to the different atoms, are taken together to form a group selected from the group consisting of a covalent bond, alkylene, haloalkylene, and a spacer selected from a group consisting of a moiety having a chain length of 2 to 5 atoms connected to form a ring selected from the group of a

saturated cycloalkyl having from 5 through 8 contiguous members, a cycloalkenyl having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;

R_{XIV-15} and R_{XIV-15} , when bonded to the same atom are taken together to form a group selected from the group consisting of oxo, thiono, alkylene, haloalkylene, and a spacer selected from the group consisting of a moiety having a chain length of 3 to 7 atoms connected to form a ring selected from the group consisting of a cycloalkyl having from 4 through 8 contiguous members, a cycloalkenyl having from 4 through 8 contiguous members, and a heterocyclyl having from 4 through 8 contiguous members;

R_{XIV-15} is independently selected, when Z_{XIV} is $(CH(R_{XIV-15}))_{p_{XIV}}-W-(CH(R_{XIV-15}))_{q_{XIV}}$ wherein p_{XIV} and q_{XIV} are integers independently selected from 0 and 1, from the group consisting of hydrido, halo, cyano, aryloxy, carboxyl, acyl, aroyl, heteroaroyl, hydroxyalkyl, heteroaryloxyalkyl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyl, heteroaryloxyalkyl, aralkoxyalkyl, heteroaralkoxyalkyl, alkylsulfonylalkyl, alkylsulfinylalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsulfonylalkyl, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyposphonoalkyl, diaralkoxyphosphonoalkyl, a spacer selected from a linear moiety having a chain length of 3 to 6 atoms connected to the point of bonding selected from the group consisting of R_{XIV-4} and R_{XIV-8} to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members and a heterocyclyl ring having from 5 through 8 contiguous members, and a spacer

selected from a linear moiety having a chain length of 2 to 5 atoms connected to the point of bonding selected from the group consisting of R_{XIV-9} and R_{XIV-13} to form a heterocyclyl ring having from 5 through 8 contiguous members;

- R_{XIV-4} , R_{XIV-5} , R_{XIV-6} , R_{XIV-7} , R_{XIV-8} , R_{XIV-9} , R_{XIV-10} , R_{XIV-11} , R_{XIV-12} , and R_{XIV-13} are
- 5 independently selected from the group consisting of perhaloaryloxy, alkanoylalkyl, alkanoylalkoxy, alkanoyloxy, N-aryl-N-alkylamino, heterocyclalkoxy, heterocyclithio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenylalkoxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamido, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy,
 - 10 heterocyclcarbonyl, hydrido, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclloxy, aralkylaryl, aralkyl, aralkenyl, aralkylaryl, heterocycl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, heteroarylramino, N-
 - 15 heteroarylramino-N-alkylramino, heteroarylraminoalkyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, heteroaralkoxy, cycloalkoxy, cycloalkenylalkoxy, cycloalkoxyalkyl, cycloalkylalkoxy, cycloalkenylalkoxyalkyl, cycloalkylenedioxy, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenylalkoxy, halocycloalkenylalkoxyalkyl, hydroxy, amino, thio, nitro, lower alkylramino, alkylthio, alkylthioalkyl,
 - 20 arylramino, aralkylramino, arylthio, arylthioalkyl, heteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl, arylsulfinylalkyl, arylsulfonylalkyl, heteroarylulfinylalkyl, heteroarylulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, haloalkylsulfinylalkyl, haloalkylsulfonylalkyl, alkylsulfonamido, alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, monoaryl amidosulfonyl, arylsulfonyl, arylsulfonyl,
 - 25 diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylulfinyl, heteroarylulfonyl, heterocyclsulfonyl, heterocyclthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenylalkoxy, alkenylalkoxyalkyl, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, cycloalkenyl, lower cycloalkylalkyl,
 - 30 lower cycloalkenylalkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, hydroxyheteroaralkyl, haloalkoxyalkyl, aryl, heteroaralkynyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocycl, partially saturated heterocycl, heteroaryl, heteroarylalkoxy, heteroarylalkoxyalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido,

- alkylamidocarbonylamido, arylamidocarbonylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbhaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl with the proviso that there are one to five non-hydrido ring substituents R_{XIV-4} , R_{XIV-5} , R_{XIV-6} , R_{XIV-7} , and R_{XIV-8} present, that there are one to five non-hydrido ring substituents R_{XIV-9} , R_{XIV-10} , R_{XIV-11} , R_{XIV-12} , and R_{XIV-13} present, and R_{XIV-4} , R_{XIV-5} , R_{XIV-6} , R_{XIV-7} , R_{XIV-8} , R_{XIV-9} , R_{XIV-10} , R_{XIV-11} , R_{XIV-12} , and R_{XIV-13} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- 10 R_{XIV-4} and R_{XIV-5} , R_{XIV-5} and R_{XIV-6} , R_{XIV-6} and R_{XIV-7} , R_{XIV-7} and R_{XIV-8} , R_{XIV-8} and R_{XIV-9} , R_{XIV-9} and R_{XIV-10} , R_{XIV-10} and R_{XIV-11} , R_{XIV-11} and R_{XIV-12} , and R_{XIV-12} and R_{XIV-13} are independently selected to form spacer pairs wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group
- 15 consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the provisos that no more than one of the group consisting of spacer pairs R_{XIV-4} and R_{XIV-5} , R_{XIV-5} and R_{XIV-6} , R_{XIV-6} and R_{XIV-7} , and R_{XIV-7} and R_{XIV-8} are used at the same time and that no more than one
- 20 of the group consisting of spacer pairs R_{XIV-9} and R_{XIV-10} , R_{XIV-10} and R_{XIV-11} , R_{XIV-11} and R_{XIV-12} , and R_{XIV-12} and R_{XIV-13} are used at the same time;
- R_{XIV-4} and R_{XIV-9} , R_{XIV-4} and R_{XIV-13} , R_{XIV-8} and R_{XIV-9} , and R_{XIV-8} and R_{XIV-13} are independently selected to form a spacer pair wherein said spacer pair is taken together to form a linear moiety wherein said linear moiety forms a ring selected from
- 25 the group consisting of a partially saturated heterocyclyl ring having from 5 through 8 contiguous members and a heteroaryl ring having from 5 through 6 contiguous members with the proviso that no more than one of the group consisting of spacer pairs R_{XIV-4} and R_{XIV-9} , R_{XIV-4} and R_{XIV-13} , R_{XIV-8} and R_{XIV-9} , and R_{XIV-8} and R_{XIV-13} is used at the same time.
- 30 Compounds of Formula XIV are disclosed in WO 00/18721, the entire disclosure of which is incorporated by reference.
- In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XIV:

- 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[3-(3-isopropylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-cyclopropylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(3-(2-furyl)phenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(2,3-dichlorophenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-fluorophenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(4-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(3-t-butylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50 3-[[3-(phenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

- 3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethyl)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-dimethylphenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-difluorophenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[cyclohexylmethoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-difluoromethoxyphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][3-(pentafluoroethylmethyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-isopropylphenoxy)phenyl][3-(pentafluoroethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(3-cyclopropylphenoxy)phenyl][3-(pentafluoroethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(3-(2-furyl)phenoxy)phenyl][3-(pentafluoroethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2,3-dichlorophenoxy)phenyl][3-(pentafluoroethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 50

- 3-[[3-(4-fluorophenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[3-(4-methylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[3-(pentafluoroethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-ethylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(3-*t*-butylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-methylphenoxy)phenyl][[3-pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(phenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-[3-(*N,N*-dimethylamino)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[[3-(pentafluoroethyl)phenyl]methyl][[3-[[3-(trifluoromethoxy)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-(trifluoromethyl)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3,5-dimethylphenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 50 3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-

-80-

- (trifluoromethylthio)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3,5-difluorophenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[cyclohexylmethoxy]phenyl]-amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(3-difluoromethoxyphenoxy)phenyl][3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(3-isopropylphenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-(3-cyclopropylphenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-(2-furyl)phenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(2,3-dichlorophenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-fluorophenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(4-methylphenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(2-fluoro-5-bromophenoxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 50

- 3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][3-(heptafluoropropyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3,5-dimethylphenoxy)phenyl][3-(heptafluoropropyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(3-ethylphenoxy)phenyl][3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-t-butylphenoxy)phenyl][3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(3-methylphenoxy)phenyl][3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(phenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trifluoromethoxy)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trifluoromethyl)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3,5-dimethylphenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trifluoromethylthio)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3,5-difluorophenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[cyclohexylmethoxy]phenyl]-amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50 3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;

- 3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-(heptafluoropropyl)-phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-isopropylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(3-cyclopropylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-(2-furyl)phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(2,3-dichlorophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2,3-dichlorophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(4-fluorophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(3,5-dimethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-ethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(3-t-butylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 50


- 3-[[3-(3-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
 - 5 3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 3-[[3-(phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 10 3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
 - 15 3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethyl)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
 - 20 3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3,5-dimethylphenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
 - 3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
 - 25 3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3,5-difluorophenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
 - 3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[cyclohexylmethoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
 - 30 3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 35 3-[[3-(3-difluoromethoxyphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 40 3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 45 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 3-[[3-(3-isopropylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
 - 50

- 3-[[3-(3-cyclopropylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[3-(3-(2-furyl)phenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2,3-dichlorophenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(4-fluorophenoxy)phenyl][[2-fluoro-4-(trifluoromethyl) phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-methylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl) phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3,5-dimethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-(3-ethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-t-butylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(3-methylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(5,6,7,8- tetrahydro-2-naphthoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(phenoxy)phenyl][[2-fluoro-4-(trifluoromethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50 3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;

- 3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethyl)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3,5-dimethylphenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3,5-difluorophenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[cyclohexylmethoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(3-difluoromethoxyphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol; and
- 30 3-[[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol.

Another class of CETP inhibitors that finds utility with the present invention consists of substituted N-Aliphatic-N-Aromatic *tertiary*-Heteroalkylamines having the Formula XV

35



Formula XV


and pharmaceutically acceptable forms thereof, wherein:

-86-


n_{XV} is an integer selected from 1 through 2;

A_{XV} and Q_{XV} are independently selected from the group consisting of

AQ-1



AQ-2



- 5 with the provisos that one of A_{XV} and Q_{XV} must be AQ-1 and that one of A_{XV} and Q_{XV} must be selected from the group consisting of AQ-2 and $-\text{CH}_2(\text{CR}_{XV-37}\text{R}_{XV-38})_{n_{XV}}-(\text{CR}_{XV-33}\text{R}_{XV-34})_{m_{XV}}-\text{T}_{XV}-(\text{CR}_{XV-35}\text{R}_{XV-36})_{p_{XV}}-\text{H}$;

T_{XV} is selected from the group consisting of a single covalent bond, O, S, S(O), S(O)₂, C(R_{XV-33})=C(R_{XV-35}), and

C \equiv C;

w_{XV} is an integer selected from 0 through 1 with the proviso that w_{XV} is 1 when any one of R_{XV-33} , R_{XV-34} , R_{XV-35} , and R_{XV-36} is aryl or heteroaryl;

w_{XV} and w_{XV} are integers independently selected from 0 through 6;

A_{XV-1} is $C(R_{XV-30})$;

- 5 D_{XV-1} , D_{XV-2} , J_{XV-1} , J_{XV-2} , and K_{XV-1} are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one of D_{XV-1} , D_{XV-2} , J_{XV-1} , J_{XV-2} , and K_{XV-1} is a covalent bond, no more than one of D_{XV-1} , D_{XV-2} , J_{XV-1} , J_{XV-2} , and K_{XV-1} is O, no more than one of D_{XV-1} , D_{XV-2} , J_{XV-1} , J_{XV-2} , and K_{XV-1} is S, one of D_{XV-1} , D_{XV-2} , J_{XV-1} , J_{XV-2} , and K_{XV-1} must be a covalent bond when two of D_{XV-1} , D_{XV-2} , J_{XV-1} , J_{XV-2} , and K_{XV-1} are O and S, and no more than four of D_{XV-1} , D_{XV-2} , J_{XV-1} , J_{XV-2} , and K_{XV-1} are N;

- 15 B_{XV-1} , B_{XV-2} , D_{XV-3} , D_{XV-4} , J_{XV-3} , J_{XV-4} , and K_{XV-2} are independently selected from the group consisting of C, $C(R_{XV-30})$, N, O, S and a covalent bond with the provisos that no more than 5 of B_{XV-1} , B_{XV-2} , D_{XV-3} , D_{XV-4} , J_{XV-3} , J_{XV-4} , and K_{XV-2} are a covalent bond, no more than two of B_{XV-1} , B_{XV-2} , D_{XV-3} , D_{XV-4} , J_{XV-3} , J_{XV-4} , and K_{XV-2} are O, no more than two of B_{XV-1} , B_{XV-2} , D_{XV-3} , D_{XV-4} , J_{XV-3} , J_{XV-4} , and K_{XV-2} are S, no more than two of B_{XV-1} , B_{XV-2} , D_{XV-3} , D_{XV-4} , J_{XV-3} , J_{XV-4} , and K_{XV-2} are simultaneously O and S, and no more than two of B_{XV-1} , B_{XV-2} , D_{XV-3} , D_{XV-4} , J_{XV-3} , J_{XV-4} , and K_{XV-2} are N;

- 20 B_{XV-1} and D_{XV-3} , D_{XV-3} and J_{XV-3} , J_{XV-3} and K_{XV-2} , K_{XV-2} and J_{XV-4} , J_{XV-4} and D_{XV-4} , and D_{XV-4} and B_{XV-2} are independently selected to form an in-ring spacer pair wherein said

spacer pair is selected from the group consisting of $C(R_{XV-33})=C(R_{XV-35})$ and $N=N$ with the provisos that AQ-2 must be a ring of at least five contiguous members, that no more than two of the group of said spacer pairs are simultaneously

- 25 $C(R_{XV-33})=C(R_{XV-35})$ and that no more than one of the group of said spacer pairs can be $N=N$ unless the other spacer pairs are other than $C(R_{XV-33})=C(R_{XV-35})$, O, N, and S;

R_{XV-1} is selected from the group consisting of haloalkyl and haloalkoxymethyl;

R_{XV-2} is selected from the group consisting of hydrido, aryl, alkyl, alkenyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl and heteroaryl;

- 30 R_{XV-3} is selected from the group consisting of hydrido, aryl, alkyl, alkenyl, haloalkyl, and haloalkoxyalkyl;

Y_{XV} is selected from the group consisting of a covalent single bond, $(CH_2)_q$ wherein q is an integer selected from 1 through 2 and $(CH_2)_j-O-(CH_2)_k$ wherein j and k are integers independently selected from 0 through 1;

Z_{XV} is selected from the group consisting of covalent single bond, $(CH_2)_q$ wherein q is an integer selected from 1 through 2, and $(CH_2)_j-O-(CH_2)_k$ wherein j and k are integers independently selected from 0 through 1;

R_{XV-4} , R_{XV-8} , R_{XV-9} and R_{XV-13} are independently selected from the group consisting of hydrido, halo, haloalkyl, and alkyl;

R_{XV-30} is selected from the group consisting of hydrido, alkoxy, alkoxyalkyl, halo, haloalkyl, alkylamino, alkylthio, alkylthioalkyl, alkyl, alkenyl, haloalkoxy, and haloalkoxyalkyl with the proviso that R_{XV-30} is selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

R_{XV-30} , when bonded to A_{XV-1} , is taken together to form an intra-ring linear spacer connecting the A_{XV-1} -carbon at the point of attachment of R_{XV-30} to the point of bonding of a group selected from the group consisting of R_{XV-10} , R_{XV-11} , R_{XV-12} , R_{XV-31} , and R_{XV-32} wherein said intra-ring linear spacer is selected from the group consisting of a covalent single bond and a spacer moiety having from 1 through 6 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl having from 3 through 10 contiguous members, a cycloalkenyl having from 5 through 10 contiguous members, and a heterocyclyl having from 5 through 10 contiguous members;

R_{XV-30} , when bonded to A_{XV-1} , is taken together to form an intra-ring branched spacer connecting the A_{XV-1} -carbon at the point of attachment of R_{XV-30} to the points of bonding of each member of any one of substituent pairs selected from the group consisting of substituent pairs R_{XV-10} and R_{XV-11} , R_{XV-10} and R_{XV-31} , R_{XV-10} and R_{XV-32} , R_{XV-10} and R_{XV-12} , R_{XV-11} and R_{XV-31} , R_{XV-11} and R_{XV-32} , R_{XV-11} and R_{XV-12} , R_{XV-31} and R_{XV-32} , R_{XV-31} and R_{XV-12} , and R_{XV-32} and R_{XV-12} and wherein said intra-ring branched spacer is selected to form two rings selected from the group consisting of cycloalkyl having from 3 through 10 contiguous members, cycloalkenyl having from 5 through 10 contiguous members, and heterocyclyl having from 5 through 10 contiguous members;

R_{XV-4} , R_{XV-5} , R_{XV-6} , R_{XV-7} , R_{XV-8} , R_{XV-9} , R_{XV-10} , R_{XV-11} , R_{XV-12} , R_{XV-13} , R_{XV-31} , R_{XV-32} , R_{XV-33} , R_{XV-34} , R_{XV-35} , and R_{XV-36} are independently selected from the group consisting of hydrido, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocycloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl,

heterocyclyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, heteroaryl amino, N-heteroaryl amino-N-alkyl amino, heteroaryl aminoalkyl, haloalkylthio, alkanoyloxy, alkoxy, 5 alkoxyalkyl, haloalkoxyalkyl, heteroaralkoxy, cycloalkoxy, cycloalkenyl oxy, cycloalkoxyalkyl, cycloalkylalkoxy, cycloalkenyl oxyalkyl, cycloalkylenedioxy, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyl oxy, halocycloalkenyl oxyalkyl, hydroxy, amino, thio, nitro, lower alkyl amino, alkylthio, alkylthioalkyl, aryl amino, aralkyl amino, arylthio, 10 arylthioalkyl, heteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl, arylsulfinylalkyl, arylsulfonylalkyl, heteroaryl sulfinylalkyl, heteroaryl sulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, haloalkylsulfinylalkyl, haloalkylsulfonylalkyl, alkylsulfonamido, alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, monoaryl amidosulfonyl, arylsulfonamido, 15 diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroaryl sulfinyl, heteroaryl sulfonyl, heterocyclylsulfonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyl oxy, alkenyl oxyalkyl, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, cycloalkenyl, lower cycloalkylalkyl, 20 lower cycloalkenylalkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, hydroxyheteroaralkyl, haloalkoxyalkyl, aryl, heteroaralkynyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryl oxy, heteroaryl oxyalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido, 25 alkylamidocarbonylamido, alkylamidocarbonylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl with the provisos that R_{XV-4} , R_{XV-5} , R_{XV-6} , R_{XV-7} , R_{XV-8} , R_{XV-9} , R_{XV-10} , R_{XV-11} , R_{XV-12} , R_{XV-13} , R_{XV-31} , R_{XV-32} , R_{XV-33} , R_{XV-34} , R_{XV-35} , and R_{XV-36} are each 30 independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen, that no more than three of the R_{XV-33} and R_{XV-34} substituents are simultaneously selected from other than the group consisting of hydrido and halo, and that no more than three of the R_{XV-35}

and R_{XV-36} substituents are simultaneously selected from other than the group consisting of hydrido and halo;

- R_{XV-9} , R_{XV-10} , R_{XV-11} , R_{XV-12} , R_{XV-13} , R_{XV-31} , and R_{XV-32} are independently selected to be oxo with the provisos that B_{XV-1} , B_{XV-2} , D_{XV-3} , D_{XV-4} , J_{XV-3} , J_{XV-4} , and K_{XV-2} are
- 5 independently selected from the group consisting of C and S, no more than two of R_{XV-9} , R_{XV-10} , R_{XV-11} , R_{XV-12} , R_{XV-13} , R_{XV-31} , and R_{XV-32} are simultaneously oxo, and that R_{XV-9} , R_{XV-10} , R_{XV-11} , R_{XV-12} , R_{XV-13} , R_{XV-31} , and R_{XV-32} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- 10 R_{XV-4} and R_{XV-5} , R_{XV-5} and R_{XV-6} , R_{XV-6} and R_{XV-7} , R_{XV-7} and R_{XV-8} , R_{XV-9} and R_{XV-10} , R_{XV-10} and R_{XV-11} , R_{XV-11} and R_{XV-31} , R_{XV-31} and R_{XV-32} , R_{XV-32} and R_{XV-12} , and R_{XV-12} and R_{XV-13} are independently selected to form spacer pairs wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the
- 15 group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the provisos that no more than one of the group consisting of spacer pairs R_{XV-4} and R_{XV-5} , R_{XV-5} and R_{XV-6} , R_{XV-6} and R_{XV-7} , R_{XV-7} and R_{XV-8} is used at the same time and that no more than
- 20 one of the group consisting of spacer pairs R_{XV-9} and R_{XV-10} , R_{XV-10} and R_{XV-11} , R_{XV-11} and R_{XV-31} , R_{XV-31} and R_{XV-32} , R_{XV-32} and R_{XV-12} , and R_{XV-12} and R_{XV-13} are used at the same time;
- R_{XV-9} and R_{XV-11} , R_{XV-9} and R_{XV-12} , R_{XV-9} and R_{XV-13} , R_{XV-9} and R_{XV-31} , R_{XV-9} and R_{XV-32} , R_{XV-10} and R_{XV-12} , R_{XV-10} and R_{XV-13} , R_{XV-10} and R_{XV-31} , R_{XV-10} and R_{XV-32} , R_{XV-11} and R_{XV-12} , R_{XV-11} and R_{XV-13} , R_{XV-11} and R_{XV-31} , R_{XV-11} and R_{XV-32} , R_{XV-12} and R_{XV-31} , R_{XV-12} and R_{XV-32} , R_{XV-13} and R_{XV-31} , and R_{XV-13} and R_{XV-32} are independently selected to form a spacer pair wherein said spacer pair is taken together to form a linear spacer moiety selected from the group consisting of a covalent single bond and a moiety having from 1 through 3 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl having from 3 through 8
- 25 contiguous members, a cycloalkenyl having from 5 through 8 contiguous members, a saturated heterocyclyl having from 5 through 8 contiguous members and a partially saturated heterocyclyl having from 5 through 8 contiguous members with the provisos that no more than one of said group of spacer pairs is used at the same time;
- 30

R_{XV-37} and R_{XV-38} are independently selected from the group consisting of hydrido, alkoxy, alkoxyalkyl, hydroxy, amino, thio, halo, haloalkyl, alkylamino, alkylthio, alkylthioalkyl, cyano, alkyl, alkenyl, haloalkoxy, and haloalkoxyalkyl.

- 5 Compounds of Formula XV are disclosed in WO 00/18723, the entire disclosure of which is incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XV:

- 10 3-[[3-(4-chloro-3-ethylphenoxy)phenyl]
 (cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(4-chloro-3-ethylphenoxy)phenyl]
 (cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-chloro-3-ethylphenoxy)phenyl]
 (cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][(3-trifluoromethyl)cyclohexyl-methyl]amino]-
 1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][(3-pentafluoroethyl)
 cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][(3-trifluoromethoxy)
 cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][(3-(1,1,2,2-
 tetrafluoroethoxy)cyclo-hexylmethyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxyphenoxy)phenyl]
 (cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(3-trifluoromethoxyphenoxy)phenyl]
 (cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxyphenoxy)phenyl]
 (cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][(3-trifluoromethyl)cyclohexyl-methyl]amino]-
 1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][(3-pentafluoroethyl)cyclohexyl-methyl]amino]-
 1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][(3-

- trifluoromethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxyphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[3-(3-isopropylphenoxy)phenyl](cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-isopropylphenoxy)phenyl](cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(3-isopropylphenoxy)phenyl](cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-isopropylphenoxy)phenyl][(3-trifluoromethyl) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(3-isopropylphenoxy)phenyl][(3-pentafluoroethyl) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-isopropylphenoxy)phenyl][(3-trifluoromethoxy) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(3-isopropylphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2,3-dichlorophenoxy)phenyl](cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(2,3-dichlorophenoxy)phenyl](cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2,3-dichlorophenoxy)phenyl](cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-(2,3-dichlorophenoxy)phenyl][(3-trifluoromethyl) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2,3-dichlorophenoxy)phenyl][(3-pentafluoroethyl) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(2,3-dichlorophenoxy)phenyl][(3-trifluoromethoxy) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(2,3-dichlorophenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(4-fluorophenoxy)phenyl](cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-fluorophenoxy)phenyl](cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(4-fluorophenoxy)phenyl](cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-fluorophenoxy)phenyl][(3-trifluoromethyl) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50

-93-

- 3-[[3-(4-fluorophenoxy)phenyl][(3-pentafluoroethyl)
cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[3-(4-fluorophenoxy)phenyl][(3-trifluoromethoxy)
cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(4-fluorophenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)cyclohexyl-methyl]amino]-
1,1,1-trifluoro-2-propanol;
- 10 3-[[3-(3-trifluoromethoxybenzyloxy)phenyl]
(cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxybenzyloxy)phenyl]
(cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[3-(3-trifluoromethoxybenzyloxy)phenyl]
(cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[3-(3-trifluoromethoxybenzyloxy)phenyl][(3-
trifluoromethyl)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxybenzyloxy)phenyl][(3-
pentafluoroethyl)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[3-(3-trifluoromethoxybenzyloxy)phenyl][(3-
trifluoromethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethoxybenzyloxy)phenyl][3-(1,1,2,2-
tetrafluoroethoxy)-cyclohexylmethyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[3-(3-trifluoromethylbenzyloxy)phenyl]
(cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethylbenzyloxy)phenyl]
(cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[3-(3-trifluoromethylbenzyloxy)phenyl]
(cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[3-(3-trifluoromethylbenzyloxy)phenyl][(3-trifluoromethyl)cyclohexyl-methyl]amino]-
1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethylbenzyloxy)phenyl][(3-pentafluoroethyl)cyclohexyl-methyl]amino]-
1,1,1-trifluoro-2-propanol;
- 45 3-[[3-(3-trifluoromethylbenzyloxy)phenyl][(3-
trifluoromethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[3-(3-trifluoromethylbenzyloxy)phenyl][3-(1,1,2,2-
tetrafluoroethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50


- 3-[[[(3-trifluoromethyl)phenyl]methyl](cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-pentafluoroethyl)phenyl]methyl](cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[[(3-trifluoromethoxy)phenyl]methyl](cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[[(3-trifluoromethyl)phenyl]methyl](4-methylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-pentafluoroethyl)phenyl]methyl](4-methylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[[(3-trifluoromethoxy)phenyl]methyl](4-methylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](4-methylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[[(3-trifluoromethyl)phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-pentafluoroethyl)phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[[(3-trifluoromethoxy)phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[[(3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-trifluoromethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)cyclo-hexyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[[(3-pentafluoroethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)cyclo-hexyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-trifluoromethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)cyclo-hexyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[[(3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-cyclohexyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[[(3-trifluoromethyl)phenyl]methyl](3-phenoxy-cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-pentafluoroethyl)phenyl]methyl](3-phenoxy-cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 50

- 3-[[[(3-trifluoromethoxy)phenyl]methyl](3-phenoxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](3-phenoxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-trifluoromethyl)phenyl]methyl](3-isopropoxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[[(3-pentafluoroethyl)phenyl]methyl](3-isopropoxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-trifluoromethoxy)phenyl]methyl](3-isopropoxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](3-isopropoxy cyclohexyl)-amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[[(3-trifluoromethyl)phenyl]methyl](3-cyclopentyloxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-pentafluoroethyl)phenyl]methyl](3-cyclopentyloxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[[(3-trifluoromethoxy)phenyl]methyl](3-cyclopentyloxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](3-cyclopentyloxy cyclohexyl)-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl](3-isopropoxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl](3-cyclopentyloxy cyclohexyl)-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl](3-phenoxy cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 40 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl](3-trifluoromethyl cyclohexyl)amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl][3-(4-chloro-3-ethylphenoxy) cyclo-hexyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl][3-(1,1,2,2-tetrafluoroethoxy) cyclo-hexyl]amino]-1,1,1-trifluoro-2-propanol;
- 50 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl](3-pentafluoroethyl cyclohexyl)-amino]-1,1,1-trifluoro-2-propanol;

- 3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl](3-trifluoromethoxycyclohexyl)-amino]-1,1,1-trifluoro-2-propanol;
- 5 3-[[[(3-trifluoromethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)propyl]-amino]-1,1,1-trifluoro-2-propanol;
- 10 3-[[[(3-pentafluoroethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)propyl]-amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-trifluoromethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)propyl]-amino]-1,1,1-trifluoro-2-propanol;
- 15 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-propyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-trifluoromethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-2,2,-difluoropropyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 3-[[[(3-pentafluoroethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-2,2-difluoropropyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-trifluoromethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-2,2,-difluoropropyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-2,2,-difluoropropyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 3-[[[(3-trifluoromethyl)phenyl]methyl][3-(isopropoxy)propyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[(3-pentafluoroethyl)phenyl]methyl][3-(isopropoxy)propyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 3-[[[(3-trifluoromethoxy)phenyl]methyl][3-(isopropoxy)propyl]amino]-1,1,1-trifluoro-2-propanol;
- 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-(isopropoxy)propyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 and
- 3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-(phenoxy)propyl]amino]-1,1,1-trifluoro-2-propanol.
- 45

Another class of CETP inhibitors that finds utility with the present invention consists of (R)-chiral halogenated 1-substituted amino-(n+1)-alkanols having the Formula XVI


-97-




Formula XVI

- 5 and pharmaceutically acceptable forms thereof, wherein:
- n_{XVI} is an integer selected from 1 through 4;
- X_{XVI} is oxy;
- R_{XVI-1} is selected from the group consisting of haloalkyl, haloalkenyl, haloalkoxymethyl, and haloalkenyloxymethyl with the proviso that R_{XVI-1} has a
- 10 higher Cahn-Ingold-Prelog stereochemical system ranking than both R_{XVI-2} and $(CHR_{XVI-3})_n-N(A_{XVI})Q_{XVI}$ wherein A_{XVI} is Formula XVI-(II) and Q is Formula XVI-(III);

-98-



XVI-II



XVI-III

R_{XVI-16} is selected from the group consisting of hydrido, alkyl, acyl, aroyl, heteroaroyl, trialkylsilyl, and a spacer selected from the group consisting of a covalent single bond and a linear spacer moiety having a chain length of 1 to 4 atoms linked to the point of bonding of any aromatic substituent selected from the group consisting of R_{XVI-4} , R_{XVI-8} , R_{XVI-9} , and R_{XVI-13} to form a heterocyclidyl ring having from 5 through 10 contiguous members;

D_{XVI-1} , D_{XVI-2} , J_{XVI-1} , J_{XVI-2} and K_{XVI-1} are independently selected from the group consisting of C, N, O, S and covalent bond with the provisos that no more than one of D_{XVI-1} , D_{XVI-2} , J_{XVI-1} , J_{XVI-2} and K_{XVI-1} is a covalent bond, no more than one of D_{XVI-1} , D_{XVI-2} , J_{XVI-1} , J_{XVI-2} and K_{XVI-1} is O, no more than one of D_{XVI-1} , D_{XVI-2} , J_{XVI-1} , J_{XVI-2} and K_{XVI-1} is S, one of D_{XVI-1} , D_{XVI-2} , J_{XVI-1} , J_{XVI-2} and K_{XVI-1} must be a covalent bond when two of D_{XVI-1} , D_{XVI-2} , J_{XVI-1} , J_{XVI-2} and K_{XVI-1} are O and S, and no more than four of D_{XVI-1} , D_{XVI-2} , J_{XVI-1} , J_{XVI-2} and K_{XVI-1} is N;

D_{XVI-3} , D_{XVI-4} , J_{XVI-3} , J_{XVI-4} and K_{XVI-2} are independently selected from the group consisting of C, N, O, S and covalent bond with the provisos that no more than one is a covalent bond, no more than one of D_{XVI-3} , D_{XVI-4} , J_{XVI-3} , J_{XVI-4} and K_{XVI-2} is O, no more than one of D_{XVI-3} , D_{XVI-4} , J_{XVI-3} , J_{XVI-4} and K_{XVI-2} is S, no more than two of D_{XVI-3} , D_{XVI-4} , J_{XVI-3} , J_{XVI-4} and K_{XVI-2} is O and S, one of D_{XVI-3} , D_{XVI-4} , J_{XVI-3} , J_{XVI-4} and K_{XVI-2} must be a covalent bond when two of D_{XVI-3} , D_{XVI-4} , J_{XVI-3} , J_{XVI-4} and K_{XVI-2} are O and S, and no more than four of D_{XVI-3} , D_{XVI-4} , J_{XVI-3} , J_{XVI-4} and K_{XVI-2} are N;

R_{XVI-2} is selected from the group consisting of hydrido, aryl, aralkyl, alkyl, alkenyl, alkenyloxyalkyl, haloalkyl, haloalkenyl, halocycloalkyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl,

perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, dicyanoalkyl, and carboalkoxycyanoalkyl, with the proviso that R_{XVI-2} has a lower Cahn-Ingold-Prelog system ranking than both R_{XVI-1} and $(CHR_{XVI-3})_n-N(A_{XVI})Q_{XVI}$;

R_{XVI-3} is selected from the group consisting of hydrido, hydroxy, cyano, aryl, aralkyl, acyl, alkoxy, alkyl, alkenyl, alkoxyalkyl, heteroaryl, alkenyloxyalkyl, haloalkyl, haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, monocyanoalkyl, dicyanoalkyl, carboxamide, and carboxamidoalkyl, with the provisos that $(CHR_{XVI-3})_n-N(A_{XVI})Q_{XVI}$ has a lower Cahn-Ingold-Prelog stereochemical system ranking than R_{XVI-1} and a higher Cahn-Ingold-Prelog stereochemical system ranking than R_{XVI-2} ;

10 Y_{XVI} is selected from a group consisting of a covalent single bond, $(C(R_{XVI-14})_2)_q$ wherein q is an integer selected from 1 and 2 and $(CH(R_{XVI-14}))_g-W_{XVI}-(CH(R_{XVI-14}))_p$ wherein g and p are integers independently selected from 0 and 1;

R_{XVI-14} is selected from the group consisting of hydrido, hydroxy, cyano, hydroxyalkyl, acyl, alkoxy, alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, monocarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl;

Z_{XVI} is selected from a group consisting of a covalent single bond, $(C(R_{XVI-15})_2)_q$, wherein q is an integer selected from 1 and 2, and $(CH(R_{XVI-15}))_j-W_{XVI}-(CH(R_{XVI-15}))_k$ wherein j and k are integers independently selected from 0 and 1;

W_{XVI} is selected from the group consisting of O, C(O), C(S), C(O)N(R_{XVI-14}), C(S)N(R_{XVI-14}), (R_{XVI-14})NC(O), (R_{XVI-14})NC(S), S, S(O), S(O)₂, S(O)₂N(R_{XVI-14}), (R_{XVI-14})NS(O)₂, and N(R_{XVI-14}) with the proviso that R_{XVI-14} is other than cyano;

R_{XVI-15} is selected, from the group consisting of hydrido, cyano, hydroxyalkyl, acyl, alkoxy, alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, monocarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl;

R_{XVI-4} , R_{XVI-5} , R_{XVI-6} , R_{XVI-7} , R_{XVI-8} , R_{XVI-9} , R_{XVI-10} , R_{XVI-11} , R_{XVI-12} , and R_{XVI-13} are independently selected from the group consisting of hydrido, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocycloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl,

- cycloalkylsulfonylalkyl, heteroaryl-amino, N-heteroaryl-amino-N-alkyl-amino, heteroaralkyl, heteroaryl-aminoalkyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, heteroaralkoxy, cycloalkoxy, cycloalkenyloxy, cycloalkoxyalkyl, cycloalkylalkoxy, cycloalkenyloxyalkyl, cycloalkylenedioxy, halocycloalkoxy,
- 5 halocycloalkoxyalkyl, halocycloalkenyloxy, halocycloalkenyloxyalkyl, hydroxy, amino, thio, nitro, lower alkyl-amino, alkylthio, alkylthioalkyl, aryl-amino, aralkyl-amino, arylthio, arylthioalkyl, heteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl, arylsulfinylalkyl, arylsulfonylalkyl, heteroaryl-sulfinylalkyl, heteroaryl-sulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, haloalkylsulfinylalkyl, haloalkylsulfonylalkyl, alkylsulfonamido,
- 10 alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl, amidosulfonyl, monoaryl-amidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroaryl-sulfinyl, heteroaryl-sulfonyl, heterocyclisulfonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl,
- 15 alkenyloxy, alkenyloxyalkyl, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, cycloalkenyl, lower cycloalkylalkyl, lower cycloalkenylalkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, hydroxyheteroaralkyl, haloalkoxyalkyl, aryl, heteroaralkynyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially
- 20 saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido, alkylamidocarbonylamido, arylamidocarbonylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and
- 25 diaralkoxyphosphonoalkyl with the proviso that R_{XVI-4} , R_{XVI-5} , R_{XVI-6} , R_{XVI-7} , R_{XVI-8} , R_{XVI-9} , R_{XVI-10} , R_{XVI-11} , R_{XVI-12} , and R_{XVI-13} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

- R_{XVI-4} and R_{XVI-5} , R_{XVI-5} and R_{XVI-6} , R_{XVI-6} and R_{XVI-7} , R_{XVI-7} and R_{XVI-8} , R_{XVI-8} and
- 30 R_{XVI-10} , R_{XVI-10} and R_{XVI-11} , R_{XVI-11} and R_{XVI-12} , and R_{XVI-12} and R_{XVI-13} are independently selected to form spacer pairs wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated

heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the provisos that no more than one of the group consisting of spacer pairs R_{XVI-4} and R_{XVI-6} , R_{XVI-5} and R_{XVI-8} , R_{XVI-6} and R_{XVI-7} , and R_{XVI-7} and R_{XVI-8} is used at the same time and that no more than one of the group consisting of spacer pairs R_{XVI-9} and R_{XVI-10} , R_{XVI-10} and R_{XVI-11} , R_{XVI-11} and R_{XVI-12} , and R_{XVI-12} and R_{XVI-13} can be used at the same time;

R_{XVI-4} and R_{XVI-9} , R_{XVI-4} and R_{XVI-13} , R_{XVI-8} and R_{XVI-9} , and R_{XVI-8} and R_{XVI-13} is independently selected to form a spacer pair wherein said spacer pair is taken together to form a linear moiety wherein said linear moiety forms a ring selected from the group consisting of a partially saturated heterocyclyl ring having from 5 through 8 contiguous members and a heteroaryl ring having from 5 through 6 contiguous members with the proviso that no more than one of the group consisting of spacer pairs R_{XVI-4} and R_{XVI-9} , R_{XVI-4} and R_{XVI-13} , R_{XVI-8} and R_{XVI-9} , and R_{XVI-8} and R_{XVI-13} is used at the same time.

Compounds of Formula XVI are disclosed in WO 00/18724, the entire disclosure of which is incorporated by reference.

In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XVI:

- (2R)-3-[[3-(3-trifluoromethoxyphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-isopropylphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-cyclopropylphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-(2-furyl)phenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(2,3-dichlorophenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(4-fluorophenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(4-methylphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;

- (2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 (2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoro-ethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 (2R)-3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 (2R)-3-[[3-(3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-t-butylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 (2R)-3-[[3-(3-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 (2R)-3-[[3-(phenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 (2R)-3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 (2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-dimethylphenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 (2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-difluorophenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 (2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[cyclohexylmethoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 50

- (2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

5 (2R)-3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

(2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

10 (2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

(2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

15 (2R)-3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

(2R)-3-[[3-(3-isopropylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

20 (2R)-3-[[3-(3-cyclopropylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

(2R)-3-[[3-(3-(2-furyl)phenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

25 (2R)-3-[[3-(2,3-dichlorophenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

30 (2R)-3-[[3-(4-fluorophenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

(2R)-3-[[3-(4-methylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

35 (2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

40 (2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

(2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[3-(pentafluoroethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

45 (2R)-3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

50 (2R)-3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

- (2R)-3-[[3-(3-ethylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 (2R)-3-[[3-(3-t-butylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-methylphenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 (2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(phenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 (2R)-3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-(trifluoromethoxy)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 (2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-(trifluoromethyl)-phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 (2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3,5-dimethylphenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-(trifluoromethylthio)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 (2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3,5-difluorophenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 (2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[cyclohexylmethoxy]phenyl]-amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 (2R)-3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 (2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50 (2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-

- (pentafluoroethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 (2R)-3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-isopropylphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]-methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 10 (2R)-3-[[3-(3-cyclopropylphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-(2-furyl)phenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 15 (2R)-3-[[3-(2,3-dichlorophenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(4-fluorophenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 (2R)-3-[[3-(4-methylphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 (2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]-methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 30 (2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[3-(heptafluoropropyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 (2R)-3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-ethylphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 (2R)-3-[[3-(3-t-butylphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-methylphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 (2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50

- (2R)-3-[[3-(phenoxy)phenyl][3-(heptafluoropropyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 (2R)-3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trifluoromethoxy)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 (2R)-3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trifluoromethyl)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3,5-dimethylphenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 (2R)-3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trifluoromethylthio)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3,5-difluorophenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 (2R)-3-[[[3-(heptafluoropropyl)phenyl]methyl][3-cyclohexylmethoxy]phenyl]-amino]-1,1,1-trifluoro-2-propanol;
- 25
- (2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 (2R)-3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 (2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][3-(heptafluoropropyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 (2R)-3-[[3-(3-trifluoromethoxyphenoxy)phenyl][2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-isopropylphenoxy)phenyl][2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 (2R)-3-[[3-(3-cyclopropylphenoxy)phenyl][2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50

- (2R)-3-[[3-(3-(2-furyl)phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 (2R)-3-[[3-(2,3-dichlorophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(4-fluorophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-3-propanol;
- 10 (2R)-3-[[3-(4-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 (2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[2-fluoro-5-(trifluoro-methyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 (2R)-3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3,5-dimethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 (2R)-3-[[3-(3-ethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 30 (2R)-3-[[3-(3-t-butylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;
- 35 (2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 (2R)-3-[[3-[3-(N,N-dimethylamino,phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 (2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-3-propanol;
- (2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethyl)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 50

- (2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3,5-dimethylphenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 5 (2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethylthio)phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[[3,5-difluorophenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 (2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[cyclohexylmethoxy-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 (2R)-3-[[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(3-difluoromethoxyphenoxy)phenyl][2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 (2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 (2R)-3-[[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(3-trifluoromethoxyphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 (2R)-3-[[[3-(3-isopropylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(3-cyclopropylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 (2R)-3-[[[3-(3-(2-furyl)phenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 (2R)-3-[[[3-(2,3-dichlorophenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[3-(4-fluorophenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 (2R)-3-[[[3-(4-methylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 50 (2R)-3-[[[3-(2-fluoro-5-bromophenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

- 5 (2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 10 (2R)-3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3,5-dimethylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 15 (2R)-3-[[3-(3-ethylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(3-*t*-butylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 20 (2R)-3-[[3-(3-methylphenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 25 (2R)-3-[[3-(phenoxy)phenyl][2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[3-[3-(*N,N*-dimethylamino)phenoxy]phenyl][2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;
- 30 (2R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[3-(trifluoromethoxy)phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 35 (3R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[3-(trifluoromethyl)phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[3,5-dimethylphenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 40 (2R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- (2R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[3,5-difluorophenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 45 (2R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[3-(cyclohexylmethoxy)-phenyl]amino]-1,1,1-trifluoro-2-propanol;
- 50

-110-

(2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;


5 (2R)-3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

(2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;

10 (2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol; and

15 (2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol.

Another class of CETP inhibitors that finds utility with the present invention consists of quinolines of Formula XVII



Formula XVII


and pharmaceutically acceptable forms thereof, wherein:

25 A_{XVII} denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with up to five identical or different substituents in the form of a halogen, nitro, hydroxyl, trifluoromethyl, trifluoromethoxy or a straight-chain or branched alkyl, acyl, hydroxyalkyl or alkoxy containing up to 7 carbon atoms each, or in the form of a group according to the formula -NR_{XVII-4}R_{XVII-5}, wherein

30 R_{XVII-4} and R_{XVII-5} are identical or different and denote a hydrogen, phenyl or a straight-chain or branched alkyl containing up to 6 carbon atoms,

D_{XVII} denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with a phenyl, nitro, halogen, trifluoromethyl or trifluoromethoxy, or a radical according to the formula

-111-



wherein


- 5 R_{XVII-6} , R_{XVII-7} , $R_{XVII-10}$ denote, independently from one another, a cycloalkyl containing 3 to 6 carbon atoms, or an aryl containing 6 to 10 carbon atom or a 5- to 7-membered, optionally benzo-condensed, saturated or unsaturated, mono-, bi- or tricyclic heterocycle containing up to 4 heteroatoms from the series of S, N and/or O, wherein the rings are optionally substituted, in the case of the nitrogen-containing rings
- 10 also via the N function, with up to five identical or different substituents in the form of a halogen, trifluoromethyl, nitro, hydroxyl, cyano, carboxyl, trifluoromethoxy, a straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl containing up to 6 carbon atoms each, an aryl or trifluoromethyl-substituted aryl containing 6 to 10 carbon atoms each, or an optionally benzo-condensed, aromatic 5- to 7-membered
- 15 heterocycle containing up to 3 heteroatoms from the series of S, N and/or O, and/or in the form of a group according to the formula $-OR_{XVII-11}$, $-SR_{XVII-12}$, $-SO_2R_{XVII-13}$, or $-NR_{XVII-14}R_{XVII-15}$;

- 20 $R_{XVII-11}$, $R_{XVII-12}$, and $R_{XVII-13}$ denote, independently from one another, an aryl containing 6 to 10 carbon atoms, which is in turn substituted with up to two identical or different substituents in the form of a phenyl, halogen or a straight-chain or branched alkyl containing up to 6 carbon atoms,

$R_{XVII-14}$ and $R_{XVII-15}$ are identical or different and have the meaning of R_{XVII-4} and R_{XVII-5} given above, or

R_{XVII-6} and/or R_{XVII-7} denote a radical according to the formula

25



R_{XVII-8} denotes a hydrogen or halogen, and

R_{XVII-9} denotes a hydrogen, halogen, azido, trifluoromethyl, hydroxyl,

5 trifluoromethoxy, a straight-chain or branched alkoxy or alkyl containing up to 6 carbon atoms each, or a radical according to the formula $NR_{XVII-16}R_{XVII-17}$;

$R_{XVII-18}$ and $R_{XVII-17}$ are identical or different and have the meaning of R_{XVII-4} and R_{XVII-5} above; or

10 R_{XVII-8} and R_{XVII-9} together form a radical according to the formula $=O$ or $=NR_{XVII-18}$;

$R_{XVII-18}$ denotes a hydrogen or a straight-chain or branched alkyl, alkoxy or acyl containing up to 6 carbon atoms each;

15 L_{XVII} denotes a straight-chain or branched alkylene or alkenylene chain containing up to 8 carbon atoms each, which are optionally substituted with up to two hydroxyl groups;

T_{XVII} and X_{XVII} are identical or different and denote a straight-chain or branched alkylene chain containing up to 8 carbon atoms; or

T_{XVII} and X_{XVII} denotes a bond;

V_{XVII} denotes an oxygen or sulfur atom or $-NR_{XVII-19}$;

20 $R_{XVII-19}$ denotes a hydrogen or a straight-chain or branched alkyl containing up to 6 carbon atoms or a phenyl;

25 E_{XVII} denotes a cycloalkyl containing 3 to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a cycloalkyl containing 3 to 8 carbon atoms or a hydroxyl, or a phenyl, which is optionally substituted with a halogen or trifluoromethyl;

R_{XVII-1} and R_{XVII-2} are identical or different and denote a cycloalkyl containing 3 to 8 carbon atoms, hydrogen, nitro, halogen, trifluoromethyl, trifluoromethoxy, carboxy, hydroxy, cyano, a straight-chain or branched acyl, alkoxycarbonyl or alkoxy with up to 6 carbon atoms, or $NR_{XVII-20}R_{XVII-21}$;

$R_{XVII-20}$ and $R_{XVII-21}$ are identical or different and denote hydrogen, phenyl, or a straight-chain or branched alkyl with up to 6 carbon atoms; and or

R_{XVII-1} and/or R_{XVII-2} are straight-chain or branched alkyl with up to 6 carbon atoms, optionally substituted with halogen, trifluoromethoxy, hydroxy, or a straight-chain or branched alkoxy with up to 4 carbon atoms, aryl containing 6-10 carbon atoms optionally substituted with up to five of the same or different substituents selected from halogen, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, straight-chain or branched alkyl, acyl, hydroxyalkyl, alkoxy with up to 7 carbon atoms and $NR_{XVII-22}R_{XVII-23}$;

10 $R_{XVII-22}$ and $R_{XVII-23}$ are identical or different and denote hydrogen, phenyl or a straight-chain or branched alkyl up to 6 carbon atoms; and/or

R_{XVII-1} and R_{XVII-2} taken together form a straight-chain or branched alkene or alkane with up to 6 carbon atoms optionally substituted with halogen, trifluoromethyl, hydroxy or straight-chain or branched alkoxy with up to 5 carbon atoms;


15 R_{XVII-3} denotes hydrogen, a straight-chain or branched acyl with up to 20 carbon atoms, a benzoyl optionally substituted with halogen, trifluoromethyl, nitro or trifluoromethoxy, a straight-chained or branched fluoroacyl with up to 8 carbon atoms and 7 fluoro atoms, a cycloalkyl with 3 to 7 carbon atoms, a straight chained or branched alkyl with up to 8 carbon atoms optionally substituted with hydroxyl, a
20 straight-chained or branched alkoxy with up to 6 carbon atoms optionally substituted with phenyl which may in turn be substituted with halogen, nitro, trifluoromethyl, trifluoromethoxy, or phenyl or a tetrazol substituted phenyl, and/or an alkyl that is optionally substituted with a group according to the formula $-OR_{XVII-24}$;

25 $R_{XVII-24}$ is a straight-chained or branched alkyl with up to 4 carbon atoms or benzyl.

Compounds of Formula XVII are disclosed in WO 98/39299, the entire disclosure is incorporated by reference.

Another class of CETP inhibitors that finds utility with the present invention consists of 4-Phenyltetrahydroquinolines of Formula XVIII

-114-




Formula XVIII

5. , N oxides thereof, and pharmaceutically acceptable forms thereof, wherein:

A_{XVIII} denotes a phenyl optionally substituted with up to two identical or different substituents in the form of halogen, trifluoromethyl or a straight-chain or branched alkyl or alkoxy containing up to three carbon atoms;

D_{XVIII} denotes the formula



or $R_{XVIII-8}-CH_2-O-CH_2-$;

10

$R_{XVIII-5}$ and $R_{XVIII-6}$ are taken together to form $=O$; or

$R_{XVIII-5}$ denotes hydrogen and $R_{XVIII-6}$ denotes halogen or hydrogen; or

$R_{XVIII-5}$ and $R_{XVIII-6}$ denote hydrogen;

$R_{XVIII-7}$ and $R_{XVIII-8}$ are identical or different and denote phenyl, naphthyl,

- 15 benzothiazolyl, quinoliny, pyrimidyl or pyridyl with up to four identical or different substituents in the form of halogen, trifluoromethyl, nitro, cyano, trifluoromethoxy, -
 SO_2-CH_3 or $NR_{XVIII-9}R_{XVIII-10}$;

$R_{XVIII-9}$ and $R_{XVIII-10}$ are identical or different and denote hydrogen or a straight-chained or branched alkyl of up to three carbon atoms;

- 20 E_{XVIII} denotes a cycloalkyl of from three to six carbon atoms or a straight-chained or branched alkyl of up to eight carbon atoms;

$R_{XVIII-1}$ denotes hydroxy;

$R_{XVIII-2}$ denotes hydrogen or methyl;

$R_{XVIII-3}$ and $R_{XVIII-4}$ are identical or different and denote straight-chained or branched alkyl of up to three carbon atoms; or


$R_{XVIII-3}$ and $R_{XVIII-4}$ taken together form an alkenylene made up of between two and four carbon atoms.

- 5 Compounds of Formula XVIII are disclosed in WO 99/15504, the entire disclosure of which is incorporated by reference.

Emulsion pre-concentrates of CETP inhibitors, formulated as described above, are encapsulated in soft gelatin capsules, or are encapsulated in hard gelatin or non-gelatin capsules. If encapsulated in hard gelatin or non-gelatin capsules, it is preferred that the seam between the two capsule shell pieces be sealed, for example with a strip of gelatin, to prevent leakage. Encapsulation in soft-gelatin is well-known and is described in "The Theory and Practice of Industrial Pharmacy", by L. Lachman, H. Lieberman, and J. Kanig, Lea and Febiger, publisher, 3rd Edition, 1986.


- 15 The invention is further disclosed and described in the following examples, which are illustrative as opposed to limiting. In the examples, "mgA" is an abbreviation for "milligrams of active drug", the weight being expressed in mg of the non-salt, free acid or base. Other commonly employed and understood abbreviations have been employed: Me, methyl; Cmpd, Compound; In the examples, the following shorthand notation means the corresponding structure listed and/or named below:

- 25 Compound A - [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, with a Clog P of 7.45 and having the following structure:



-116-


- 5 Compound B, Propanethioic acid, 2-methyl-, S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] ester with a Clog P of 7.15 having the structure:



10

15


- Compound C, (S,S)-4'-(4-fluorophenyl)-3'-[fluoro[4-(trifluoromethyl)phenyl]methyl]-5',8'-dihydro-2'-(1-methylethyl)-spiro[cyclobutane-1,7'(6'H)-quinolin]-5'-ol, with a Clog P of 8.93 and having the following structure:




20

- 25 Compound D [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester, with a Clog P of 6.52 and the following structure:


-117-



- Compound E - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester, with a Clog P of 7.76 and having the following structure:




- Compound F - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester, having a Clog P of 7.98 and having the following structure:




Compound G - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester, having a Clog P of 7.58 and having the following structure:

5




10 Compound H - [2S, 4R] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester, having a Clog P of 7.58 and having the following structure:




15 Compound I - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-7-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, having a Clog P of 6.92 and having the following structure:

-119-



- 5 Compound J [2S, 4R] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-2,3,4,6,7,8-hexahydro-cyclopenta[g]quinoline-1-carboxylic acid ethyl ester, having a Clog P of 7.05 and having the following structure:




10


- Compound K - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, having a Clog P of 6.92 and having the following structure:

15


-120-



Compound L - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, having a Clog P of 6.92 and having the following structure:




Compound M - [2R, 4S] 4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester, having a Clog P of 6.56 and having the following structure:




-121-

- 5 Compound N - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester, having a Clog P of 6.33 and having the following structure:




- 10 Compound O - [2R, 4S] 4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, having a Clog P of 5.68 and having the following structure:




15

- 20 Compound P - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-formyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, having a Clog P of 5.97 and having the following structure:

-122-



- 5 Compound Q - [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, having a Clog P of 5.45 and having the following structure:



10 Example 1

This Example (and Examples 2 through 5) illustrates making a composition according to the invention and using it to make softgel capsules containing it.

- 15 Capmul® MCM was heated to 55 °C and mixed. To a 2 liter glass beaker was added 277 gm of Miglyol® 812, 510 gm of triacetin, 318 gm of Polysorbate 80, and 442 gm of Capmul® MCM. After stirring for one hour, this solution was added to 161 gm Compound A and the resulting mixture stirred at ambient temperature for 8 hours with scraping of walls as needed. It was then filtered to remove gross particulates. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 1.

- 20 The above 100 mgA/mL fill was encapsulated into #10 oval and #5 oval softgels to provide fill volumes of 0.6 mL and 0.3 mL respectively. The doses per softgel are therefore 60 mgA and 30 mgA, respectively. The shell was prepared from gelatin, glycerin, and water.

25

Table 1

Ingredient	mg/g
Compound A	94
Miglyol® 812	162
Triacetin	299
Polysorbate 80	186
Capmul® MCM	259

Example 2

5

Capmul® MCM was heated to 55°C and mixed. Cremophor® RH40 was also heated to 65°C with stirring. Then 539 g of Miglyol 812, 998 g of triacetin, 608 g of Cremophor® RH40, and 860 g of Capmul® MCM were combined and mixed for 20 min.

10 To this mixture was then added 312 gm of Compound D and the resulting mixture stirred at ambient temperature for 3 hours with scraping of walls as needed. It was then filtered to remove gross particulates. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 2.

15 The above 100 mgA/mL fill was encapsulated into #2 and #5 oval softgels to provide fill volumes of 0.1 mL and 0.3 mL, respectively. The doses per softgel were therefore 10 and 30 mgA, respectively. The shell was prepared from gelatin, glycerin, and water.

Table 2

Ingredient	mg/g
Compound D	94
Miglyol 812	163
Triacetin	301
Cremophor RH40	183
Capmul MCM	259

20

Example 3

25 Capmul® MCM was heated to 55°C and mixed. Alpha-tocopheryl polyethyleneglycol 1000 succinate (TPGS) was also heated to 55°C with stirring. Then 264 gm of Miglyol® 812, 333 gm of propylene carbonate, 103 gm of TPGS, and 562 gm of Capmul® MCM were combined and mixed for 1 hr. This mixture was then added to 130.4 gm of Compound A and the resulting mixture stirred at ambient temperature for 8 hours with scraping of walls as needed. It was then filtered to

-124-

remove gross particulates. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 3.

The above 100 mgA/mL fill was encapsulated into #11 oblong softgels to provide a fill volume of 0.6 mL. The dose per softgel is therefore 60 mgA. The shell
5 was prepared from gelatin, glycerin, and water.

Table 3

Ingredient	mg/g
Compound A	94
Miglyol® 812	164
Propylene carbonate	207
Alpha-tocopheryl polyethyleneglycol 1000 succinate	185
Capmul® MCM	350

10

Example 4

Capmul® MCM was heated to 55°C and mixed. Then 264 gm of Miglyol® 812,
15 333 gm of propylene carbonate, 303 gm of Polysorbate 80 and 562 gm of Capmul®
MCM were combined and mixed for 1 hr. This mixture was then added to 130.5 gm of
Compound A and the resulting mixture stirred at ambient temperature for 8 hours with
scraping of walls as needed. It was then filtered to remove gross particulates. The
amounts (in mg) of each component in the fill per gram of fill are set forth in Table 4.

20 The above 100 mgA/mL fill was encapsulated into #11 oblong softgels to
provide a fill volume of 0.6 mL. The dose per softgel is therefore 60 mgA. The shell
was prepared from gelatin, glycerin, and water.

25

Table 4

Ingredient	mg/g
Compound A	95
Miglyol® 812	163
Propylene carbonate	206
Polysorbate 80	188
Capmul® MCM	348

Example 5

Capmul® MCM was heated to 55°C and mixed. Then 271 gm of Miglyol® 812, 250 gm of triacetin, 779 gm of Polysorbate 80 and 217 gm of Capmul® MCM were combined and mixed for 20 min. This mixture was then added to 75.7 gm of COMPOUND A and the resulting mixture stirred at ambient temperature for 8 hours with scraping of walls as needed. It was filtered to remove gross particulates. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 5.

The above 50 mgA/mL fill was encapsulated into #11 oblong softgels to provide a fill volume of 0.6 mL. The dose per softgel is therefore 30 mgA. The shell was prepared from gelatin, glycerin, and water.

Table 5

Ingredient	mg/g
Compound A	48
Miglyol® 812	170
Triacetin	157
Polysorbate 80	489
Capmul® MCM	136

Example 6

This Example (and Example 7) illustrates the composition of fills according to the invention. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 6. This fill was prepared at a concentration of 50 mgA/mL in a manner similar to that described in Examples 1-5 but at a small volume for dog PK studies. It could be prepared at a larger scale for encapsulation into #11 oblong softgels to provide a fill volume of 0.6 mL and a dose of 30 mgA.

Table 6

Composition	mg/g
Compound A	48
Miglyol® 812	143
Triacetin	143
Cremophor® RH 40	381
Capmul® MCM	286

Example 7

5 The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 7. The fill was prepared at a concentration of 150 mgA/mL in a manner similar to that described in Examples 1-5, but at a small volume for dog PK studies. It could be prepared at a larger scale for encapsulation into #11 oblong softgels to provide a fill volume of 0.6 mL and a dose of 90 mgA.

10

Composition	mg/g
Compound A	142
Miglyol® 812	86
Ethyl lactate	429
Cremophor® RH 40	257
Capmul® MCM	86

Example 8

15

To 80.1 g of Compound A was added 1451 gm Miglyol® 812. The resulting mixture was stirred at ambient temperature for 8 hours with scraping of walls as needed. It was filtered to remove gross particulates. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 8.

20

The above 50 mgA/mL fill was encapsulated into #11 oblong and #4 oval softgels to provide fill volumes of 0.6 mL and 0.2 ml, respectively. The doses per softgel were therefore 30 and 10 mgA, respectively. The shell was prepared from gelatin, glycerin, and water.

25

30

Table 8

Ingredient	mg/g
Compound A	52
Miglyol® 812	948

Example 9

5

This example describes the determination of solubility of CETP inhibitors in excipients and emulsion preconcentrates and also an initial assessment of emulsion quality (Table 9a-9d).

10 The solubility of CETP inhibitors in excipients and in formulations was determined by adding an excess of compound to the medium in question. The mixture was agitated by rotation over a period of days at ambient temperature until the concentration in solution had reached an equilibrium as judged by similar measurements for consecutive time points. Concentrations were measured by filtration of aliquots with a PTFE syringe filter and assay by HPLC as described in

15 Example 11.

For CETP inhibitors where quantities were limited, an estimate of solubility was obtained by addition of vehicle to a known quantity of the compound and mixing in an ultrasonicator bath for 90 minutes, followed by overnight equilibration at ambient temperature. Addition of vehicle was repeated until a solution was achieved.

20 The extent of emulsification was determined by mixing the preconcentrate and water in a ratio of 1:100 and 1:10 by gentle inversion (5 x), visual inspection, and examination under an optical microscope, using a polarizing filter to check for the appearance of crystals. Droplet size determined by this approach is expressed as the upper limit for the average droplet size, since submicron droplets cannot be detected

25 by this method.

The results in Table 9a show that the solubility of Compound A in Miglyol® 812 is only sufficient for a 50 mgA/mL fill (30 mgA in a 0.6 mL softgel), while cosolvents such as triacetin and propylene carbonate provide ca. 4x higher solubility and those such as ethyl lactate and dimethyl isosorbide nearly double those levels. Solubility and emulsification data for preconcentrate solutions of Compound A is shown in Table 9c.

30 Use of propylene carbonate and triacetin as cosolvents allow solubilities sufficient in some cases for a 100 mgA/mL self-emulsifying fill. (e.g., Formulations M, O, Q, and R, see Table 9c)

Higher levels of surfactants are often required to yield self-microemulsifying formulations and in these cases solubilities only permit in general a 50 mgA/mL fill using triacetin as the cosolvent (e.g. Formulation EE, Y, and PP). Use of propylene carbonate or ethyl lactate as cosolvent can permit a 100mgA/mL fill (e.g., Formulations A, B, XX, YY, and ZZ) that has sufficient surfactant to yield microemulsions. However, triacetin has the advantage of good precedence in oral dosage forms (and has GRAS status). Dynamic light scattering was utilized to further characterize the sub-micron particle size distribution for microemulsions as described in Example 10.

The solubility in ethyl lactate permits a self-emulsifying 150 mgA/mL fill to be prepared (e.g Formulation WW). However, the solubilities of emulsion preconcentrates shown in Table 9a and 9c cannot reliably be predicted based on the solubilities of the components alone. This is exemplified by formulation WW (Table 9c), which exhibits considerably greater solubility than the corresponding formulation using dimethyl isosorbide (Formulation AAA), although the opposite would have been predicted based on solubilities in the individual cosolvents. Also, lack of data for excipients that are solids at room temperature also hinders prediction.

All of the emulsions prepared from these formulations exhibited good physical stability, i.e. there was no sign of crystallization or change in particle size based on microscopic examination after standing overnight at ambient temperature.

20 Results obtained for other CETP inhibitors are shown in Tables 9b and 9d. In case of Compound D (Table 9b), the average emulsion particle size is < 5 microns.

25 Table 9a. Equilibrium Solubility Data for Compound A in Oils, Solvents, and Surfactants

		Solubility (mgA/ml)
Vehicle	HLB	
Water		< 0.00004
Oleic acid		8.5
Maisine 35-1	4	9
Peceol	3	10
Olive oil		17
Plurol Oleique CC 497	6	17

-129-

Cremophor® EL		20
Polysorbate 80 (Tween 80)	15	23
Labrafil® M 1944	4	26
Labrafil® M 2125	4	27
Tagat TO (Polyoxyethylene glycerol trioleate)	11	32
Pluronic® L-44		36
Capmul® MCM	6	41
Labrasol®	14	41
Miglyol® 812		65
Lauroglycol FCC	4	70
Glycofurool		99
Caprylic acid		145
Transcutol P		174
Propylene carbonate		227
Triacetin		235
Triethyl citrate		240
peppermint oil		266
Ethyl lactate		400
Dimethylisosorbide		439
N-methyl-2-pyrrolidone		813

5

Table 9b: Equilibrium Solubility Data for Other CETP inhibitors

Vehicle	Solubility (mgA/ml)	
	Compound D	Compound E
Olive oil	13	39
Olive oil /Cremophor® EL 80/20	14	
Cremophor® EL	18	
Miglyol® 812/Cremophor® EL 80/20	51	
Capmul® MCM	58	
Miglyol® 812	61	167

-130-

Miglyol®/propylene carbonate/Cremophor® EL (60/20/20)	208	394
Triacetin	239	

Table 9c. Solubility and emulsification data for Compound A in preconcentrates*

5

Formul. No.	Composition (% v/v)			Solubility (mgA/mL)	Ave Droplet Size (μ) (1:100 dilution)
	Miglyol® 812	Cosolvent*	Surfactants		
			Vitamin E TPGS/ Capmul® MCM		
A	20	20 P.C.	20/40	145	<1
H	20	20 triacetin	20/40	113	<2
I	20	30 P.C.	20/30	189	<2
S	10	30 triacetin	20/40	131	<5
			Polysorbate 80/ Capmul® MCM		
B	20	20 P.C.	20/40	142	<5
O	20	30 triacetin	20/30	141	<2
EE	20	15 triacetin	50/15	64	<1
			Vitamin E TPGS/ Labrafil® M 1944 CS		
C	20	20 P.C.	20/40	114	<1
Q	10	40 triacetin	20/30	142	<2
			Gelucire® 44/14/ Capmul® MCM		
D	20	20 P.C.	20/40	151	<5
			Cremophor® RH40/ Capmul® MCM		
E	20	20 P.C.	20/40	147	<1
M	20	30 triacetin	20/30	145	<1
R	20	30 triacetin	35/15	122	<1
SS	0	28 triacetin	30/42	108	<1
PP	17	13 triacetin	39/31	77	<1
Y	20	10 triacetin	50/20	67	<1
WW	11	50 ethyl lactate	29/10	203	<2
XX	11	40 ethyl lactate	29/20	159	<1

-131-

YY	16	35 ethyl lactate	39/10	142	<1
ZZ	22	29 ethyl lactate	19/30	145	<1
AAA	11	47 dimethyl isosorbide	31/11	157	<1

* P.C. = propylene carbonate

- 5 Table 9d. Solubility and emulsification data for other CETP Inhibitor pre-concentrates

Compound	Composition (% v/v)			Solubility (mgA/mL)	Ave Droplet Size (μ) (1:100 dilution)
	Miglyol®8 12	Triacetin	Surfactants		
			Polysorbate 80/ Capmul®MCM		
Compound B*	20	30	20/30	≥ 100	<5
Compound C*	6	55	15/24	≥ 30	<5
Compound E	22	27	20/31	308	<2
			Cremophor® RH40/ Capmul® MCM		
Compound D	20	30	20/30	172	<5

* Amorphous solids

10

Example 10

- Preliminary particle size analysis data has been obtained on selected formulations using a dynamic light scattering particle size analyzer (ZetaPals, Brookhaven Instruments, Inc.) for measurement of sub-micron particle distribution. The formulation solutions were diluted 1:100 in HPLC-grade water (previously filtered through a 0.22 μ m syringe filter). The resulting mixture was gently inverted five times to create the emulsion. Each emulsion sample was then analyzed at a temperature of 37°C. Triplicate measurements were made at each time point (0, 30 min).

The results shown in Table 10 confirm that formulations O, Q and R are self-emulsifying formulations with a mean particle size above 100 nm. Formulations

- such as A and B have mean particle sizes in the microemulsion range but with significant populations of larger particles and are slightly turbid. Formulation EE is very slightly turbid with a trace of larger particles. Use of Cremophor® RH 40 as the high HLB surfactant yielded formulations Y, PP, XX, and ZZ that form transparent
- 5 microemulsions with all particles smaller than ca. 100 nm, as is the case for Neoral®. Only formulation Y showed a stable unimodal distribution that did not change, even with stirring.

10 Table 10a. Dynamic Light Scattering Particle Size Analysis of Emulsions from Compound A Self-Emulsifying Formulations*

Form..	Pre-concentrate Composition (% v/v)	Mean Diam. (nm)	Distribution #		
			Peak 1	Peak 2	Peak 3
A	Miglyol® 812/propylene carbonate/Vitamin E-TPGS/Capmul® MCM (20/20/20/40)	78.6	22	73	349
B	Miglyol® 812/propylene carbonate/Polysorbate 80/Capmul® MCM (20/20/20/40)	45.3	33	217	
C	Miglyol® 812/propylene carbonate/Vitamin E-TPGS/Labrafil M® 1944 CS (20/20/20/40)	21.6	17	38	(197)
O	Miglyol® 812/Triacetin/Polysorbate 80/Capmul® MCM (20/30/20/30)	256.6	257		
Q	Miglyol® 812/Triacetin/Vitamin E-TPGS/Labrafil M® 1944 CS (10/40/20/30)	440.9	259	537	
R	Miglyol® 812/Triacetin/Cremophor® RH40/Capmul MCM (20/30/35/15)	245.2	245		
X	Neoral®/propylene carbonate (90:10)	19.0	11	29	
Y	Miglyol® 812/Triacetin/Cremophor® RH40/Capmul® MCM (20/10/50/20)	22.3	22		
EE	Miglyol® 812/Triacetin/Polysorbate 80/Capmul® MCM (20/15/50/15)	19.6	13	64	(220)

-133-

PP	Miglyol® 812/Triacetin/ Cremophor® RH40/ Capmul® MCM (17/13/39/31)	27.1	27		
SS	Triacetin/Cremophor® RH40/ Capmul® MCM (28/30/42)	32.4	26	(116)	
WW	Miglyol® 812/Ethyl lactate/ Cremophor® RH40/ Capmul® MCM (11/50/29/10)	293.8	324		
XX	Miglyol® 812/Ethyl lactate/ Cremophor® RH40/ Capmul® MCM (11/40/29/20)	24.9	22	(107)	
YY	Miglyol® 812/Ethyl lactate/ Cremophor® RH40/ Capmul® MCM (16/35/39/10)	31.5	28	(135)	
ZZ	Miglyol® 812/Ethyl lactate/ Cremophor® RH40/ Capmul® MCM (22/29/19/30)	36.3	34	(103)	
	Neoral®	27.4	27	(65)	

Parentheses indicate trace levels.

* Measured immediately after preparation unless indicated otherwise

5

Table 10b. Dynamic Light Scattering Particle Size Analysis of Emulsions prepared for Other Compounds

Cmpd.	Conc. (mg/mL)	Pre-Concentrate Composition (% v/v)	Mean Diam. (nm)#	
			Initial*	30 min.*
D	100	Miglyol® 812/Triacetin/ Cremophor® RH40/ Capmul® MCM (20/30/20/30)	—	182 ± 17 (3)
E	100	Miglyol® 812/Triacetin/ Polysorbate 80/Capmul ®MCM (22/27/20/31)	181	175
E	200	Miglyol® 812/Triacetin/ Polysorbate 80/Capmul ®MCM (22/27/20/31)	239 ± 17 (4)	251 ± 45 (4)

10 # Number of samples in parentheses

* Time after preparation of emulsion

Example 11

5

The fills prepared in the above examples were hand-filled into hydrophobic softgel shells and heat sealed, and then placed on stability under accelerated conditions in sealed HPDE bottles with child-resistant caps. The fills were assayed at intervals by dilution of aliquots into acetonitrile and gradient HPLC analysis on a
10 Water Symmetry C-8 column (3.9 x 150 mm, 5 micron) at 30°C at a flow rate of 1 mL/min. The mobile phase program was a 25 minute gradient from 100 % A to 50% A/50 % B (A = 400/300/300/0.8 v/v DI H₂O/Acetonitrile/2-Propanol/Phosphoric Acid and B = 2-Propanol), followed by a 5 minute hold at this condition and a 10 minute gradient to the initial condition. The detection method was UV absorbance at 210
15 nm.

There was no impurity formed at ≥ 0.1 % peak area vs. parent for any formulation in Table 11. There was no sign of crystallization in the fill under any condition based on microscopic examination. There was also no indication of seal leakage.

20

Disintegration times in water at 37°C were less than 15 min for Formulations A, B, and O after storage under accelerated conditions for 6 weeks.

Formulation O softgels of Compound A manufactured by machine have been shown to be stable for 9 months under accelerated conditions. Formulation M softgels of Compound D have been shown to be stable for 6 months under
25 accelerated conditions.

Table 11. Accelerated Stability data for selected formulations of Compound A in hand- filled soft gels

Test	Assay of Fill					
	Assay of Fill Potency					
Formulation #	A	B	C	E	M	O
Initial	100.6 ± 0.6	99.4 ± 0.7	101.3 ± 0.8	102.0 ± 0.1	101.6 ± 0.2	102.6 ± 0.6
1 Week						
5°C/75%RH	101.8 ± 0.8	99.5 ± 2.3	99.1 ± 0.4	101.5 ± 0.4		
30°C/60%RH	100.8 ± 0.6	98.8 ± 0.6	100.5 ± 0.7	101.1 ± 0.1		
40°C/75%RH	101.4 ± 0.5	98.6 ± 1.4	99.7 ± 0.5	102.6 ± 0.1		
3 Week OR 4 Week	*	*				
5°C/75%RH	99.9 ± 0.4	99.0 ± 0.3	99.3 ± 1.0	100.5 ± 0.6	100.6 ± 0.5	101.1 ± 0.6
30°C/60%RH	100.7 ± 0.8	98.4 ± 0.7	100.0 ± 0.6	99.9 ± 0.5	100.3 ± 0.6	101.4 ± 1.3
40°C/75%RH	101.3 ± 0.3	100.7 ± 1.0	101.8 ± 0.5	102.3 ± 0.4	102.9 ± 0.6	101.7 ± 0.2
6 Week						
5°C/75%RH	100.7 ± 0.8	100.7 ± 0.1	98.4 ± 0.3	100.0 ± 0.3	101.2 ± 0.5	101.9 ± 0.2
30°C/60%RH	100.4 ± 0.8	100.5 ± 0.4	101.1 ± 0.6	101.1 ± 0.2	101.6 ± 0.6	101.9 ± 0.8
40°C/75%RH	102.4 ± 0.7	102.1 ± 1.0	102.5 ± 0.4	102.7 ± 0.7	101.6 ± 0.5	101.9 ± 0.9

* 4 Week time point.

Example 12

Fills were prepared as described in above examples and then encapsulated in #00 hard gelatin capsules. Male Beagle dogs (n=6) between the ages of 2-5 and weighing 6-12 kg were dosed with capsules followed by 50 mL of water. Dogs were also dosed with 30 mgA Miglyol® 812 softgels and aqueous, crystalline drug suspension. The dogs were either fasted or fed just prior to dosing with 14 g of dry dog food and 8 gm olive oil. The same set of dogs were used for all formulations, except where indicated. Blood samples were obtained from the jugular vein of each dog at 0, 0.5, 1, 2, 3, 4, 6, 8 and 12 hr and analyzed by acidifying the plasma, solid phase extraction, and analysis by LC/MS/MS with a lower limit of quantitation of 25 ng/mL.

The results, in Table 12a and 12b are shown in terms of Area Under the Curve (AUC), C_{max}, the maximum concentration of drug measured in the plasma, and T_{max}, the time in hours it took to reach C_{max}. Unless otherwise indicated, results are for the fasted state. Miglyol® softgels have a very low fasted exposure and thus a high food effect. The fasted exposure is higher than that for crystalline suspension, while the fed exposure using this high oil meal is the same. Thus Miglyol softgels provide a lower food effect than crystalline drug. At the same dose of 90 mgA, formulations such as A, O, and C that include surfactants and cosolvent have much higher fasted exposures and only a ca. 3x food effect. The fed exposures are also higher than for Miglyol® 812 softgels and crystalline drug. Poorer fasted exposure was obtained for Formulation WW, which contains a high level of ethyl lactate as a cosolvent.

The transparent self-microemulsifying formulations EE and PP at a dose of 30 mgA have a food effect of only 2.2-2.4. For the stable, monodisperse microemulsion Y there is a much higher fasted exposure at 30 mgA than for the self-emulsifying formulation O. The fasted exposure for Y was the same as the fed, i.e. there was no food effect.

Similar results were obtained for formulation M for Compound D (Table 12b) as were observed for the same formulation of Compound A.

Table 12a. Pharmacokinetic results of Compound A Formulations in dogs

#	Formulation Composition (v/v)	n*	Conc. (mg/mL)	Dose (mg)	AUC 0- 12h ($\mu\text{g}\cdot\text{h}/\text{mL}$)	Cmax ($\mu\text{g}/\text{mL}$)	Tmax (hr)
	Miglyol® 812 <u>soft gels</u>						
	Fed	4	50	90	3.0 ± 2.0	0.77 ± 0.48	2.0
		6	50	90	0.6 ± 0.3	0.2 ± 0.14	3.7
	Crystalline drug suspension in 0.1% Polysorbate 80/ 0.5% methyl cellulose	6*	—	90	0.16 ± 0.14	0.04 ± 0.11	1.3
	Fed	6	—	90	2.9 ± 1.3	0.98 ± 0.53	2.7
A	Miglyol® 812 /Propylene carbonate/ Vitamin E-TPGS/Capmul® MCM (20/20/20/40)	6	100	90	2.7 ± 0.9	0.67 ± 0.17	1.2
	Fed	5	100	90	9.6 ± 3.4	2.49 ± 1.30	1.4
B	Miglyol® 812 /Propylene carbonate/ Polysorbate 80/Capmul® MCM (20/20/20/40)	6	100	90	2.3 ± 0.5	0.73 ± 0.16	1.8
C	Miglyol® 812 /propylene carbonate/ Vitamin E-TPGS/ Labrafil® M 1944 (20/20/20/40)	5	80	90	3.4 ± 1.3	1.2 ± 0.41	1.2
	Fed	6	80	90	9.3 ± 3.5	4.31 ± 1.89	1.0
I	Miglyol® 812 /Propylene carbonate/ Vitamin E-TPGS/Capmul® MCM (20/30/20/30)	6	125	90	1.6 ± 0.5	0.61 ± 0.27	0.9
J	Miglyol® 812 /Propylene carbonate/ Vitamin E-TPGS (20/40/40)	6	125	90	2.0 ± 0.8	0.71 ± 0.36	1.7
M	Miglyol® 812 /Triacetin/ Cremophor® RH40/ Capmul® MCM (20/30/20/30)	5	100	90	2.6 ± 1.2	0.73 ± 0.26	1.2
O	Miglyol® 812 /Triacetin/ Polysorbate 80/Capmul® MCM (20/30/20/30)	6	100	90	2.7 ± 0.7	0.97 ± 0.36	1.2

-138-

	Fed	4	100	90	8.5 ± 3.6	2.7 ± 1.0	1.5
		6	100	30	1.1 ± 0.5	0.37 ± 0.22	1.0
Q	Miglyol® 812 /Triacetin/ Vitamin E-TPGS/ Labrafil® M 1944 (10/40/20/30)	5**	100	90	2.9 ± 0.8	1.1 ± 0.2	1.0
R	Miglyol® 812 /Triacetin/ Cremophor® RH40/ Capmul® MCM (20/30/35/15)	6	100	90	2.8 ± 1.2	1.0 ± 0.4	1.0
		6	50	90	4.0 ± 1.3	1.1 ± 0.4	1.5
X	Neoral®/propylene carbonate (90:10)	3	50	90	2.4 ± 1.9	0.67 ± 0.23	1.3
Y	Miglyol® 812 /Triacetin/ Cremophor® RH40/ Capmul® MCM (20/10/50/20)	6	50	90	4.6 ± 1.4	1.35 ± 0.26	1.7
		4**	50	30	4.6 ± 2.0	1.32 ± 0.60	2.0
	Fed	5	50	30	4.7 ± 1.1	1.94 ± 0.74	1.0
EE	Miglyol® 812 /Triacetin/ Polysorbate 80/ Capmul® MCM (20/15/50/15)	6	50	90	2.7 ± 1.5	0.86 ± 0.31	1.3
	Fed	5	50	30	1.7 ± 0.3	0.64 ± 0.21	1.0
		6	50	30	3.8 ± 1.2	1.6 ± 0.6	1.0
PP	Miglyol® 812 /Triacetin/ Cremophor® RH40/ Capmul® MCM (17/13/39/31)	5	50	30	1.6 ± 0.6	0.61 ± 0.18	1.2
	Fed	5	50	30	3.8 ± 0.8	1.55 ± 0.38	1.4
SS	Triacetin/Cremophor® RH40 /Capmul® MCM (28/30/42)	6	75	90	1.9 ± 1.7	0.44 ± 0.26	1.3
	Fed	4	75	90	7.3 ± 1.3	1.8 ± 0.5	1.5
WW	Miglyol® 812 /Ethyl lactate /Cremophor ®RH40 /Capmul® MCM (11/50/29/10)	5	150	90	1.5 ± 0.7	0.54 ± 0.17	0.9

* n < 6 due to emesis.

** Due to emesis and outlier

Different set of dogs

Table 12b Pharmacokinetic results for Other Compounds in dogs

Cmpd	Formulation Composition	n	Conc. (mg/mL)	Dose (mg)	AUC 0-tlast [#] (µg*hr/mL)	Cmax (µg/mL)	Tmax (hr)
D*	Miglyol [®] 812 /Triacetin/ Cremophor [®] RH40/ Capmul [®] MCM (20/30/20/30)	3*	100	90	3.45 ± 0.96	0.86 ± 0.31	1.7
	Fed	4*	100	90	4.84 ± 1.23	1.20 ± 0.41	1.5
E	Miglyol [®] 812/Triacetin/ Polysorbate 80/Capmul [®] MCM (22/27/20/31)	4**	100	60	2.90 ± 0.67	0.20 ± 0.14	1.5

- 5 * Emesis in 1 fasted dog (data not included) and in 4 fed dogs (included); dosed with 50 mL water.
 ** Emesis in 3 dogs (included), dosed with 10 mL water. Different set of dogs from those receiving Compound D.
 # Tlast = 24 hr for Compound D and 48 hr for Compound E.

10

Example 13:

15 This example further illustrates the determination of equilibrium solubilities of CETP inhibitors in vehicles. For experimental methods, see Example 9.

20 The solubility of crystalline CETP inhibitors in representative vehicles was determined by adding an excess of compound to the vehicle in question. The mixture was agitated by rotation over a period of days at ambient temperature until the concentration in solution had reached equilibrium as judged by similar measurements for consecutive time points. Concentrations were measured by filtration of aliquots with a PTFE syringe filter and assayed by HPLC.

25 The concentrations of CETP inhibitor in each vehicle were assayed at intervals by dilution of aliquots into acetonitrile and gradient HPLC analysis on a Water Symmetry C-8 column (3.9 x 150 mm, 5 micron) at 30 °C at a flow rate of 1 mL/min. The mobile phase program was a 25 minute gradient from 100 % A to 50% A/50 % B (A = 400/300/300/0.8 v/v DI H₂O/Acetonitrile/2-Propanol/Phosphoric Acid and B = 2-Propanol), followed by a 5 minute hold at this condition and a 10 minute

-140-

gradient to the initial condition. The detection method was UV absorbance at 210 nm.

The results of the equilibrium solubility studies are given in Tables 13a-13c.

5

Table 13a. Equilibrium Solubilities of Compound A in Triglyceride/ surfactant(s)

Vehicle	Solubility (mgA/ml) Cmpd A
Miglyol® 812/Capmul® MCM (80/20)	74
Miglyol® 812/Capmul® MCM/Polysorbate 80 (40/40/20)	58
Miglyol® 812/Capmul® MCM/Polysorbate 80 (20/60/20)	63
Miglyol® 812/Tagat® TO (80/20)	58
Miglyol® 812/Labrafil® M 1944 (80/20)	59
Miglyol® 812/Labrafil® M 2125 (80/20)	57
Miglyol® 812/Labrasol® (80/20)	69
Miglyol® 812/Cremophor® EL 80/20	68
Olive oil/Capmul® MCM (80/20)	23

10

Table 13b. Equilibrium Solubility of Compound A in Triglyceride/solvent

Vehicle	Solubility (mgA/ml)
Miglyol® 812/triacetin (90/10)*	106
Miglyol® 812/Peppermint oil (90/10)	79
Miglyol® 812/Peppermint oil (80/20)	93
Olive oil /Peppermint oil (90/10)	25

15 * Not completely miscible

20

-141-

Table 13c. Equilibrium Solubility of Compound A in Miglyol/Solvent/surfactant

Vehicle	Solubility (mgA/ml)
Miglyol® 812/Propylene carbonate/Cremophor® EL	
72/8/20	108
60/20/20	146
55/25/20	158
40/40/20	209
30/50/20	228
Miglyol® 812/Ethyl lactate/Cremophor® EL	
72/8/20	94
70/10/20	99
65/15/20	120
60/20/20	143
50/30/20	196
40/40/20	221
30/50/20	256
Miglyol® 812/Triacetin/Cremophor® EL	
72/8/20	94
65/15/20	111
60/20/20	133
50/30/20	158
40/40/20	183
30/50/20	198
Miglyol® 812/Peppermint Oil/Cremophor® EL (72/8/20)	72
Miglyol® 812/EtOH/Cremophor® EL (76/4/20)	89
Miglyol® 812/Ethyl lactate/Tagat® TO (72/8/20)	87
Miglyol® 812/Ethyl lactate/Labrasol® (72/8/20)	98
Miglyol® 812/Propylene carbonate/Tagat® TO (72/8/20)	111
Miglyol® 812/Propylene carbonate/Labrasol® (72/8/20)	116

Example 14:

- 5 For CETP inhibitors where quantities were limited or the samples were amorphous solids, an estimate of solubility was obtained by addition of vehicle to a known quantity of the compound and mixing in an ultrasonicator bath for 90 minutes, followed by overnight equilibration at ambient temperature. Addition of vehicle was repeated until a solution was achieved. From the total volume of vehicle added to
- 10 solubilize the CETP inhibitor compound, the solubility value, or so-called microsolubility, was calculated by the equation:

$$\text{Weight of sample (mgA) / vehicle volume (mL) = Microsolubility (mgA/mL)}$$

- 15 The microsolubility values for CETP inhibitors in various vehicles are given in Tables 14a – 14c.

Table 14a. Microsolubility Data for Crystalline Compounds

20

Solvent	Solubility (mg/mL)	
	Cmpd A	Cmpd B
Crodamol® GTCC	< 75	<20
Miglyol® 810	< 100	
Long chain triglycerides (soy, peanut, corn, safflower, sesame)	<75	<100
Cotton oil	<75	
Olive oil		<100
Capmul® MCM		<100
PEG 400		<100
Crodamol® GTCC /Capmul® MCM/ Polysorbate 80 (40/40/20)		<100
Linoleic acid	< 60	
Incromega® TG2671	<75	
propylene glycol	< 75	
Glycerin	< 75	
mineral oil	<75	

-143-

Table 14b. Microsolubilities of amorphous compounds (mg/mL)

	Cmpd F	Cmpd G	Cmpd H	Cmpd I	Cmpd J
Miglyol [®] 812	<100				
Crodamol [®] GTCC			>300	>20	>100
Corn, Safflower, Soybean oils			>300	<20	>100
Peanut oil				<20	>100
Olive oil	303	>300	>300	<20	>100
Sesame oil		>300		<20	>100
Cremophor [®] EL		>300	<160		
Capmul [®] MCM			>300	>20	>100
PEG 400			<160	<20	50-100
Corn oil/Polysorbate 80 (80/20)				>20	
Corn oil/Labrafil (80/20)				<20	
Crodamol [®] GTCC /Capmul [®] MCM/ Polysorbate 80 (40/40/20)		>300		>20	>100

5 Table 14c. Microsolubilities of amorphous compounds (mg/mL)

	Olive oil	Safflower oil	Miglyol [®] 812	Capmul [®] MCM
Cmpd L	<300	>300	>300	>300
Cmpd M	<300	<300	>300	>300
Cmpd A	>300	>300	>300	>300
Cmpd N	>300	>300	>300	>300
Cmpd O	<300	<300	>300	>300
Cmpd P	>300	<300	>300	>300
Cmpd Q	<300	<300	>300	>300

Example 15:

To 1.41 mL of Miglyol® 812, 0.471 mL of propylene carbonate and 0.471 mL of Cremophor® EL was added 900 mg of Compound E. The resulting mixture was stirred at ambient temperature for 20 minutes with scraping of the container walls as needed. It was then probe sonicated for 30 seconds with occasional mixing to completely dissolve the drug, and then stirred for 20 minutes at ambient temperature. The amounts (in mg) of each component in the oil solution per gram of solution are set forth in Table 15.

Table 15

Ingredient	mg/g
Compound E	275
Miglyol® 812	406
Propylene carbonate	166
Cremophor® EL	153

An emulsion was prepared by combining 1 volume of oil solution with an equal volume of de-ionized water. This mixture was stirred for 10 minutes and then vortex mixed for 1 minute to yield an emulsion with an average particle size less than 10 microns. The emulsion is then stirred continuously to maintain homogeneity. No chemical degradation based on HPLC analysis or crystallization based on microscopic examination was detected in the oil or emulsion after storage for 24 hr.

Example 16:

Capmul® MCM was heated to 55°C and mixed. Cremophor® RH40 was also heated to 65°C with stirring. Then 2.70 g of triacetin, 2.71 g of Cremophor® RH40, and 3.60 g of Capmul® MCM were combined and mixed for 20 min. To this mixture was then added 1.01 gm of Compound A and the resulting mixture stirred at ambient temperature for 3 hours with scraping of walls as needed. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 16a.

Table 16a

Ingredient	mg/g
Cmpd A	100
Triacetin	270
Cremophor® RH40	270
Capmul® MCM	360

5

Example 17:

To 495 mg of Miglyol® 812, 203 mg of propylene carbonate and 187 mg of Cremophor® EL was added 115 mg of Compound A. The resulting mixture was stirred at ambient temperature for 20 minutes with scraping of the container walls as needed. It was then probe sonicated for 3 minutes with occasional mixing to completely dissolve the drug, and then stirred for 20 minutes at ambient temperature. The amounts (in mg) of each component in the oil solution per gram of solution are set forth in Table 17a.

15

Table 17a

Ingredient	mg/g
Cmpd A	115
Miglyol® 812	495
Propylene carbonate	203
Cremophor® EL	187

An emulsion was prepared by combining 1 volume of oil solution with an equal volume of de-ionized water. This mixture was stirred for 10 minutes and then vortex mixed for 2 minutes. The emulsion had an average particle size of less than 10 microns. It was stirred continuously to maintain homogeneity. No chemical degradation based on HPLC analysis or crystallization based on microscopic examination was detected in the oil after storage for 8 days or the emulsion after storage for 24 hr.

25

Example 18:

To 764 mg of olive oil and 223 mg of Cremophor® EL was added 13 mg of Compound

- 5 A. The resulting mixture was stirred at ambient temperature for 20 minutes with scraping of container walls as needed. It was then probe sonicated for 3 minutes with occasional mixing to completely dissolve the drug. The solution was then stirred for 20 minutes at ambient temperature. The amounts (in mg) of each component in the oil solution per gram of solution are set forth in Table 18a.

10

Table 18a

Ingredient	mg/g
Compound A	13
Olive oil	764
Cremonphor [®] EL	223

- 15 An emulsion was prepared by combining combining 1 volume of oil solution with an equal volume of de-ionized water. This mixture was stirred for 10 minutes and then vortex mixed for 2 minutes. The emulsion had an average particle size of less than 10 microns. It was stirred continuously to maintain homogeneity. No chemical degradation based on HPLC analysis or crystallization based on microscopic
20 examination was detected in the oil after storage for 8 days or the emulsion after storage for 24 hr.

Example 19:

- 25 To 485 mg of Miglyol® 812, 199 mg of propylene carbonate and 183 mg of
Cremophor® EL was added 133 mg of Compound D. The resulting mixture was stirred
at ambient temperature for 20 minutes with scraping of container walls as needed. It
was then probe sonicated for 3 minutes with occasional mixing to completely dissolve
the drug. The solution was stirred for further stirred for 20 minutes at ambient
30 temperature. The amounts (in mg) of each component in the oil solution per gram of
solution are set forth in Table 19A.

Table 19A

Ingredient	mg/g
Cmpd D	133
Miglyol® 812	485
Propylene carbonate	199
Cremophor® EL	183

An emulsion was prepared by combining combining 1 volume of oil solution with an equal volume of de-ionized water. This mixture was stirred for 10 minutes and then vortex mixed for 2 minutes. The emulsion had an average particle size of less than 10 microns. It was stirred continuously to maintain homogeneity. No chemical degradation based on HPLC analysis or crystallization based on microscopic examination was detected in the oil after storage for 8 days or the emulsion after storage for 24 hr.

10

Example 20:

Chemical and physical stability for the formulation of Example 8 was determined for 30 mgA Miglyol® (#11 oblong) softgels stored in white HPDE bottles (child-resistant closures). After storage at 40°C/75%RH for 6 months there was no change in potency and no degradation was detected (peak area < 0.05 % relative to parent) as determined by HPLC analysis of the entire softgel. The appearance (color, shape, seal integrity) was unchanged, and disintegration occurred within 15 minutes in water (USP<701>). Softgels stored at 5°C and 25°C/60% RH were stable for 18 months.

15

Example 21:

Either oils or preformed emulsions of Compound A were administered to Sprague Dawley rats by oral gavage and the results are shown in Table 21a. Emulsions were prepared as indicated in Examples 17-19. Emulsions prepared from olive oil/surfactant provided the best results. The solubility and thus the accessible dose could be increased by using cosolvents (e.g. caprylic acid and/or triacetin) or using a triglyceride with improved solubility (Miglyol® 812), but this did not provide any improvement in exposure over much lower doses in olive oil/Cremophor® EL. Administration of pre-formed emulsions gave superior results to the oil, especially at higher dose volumes where mixing of phases in vivo may be less efficient.

25

In contrast to the results in rats, emulsions in Miglyol® 812/Cremophor® EL yielded far superior results to olive oil/Cremophor® EL in cynomolgous monkeys (Table 21b), and much better results than for Miglyol® alone. Use of an emulsion prepared from crystalline (ethanolate) drug allowed comparable exposures to be achieved to those for more soluble amorphous drug in Miglyol® alone. Excellent dose proportionality was also obtained.

10 The need for the presence of a high concentration of the long chain triglyceride olive oil for efficient absorption in the rat, but not the monkey, suggests that the lymphatic pathway plays a more important role for absorption of this drug in rats. An important role for lymphatic absorption for Compound A is consistent with its very high lipophilicity.

15 Table 21a. PK results in rat for Compound A

Drug Form	Vehicle	Dose (mg /kg)	Conc. in oil (mg/mL)	Vol. of oil (mg/kg)	Cmax (µg/mL)	AUC (0-Tlast) (µg-hr/mL)
Ethanol.	Olive oil/ Cremophor® / water 40/10/50	100	20	5	6.2	33*
Ethanol.	Miglyol® /Cremophor® /water 40/10/50	500	100	5	4.6	18*
Ethanol.	Olive oil/caprylic acid/ Cremophor®/water 10/30/10/50	375	75	5	4.1	21*
Ethanol.	Olive oil/caprylic acid/triacetin/ Cremophor®/water 10/15/15/10/50	625	125	5	4.8	26*
Ethanol.	Olive oil/ Cremophor® 80/20	100	20	5	3.6	45
Ethanol.	Miglyol® / Cremophor® / water 40/10/50	100	100	1	1.9	23
Ethanol.	Miglyol®/Cremophor®/ 0.5 % HPMCAS 40/10/50	100	100	1	1.6	15
Ethanol.	Miglyol®	500	100	5	2.1	27
Amorph.	Olive oil	300	60	5	7.3	50

-149-

* T_{last} = 9 hr. Otherwise, T_{last} = 24 hr.

Amorph. = amorphous anhydrous

Ethanol. = crystalline ethanolate

5 HPMCAS=Hydroxypropyl methyl cellulose acetate succinate

Table 21b. PK results in monkeys for Compound A

Form*	Vehicle	Dose (mg/kg)	Conc. in oil (mg/mL)	Vol. of oil (mg/kg)	C _{max} (µg/mL)	AUC (µg-hr/mL)
Ethanol.	Miglyol®/Cremophor®/ water 40/10/50	100 (BID)	100	1	1.6-2.3	24-29
Ethanol.	Miglyol®/Cremophor®/ water 40/10/50	50 (BID)	50	1	0.8 - 1.1	13-15
Ethanol.	Miglyol®/Cremophor®/ water 40/10/50	100	100	1	0.4-1.8	
Ethanol.	Olive oil/ Cremophor®/ water 40/10/50	20	20	1	0.1, 0.16	N.D.
Ethanol.	Miglyol®	100	100	1	ca. 0.17	N.D.
Amorph.	Miglyol®	100	100	1	ca. 1.6	ca. 29

* Amorph. = amorphous anhydrous

Ethanol. = crystalline ethanolate

Example 22:

A. 100 mgA/mL fill

Capmul® MCM was heated to 55°C and mixed. Then 48.5 gm of Miglyol® 812, 72.8 gm of triacetin, 48.5 gm of Polysorbate 80, and 72.8 gm of Capmul® MCM were combined. To this mixture was then added 25.0 gm Compound E and the resulting mixture stirred at ambient temperature for 10 minutes with scraping of walls as needed. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 22. The fill could be prepared on a larger scale for encapsulation into #10 oval softgels to provide a fill volume of 0.6 mL and a dose per softgel of 60 mgA.

B. 200 mgA/mL fill

Capmul® MCM was heated to 55°C and mixed. Then 650 mg of Miglyol® 812, 976 mg of triacetin, 650 mg of Polysorbate 80, and 976 mg of Capmul® MCM were combined and mixed for 10 min. To this mixture was then added 748 mg Compound E and the resulting mixture stirred at ambient temperature for 10 minutes with scraping of wall as needed. The amounts (in mg) of each component in the fill per gram of fill are set forth in Table 22. The fill could be prepared on a larger scale for encapsulation into #10 oval softgels to provide a fill volume of 0.6 mL and a dose per softgel of 120 mgA.

10 Table 22

Ingredient	mg/g	
	100 mgA/mL	200 mgA/mL
Compound E	94	184
Miglyol® 812	181	163
Triacetin	272	245
Polysorbate 80	181	163
Capmul® MCM	272	245

-151-

What is claimed is:


1. A composition comprising a CETP inhibitor and a lipophilic vehicle selected from digestible oils, lipophilic solvents, surfactants, and mixtures of any two or more thereof.
2. A composition, comprising
a CETP inhibitor;
a co-solvent;
a high HLB surfactant;
a low HLB surfactant; and
optionally, a digestible oil.
3. A composition as defined in claim 2, wherein said CETP inhibitor has an aqueous solubility less than 10 µg/mL.
4. A composition as defined in claim 2, wherein said co-solvent is selected from triacetin, propylene carbonate, transcitol, ethyl lactate, triethyl citrate, N-methyl-2-pyrrolidone, dimethylisobornide and glycofurool.
5. A composition as defined in claim 2, wherein said (high HLB) hydrophilic surfactant is selected from polyoxyethylene 20 sorbitan monooleate (polysorbate 80), polyoxyethylene 20 sorbitan monolaurate, polyethylene (40 or 60) hydrogenated castor oil, polyoxyethylene (35) castor oil, alpha tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), glyceryl PEG 8 caprylate/caprate, PEG 32 glyceryl laurate, polyoxyethylene fatty acid esters, and polyoxyethylene fatty acid ethers.
6. A composition as defined in claim 2, wherein said (low HLB) lipophilic surfactant is selected from mono and diglycerides of capric and caprylic acid, polyoxyethylene 6 apricot kernel oil, polyoxyethylene corn oil, propylene glycol monolaurate, propylene glycol dicaprylate/caprate, polyglyceryl oleate, sorbitan esters of fatty acids, and glyceryl monooleate.
7. A composition as defined in claim 2, which is self-emulsifying and comprises the following amounts of components:
1-50 % CETP inhibitor;
5 - 60 % cosolvent;
5 - 75 % high HLB surfactant; and
5 - 75 % low HLB surfactant.

-152-

8. A composition as defined in claim 1, wherein said CETP inhibitor is selected from any of the following classes:

(1) an oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoline having the Formula I

5



Formula I

or a pharmaceutically acceptable salt, enantiomer, or stereoisomer of said compound;

10

wherein R_{1-1} is hydrogen, Y_1 , W_1-X_1 , W_1-Y_1 ;

wherein W_1 is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

X_1 is $-O-Y_1$, $-S-Y_1$, $-N(H)-Y_1$ or $-N-(Y_1)_2$;

wherein Y_1 for each occurrence is independently Z_1 or a fully saturated,

15

partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_1 ;

20

wherein Z_1 is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected

25

independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_1 substituent is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxyl, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-,
 5 di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxyl, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

R_{1-3} is hydrogen or Q_1 ;

10 wherein Q_1 is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with
 15 hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_1 ;

wherein V_1 is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected
 20 independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V_1 substituent is optionally mono-, di-, tri-, or tetra-substituted
 25 independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carbamoyl, mono-N- or di-N,N- (C_1-C_6) alkylcarbamoyl, carboxyl, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxyl, (C_1-C_6) alkyloxycarbonyl, mono-N- or
 30 di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituents are also optionally substituted with from one to nine fluorines;

R_{1-4} is Q_{1-1} or V_{1-1}

wherein Q_{i-1} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{i-1} ;

10 wherein V_{i-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V_{i-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;


wherein either R_{i-3} must contain V_i or R_{i-4} must contain V_{i-1} ; and R_{i-5} , R_{i-6} , R_{i-7} and R_{i-8} are each independently hydrogen, hydroxy or oxy wherein said oxy is substituted with T_i or a partially saturated, fully saturated or fully unsaturated one to twelve membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with T_i ;

wherein T_i is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

-155-

wherein said T₁ substituent is optionally mono-, di- or tri-substituted independently with halo, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl substituent is also optionally substituted with from one to nine fluorines;

- (2) a 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinoline, having the
Formula II



Formula II

or a pharmaceutically acceptable salt, enantiomer, or stereoisomer of said compound;

wherein R_{II-1} is hydrogen, Y_{II}, W_{II}-X_{II}, W_{II}-Y_{II};

wherein W_{II} is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

- 20 X_{II} is -O-Y_{II}, -S-Y_{II}, -N(H)-Y_{II} or -N-(Y_{II})₂;

wherein Y_{II} for each occurrence is independently Z_{II} or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted

with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_{II} ;

Z_{II} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_{II} substituent is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl is also optionally substituted with from one to nine fluorines;

R_{II-3} is hydrogen or Q_{II} ;

wherein Q_{II} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{II} ;

wherein V_{II} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V_{II} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N- (C_1-C_6)

- alkylcarboxamoyl, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl or (C₂-C₆)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino or said (C₁-C₆)alkyl or (C₂-C₆)alkenyl substituents are optionally substituted with from one to nine fluorines;

R_{II-4} is Q_{II-1} or V_{II-1}

- wherein Q_{II-1} a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{II-1};

wherein V_{II-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

- wherein said V_{II-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, amino, nitro, cyano, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-substituted with oxo, said (C₁-C₆)alkyl substituent is optionally substituted with from one to nine fluorines;

wherein either R_{II-3} must contain V_{II} or R_{II-4} must contain V_{II-1}; and

- R_{II-5}, R_{II-6}, R_{II-7} and R_{II-8} are each independently hydrogen, a bond, nitro or halo wherein said bond is substituted with T_{II} or a partially saturated, fully saturated or fully unsaturated (C₁-C₁₂) straight or branched carbon chain wherein carbon may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon is optionally mono-substituted with T_{II};

-158-


wherein T_{II} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected

5 wherein said T_{II} substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or

10 di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

15 provided that at least one of substituents R_{II-5} , R_{II-6} , R_{II-7} and R_{II-8} is not hydrogen and is not linked to the quinoline moiety through oxy;

(3) an annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinoline having the Formula III



20

Formula III

or a pharmaceutically acceptable salt, enantiomer, or stereoisomer of said

25 compound;

wherein R_{III-1} is hydrogen, Y_{III} , $W_{III}-X_{III}$, $W_{III}-Y_{III}$;

wherein W_{III} is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

X_{III} is $-O-Y_{III}$, $-S-Y_{III}$, $-N(H)-Y_{III}$ or $-N-(Y_{III})_2$;

Y_{III} for each occurrence is independently Z_{III} or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_{III};

wherein Z_{III} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_{III} substituent is optionally mono-, di- or tri-substituted independently with halo, (C₂-C₆)alkenyl, (C₁-C₆) alkyl, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl optionally substituted with from one to nine fluorines; R_{III-3} is hydrogen or Q_{III};

wherein Q_{III} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{III};

wherein V_{III} is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two

-160-

fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V_{III} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N- (C_1-C_6) alkylcarboxamoyl, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino or said (C_1-C_6) alkyl or (C_2-C_6) alkenyl are optionally substituted with from one to nine fluorines;

R_{III-4} is Q_{III-1} or V_{III-1} ;

wherein Q_{III-1} a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{III-1} ;

wherein V_{III-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V_{III-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent optionally having from one to nine fluorines;

wherein either R_{III-3} must contain V_{III} or R_{III-4} must contain V_{III-1} ; and R_{III-5} and R_{III-6} , or R_{III-6} and R_{III-7} , and/or R_{III-7} and R_{III-8} are taken together and form at least one four to eight membered ring that is partially saturated or fully unsaturated


-161-

optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;

- wherein said ring or rings formed by R_{III-5} and R_{III-6} , or R_{III-6} and R_{III-7} , and/or R_{III-7} and R_{III-8} are optionally mono-, di- or tri-substituted independently with halo, (C₁-C₆)alkyl, (C₁-C₄)alkylsulfonyl, (C₂-C₆)alkenyl, hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C₁-C₆)alkoxy, (C₁-C₄)alkylthio, amino, nitro, cyano, oxo, carboxy, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl substituent optionally having from one to nine fluorines;

provided that the R_{III-5} , R_{III-6} , R_{III-7} and/or R_{III-8} , as the case may be, that do not form at least one ring are each independently hydrogen, halo, (C₁-C₆)alkoxy or (C₁-C₆)alkyl, said (C₁-C₆)alkyl optionally having from one to nine fluorines;

- (4) a 4-carboxyamino-2-substituted-1,2,3,4,-tetrahydroquinoline, having the Formula IV



Formula IV

- and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds;

wherein R_{IV-1} is hydrogen, Y_{IV} , $W_{IV}-X_{IV}$ or $W_{IV}-Y_{IV}$;

wherein W_{IV} is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

X_{IV} is $-O-Y_{IV}$, $-S-Y_{IV}$, $-N(H)-Y_{IV}$ or $-N-(Y_{IV})_2$;

wherein Y_{IV} for each occurrence is independently Z_{IV} or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally
5 be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said
10 carbon chain is optionally mono-substituted with Z_{IV} ;

wherein Z_{IV} is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered
15 rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z_{IV} substituent is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or
20 di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

R_{IV-2} is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is
30 optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R_{IV-2} is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to

two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said R_{IV-2} ring is optionally attached through (C_1-C_4) alkyl;

wherein said R_{IV-2} ring is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, oxo or (C_1-C_6) alkyloxycarbonyl;

with the proviso that R_{IV-2} is not methyl;

10 R_{IV-3} is hydrogen or Q_{IV} ;

wherein Q_{IV} is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{IV} ;

wherein V_{IV} is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V_{IV} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N- (C_1-C_6) alkylcarboxamoyl, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituents are also optionally substituted with from one to nine fluorines;

R_{IV-4} is Q_{IV-1} or V_{IV-1} ;

wherein Q_{IV-1} a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{IV-1} ;

10 wherein V_{IV-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V_{IV-1} substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, amino, nitro, cyano, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

wherein either R_{IV-3} must contain V_{IV} or R_{IV-4} must contain V_{IV-1} ;
 R_{IV-5} , R_{IV-6} , R_{IV-7} and R_{IV-8} are each independently hydrogen, a bond, nitro or halo
20 wherein said bond is substituted with T_{IV} or a partially saturated, fully saturated or fully unsaturated (C_1-C_{12}) straight or branched carbon chain wherein carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted
25 with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon is optionally mono-substituted with T_{IV} ;

wherein T_{IV} is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected
30 independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;


wherein said T_{IV} substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-,
 5 di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines; and

wherein R_{IV-5} and R_{IV-6} , or R_{IV-6} and R_{IV-7} , and/or R_{IV-7} and R_{IV-8} may also be
 10 taken together and can form at least one four to eight membered ring that is partially saturated or fully unsaturated optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring or rings formed by R_{IV-5} and R_{IV-6} , or R_{IV-6} and R_{IV-7} , and/or R_{IV-7} and R_{IV-8} are optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_4) alkylsulfonyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio,
 15 amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine
 20 fluorines;

with the proviso that when R_{IV-2} is carboxyl or (C_1-C_4) alkylcarboxyl, then R_{IV-1} is not hydrogen;

(5) a 4-amino substituted-2-substituted-1,2,3,4,-tetrahydroquinoline, having the
 25 Formula V



Formula V

or a pharmaceutically acceptable salt, enantiomer, or stereoisomers of said compound;

wherein R_{V-1} is Y_V , W_V-X_V or W_V-Y_V ;

wherein W_V is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

5 X_V is $-O-Y_V$, $-S-Y_V$, $-N(H)-Y_V$ or $-N-(Y_V)_2$;

wherein Y_V for each occurrence is independently Z_V or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z_V ;

15 wherein Z_V is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

20 wherein said Z_V substituent is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, 25 di- or tri-substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent is also optionally substituted with from one to nine fluorines;

30 R_{V-2} is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with

hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R_{V-2} is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein
5 said R_{V-2} ring is optionally attached through (C_1-C_4) alkyl;

wherein said R_{V-2} ring is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6) alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-
10 substituted independently with halo, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, oxo or (C_1-C_6) alkyloxycarbonyl;

R_{V-3} is hydrogen or Q_V ;

wherein Q_V is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than
15 the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted
20 with oxo, and said carbon chain is optionally mono-substituted with V_V ;

wherein V_V is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered
25 rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V_V substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N- (C_1-C_6) alkylcarboxamoyl, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl or (C_2-C_6) alkenyl substituent is optionally
30 mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or

di-N,N-(C₁-C₆)alkylamino, said (C₁-C₆)alkyl or (C₂-C₆)alkenyl substituents are also optionally substituted with from one to nine fluorines;

R_{V-4} is cyano, formyl, W_{V-1}Q_{V-1}, W_{V-1}V_{V-1}, (C₁-C₄)alkyleneV_{V-1} or V_{V-2};

wherein W_{V-1} is carbonyl, thiocarbonyl, SO or SO₂,

- 5 wherein Q_{V-1} a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is
10 optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V_{V-1};

- wherein V_{V-1} is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected
15 independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

- wherein said V_{V-1} substituent is optionally mono-, di-, tri-, or tetra-substituted
20 independently with halo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy, oxo, amino, nitro, cyano, (C₁-C₆)alkyloxycarbonyl, mono-N- or di-N,N-(C₁-C₆)alkylamino wherein said (C₁-C₆)alkyl substituent is optionally mono-substituted with oxo, said (C₁-C₆)alkyl substituent is also optionally substituted with from one to nine fluorines;

- wherein V_{V-2} is a partially saturated, fully saturated or fully unsaturated five to
25 seven membered ring containing one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;

- wherein said V_{V-2} substituent is optionally mono-, di- or tri-substituted independently with halo, (C₁-C₂)alkyl, (C₁-C₂)alkoxy, hydroxy, or oxo wherein said (C₁-C₂)alkyl optionally has from one to five fluorines; and

- 30 wherein R_{V-4} does not include oxycarbonyl linked directly to the C⁴ nitrogen; wherein either R_{V-3} must contain V_V or R_{V-4} must contain V_{V-1};

R_{V-5}, R_{V-6}, R_{V-7} and R_{V-8} are independently hydrogen, a bond, nitro or halo wherein said bond is substituted with T_V or a partially saturated, fully saturated or fully unsaturated (C₁-C₁₂) straight or branched carbon chain wherein carbon may

optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is
 5 optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with T_V ;

wherein T_V is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two
 10 fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;


wherein said T_V substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or
 15 di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent also optionally has from one to nine
 20 fluorines;

wherein R_{V-5} and R_{V-6} , or R_{V-6} and R_{V-7} , and/or R_{V-7} and R_{V-8} may also be taken together and can form at least one ring that is a partially saturated or fully unsaturated four to eight membered ring optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said rings formed by R_{V-5} and R_{V-6} , or R_{V-6} and R_{V-7} , and/or R_{V-7} and R_{V-8} are optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6) alkyl, (C_1-C_4) alkylsulfonyl, (C_2-C_6) alkenyl, hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino wherein said (C_1-C_6) alkyl substituent is optionally mono-, di- or tri-
 25 substituted independently with hydroxy, (C_1-C_6) alkoxy, (C_1-C_4) alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6) alkyloxycarbonyl, mono-N- or di-N,N- (C_1-C_6) alkylamino, said (C_1-C_6) alkyl substituent also optionally has from one to nine fluorines;
 30

(6) a cycloalkano-pyridine having the Formula VI

-170-



Formula VI

or a pharmaceutically acceptable salt, enantiomer, or stereoisomer of said compounds;


5 in which

A_{VI} denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with up to five identical or different substituents in the form of a halogen, nitro, hydroxyl, trifluoromethyl, trifluoromethoxy or a straight-chain or branched alkyl, acyl, hydroxyalkyl or alkoxy containing up to 7 carbon atoms each, or in the form of a group according to the formula $-BNR_{VI-3}R_{VI-4}$, wherein

R_{VI-3} and R_{VI-4} are identical or different and denote a hydrogen, phenyl or a straight-chain or branched alkyl containing up to 6 carbon atoms,

D_{VI} denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with a phenyl, nitro, halogen, trifluoromethyl or trifluoromethoxy, or a

15 radical according to the formula $R_{VI-5}-L_{VI}$,



or $R_{VI-5}-T_{VI}-V_{VI}-X_{VI}$, wherein

20 R_{VI-5} , R_{VI-6} and R_{VI-9} denote, independently from one another, a cycloalkyl containing 3 to 6 carbon atoms, or an aryl containing 6 to 10 carbon atom or a 5- or 7-membered, optionally benzo-condensed, saturated or unsaturated, mono-, bi- or tricyclic heterocycle containing up to 4 heteroatoms from the series of S, N and/or O, wherein the rings are optionally substituted, in the case of the nitrogen-containing

25 rings also via the N function, with up to five identical or different substituents in the form of a halogen, trifluoromethyl, nitro, hydroxyl, cyano, carboxyl, trifluoromethoxy, a straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxy carbonyl containing up to 6 carbon atoms each, an aryl or trifluoromethyl-

-171-


substituted aryl containing 6 to 10 carbon atoms each, or an optionally benzo-condensed, aromatic 5- to 7-membered heterocycle containing up to 3 heteroatoms from the series of S, N and/or O, and/or in the form of a group according to the formula $\text{BOR}_{\text{VI-10}}$, $-\text{SR}_{\text{VI-11}}$, $-\text{SO}_2\text{R}_{\text{VI-12}}$ or $\text{BNR}_{\text{VI-13}}\text{R}_{\text{VI-14}}$, wherein

- 5 $\text{R}_{\text{VI-10}}$, $\text{R}_{\text{VI-11}}$ and $\text{R}_{\text{VI-12}}$ denote, independently from one another, an aryl containing 6 to 10 carbon atoms, which is in turn substituted with up to two identical or different substituents in the form of a phenyl, halogen or a straight-chain or branched alkyl containing up to 6 carbon atoms,

$\text{R}_{\text{VI-13}}$ and $\text{R}_{\text{VI-14}}$ are identical or different and have the meaning of $\text{R}_{\text{VI-3}}$ and

- 10 $\text{R}_{\text{VI-4}}$ given above, or

$\text{R}_{\text{VI-5}}$ and/or $\text{R}_{\text{VI-6}}$ denote a radical according to the formula



$\text{R}_{\text{VI-7}}$ denotes a hydrogen or halogen, and

- 15 $\text{R}_{\text{VI-8}}$ denotes a hydrogen, halogen, azido, trifluoromethyl, hydroxyl, trifluoromethoxy, a straight-chain or branched alkoxy or alkyl containing up to 6 carbon atoms each, or a radical according to the formula



wherein

- 20 $\text{R}_{\text{VI-15}}$ and $\text{R}_{\text{VI-16}}$ are identical or different and have the meaning of $\text{R}_{\text{VI-3}}$ and $\text{R}_{\text{VI-4}}$ given above, or

$\text{R}_{\text{VI-7}}$ and $\text{R}_{\text{VI-8}}$ together form a radical according to the formula $=\text{O}$ or $=\text{NR}_{\text{VI-17}}$, wherein

$\text{R}_{\text{VI-17}}$ denotes a hydrogen or a straight-chain or branched alkyl, alkoxy or acyl containing up to 6 carbon atoms each,

- 25 L_{VI} denotes a straight-chain or branched alkylene or alkenylene chain containing up to 8 carbon atoms each, which are optionally substituted with up to two hydroxyl groups,

T_{VI} and X_{VI} are identical or different and denote a straight-chain or branched alkylene chain containing up to 8 carbon atoms, or


- 30 T_{VI} or X_{VI} denotes a bond,

V_{VI} denotes an oxygen or sulfur atom or an $\text{BNR}_{\text{VI-18}}$ group, wherein

$\text{R}_{\text{VI-18}}$ denotes a hydrogen or a straight-chain or branched alkyl containing up to 6 carbon atoms or a phenyl,

E_{V1} denotes a cycloalkyl containing 3 to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a cycloalkyl containing 3 to 8 carbon atoms or a hydroxyl, or a phenyl, which is optionally substituted with a halogen or trifluoromethyl.

5 R_{VI-1} and R_{VI-2} together form a straight-chain or branched alkylene chain containing up to 7 carbon atoms, which must be substituted with a carbonyl group and/or a radical according to the formula



10 wherein

a and b are identical or different and denote a number equaling 1, 2 or 3,

R_{VI-19} denotes a hydrogen atom, a cycloalkyl containing 3 to 7 carbon atoms, a straight-chain or branched silylalkyl containing up to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a hydroxyl, a straight-chain or a branched alkoxy containing up to 6 carbon atoms or a phenyl, which may in turn be substituted with a halogen, nitro, trifluoromethyl, trifluoromethoxy or phenyl or tetrazole-substituted phenyl, and an alkyl that is optionally substituted with a group according to the formula BOR_{VI-22} , wherein

20 R_{VI-22} denotes a straight-chain or branched acyl containing up to 4 carbon atoms or benzyl, or


R_{VI-19} denotes a straight-chain or branched acyl containing up to 20 carbon atoms or benzoyl, which is optionally substituted with a halogen, trifluoromethyl, nitro or trifluoromethoxy, or a straight-chain or branched fluoroacyl containing up to 8 carbon atoms.

R_{VI-20} and R_{VI-21} are identical or different and denote a hydrogen, phenyl or a straight-chain or branched alkyl containing up to 6 carbon atoms, or

R_{V1-20} and R_{V1-21} together form a 3- to 6-membered carbocyclic ring, and a the carbocyclic rings formed are optionally substituted, optionally also geminally, with up to six identical or different substituents in the form of trifluoromethyl, hydroxyl, nitrile, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy containing 3 to 7 carbon atoms each, a straight-chain or branched alkoxy carbonyl, alkoxy or alkylthio

-173-

containing up to 6 carbon atoms each, or a straight-chain or branched alkyl containing up to 6 carbon atoms, which is in turn substituted with up to two identical or different substituents in the form of a hydroxyl, benzyloxy, trifluoromethyl, benzoyl, a straight-chain or branched alkoxy, oxyacyl or carboxyl containing up to 4 carbon atoms each and/or a phenyl, which may in turn be substituted with a halogen, trifluoromethyl or trifluoromethoxy, and/or the carbocyclic rings formed are optionally substituted, also geminally, with up to five identical or different substituents in the form of a phenyl, benzoyl, thiophenyl or sulfonylbenzyl, which in turn are optionally substituted with a halogen, trifluoromethyl, trifluoromethoxy or nitro, and/or optionally in the form of a radical according to the formula




wherein

c is a number equaling 1, 2, 3 or 4,

d is a number equaling 0 or 1,

$\text{R}_{\text{VI}-23}$ and $\text{R}_{\text{VI}-24}$ are identical or different and denote a hydrogen, cycloalkyl containing 3 to 6 carbon atoms, a straight-chain or branched alkyl containing up to 6 carbon atoms, benzyl or phenyl, which is optionally substituted with up to two identical or different substituents in the form of halogen, trifluoromethyl, cyano, phenyl or nitro, and/or the carbocyclic rings formed are optionally substituted with a spiro-linked radical according to the formula



wherein

W_{VI} denotes either an oxygen atom or a sulfur atom,

Y_{VI} and Y'_{VI} together form a 2- to 6-membered straight-chain or branched alkylene chain,

e is a number equaling 1, 2, 3, 4, 5, 6 or 7,


f is a number equaling 1 or 2,

-174-

R_{VI-25} , R_{VI-26} , R_{VI-27} , R_{VI-28} , R_{VI-29} , R_{VI-30} and R_{VI-31} are identical or different and denote a hydrogen, trifluoromethyl, phenyl, halogen or a straight-chain or branched alkyl or alkoxy containing up to 6 carbon atoms each, or

5 R_{VI-25} and R_{VI-26} or R_{VI-27} and R_{VI-28} each together denote a straight-chain or branched alkyl chain containing up to 6 carbon atoms or

R_{VI-25} and R_{VI-26} or R_{VI-27} and R_{VI-28} each together form a radical according to the formula



wherein


10 W_{VI} has the meaning given above,

g is a number equaling 1, 2, 3, 4, 5, 6 or 7,

R_{VI-32} and R_{VI-33} together form a 3- to 7-membered heterocycle, which contains an oxygen or sulfur atom or a group according to the formula SO , SO_2 or BNR_{VI-34} , wherein

15 R_{VI-34} denotes a hydrogen atom, a phenyl, benzyl, or a straight-chain or branched alkyl containing up to 4 carbon atoms, and salts and N oxides thereof, with the exception of 5(6H)-quinolones, 3-benzoyl-7,8-dihydro-2,7,7-trimethyl-4-phenyl;

(7) a substituted-pyridine having the Formula VII



Formula VII

or a pharmaceutically acceptable salt or tautomer thereof,


wherein

25 R_{VII-2} and R_{VII-6} are independently selected from the group consisting of hydrogen, hydroxy, alkyl, fluorinated alkyl, fluorinated aralkyl, chlorofluorinated alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, alkoxyalkyl, and alkoxy carbonyl; provided that at least one of R_{VII-2} and R_{VII-6} is fluorinated alkyl, chlorofluorinated alkyl or alkoxyalkyl;

-176-


wherein $R_{VII-10a}$ and $R_{VII-10b}$ are independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, and -OP(S) ($OR_{VII-11a}$) ($OR_{VII-11b}$), wherein $R_{VII-11a}$ and $R_{VII-11b}$ are independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;

- 5 R_{VII-5} is selected from the group consisting of hydrogen, hydroxy, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclioxy, alkylcarbonyloxyalkyl, alkenylcarbonyloxyalkyl, alkynylcarbonyloxyalkyl, arylcarbonyloxyalkyl, heteroarylcarbonyloxyalkyl, heterocyclylcarbonyloxyalkyl, cycloalkylalkyl, cycloalkenylalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkylalkenyl, cycloalkenylalkenyl, aralkenyl, heteroarylalkenyl, heterocyclylalkenyl, alkylthioalkyl, cycloalkylthioalkyl, alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, heteroarylthioalkyl, heterocyclylthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl, arylthioalkenyl, heteroarylthioalkenyl, heterocyclylthioalkenyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, heterocyclioxyalkyl, alkoxyalkenyl, alkenoxyalkenyl, alkynoxyalkenyl, aryloxyalkenyl, heteroaryloxyalkenyl, heterocyclioxyalkenyl, cyano, hydroxymethyl, $-CO_2R_{VII-14}$, wherein R_{VII-14} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;
- 20




- wherein $R_{VII-15b}$ is selected from the group consisting of hydroxy, hydrogen, halogen, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclioxy, aryloxy, and alkylsulfonyloxy, and
- 25

$R_{VII-16b}$ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, arylalkoxy, and trialkylsilyloxy;



-177-

wherein R_{VII-17} and R_{VII-18} are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;




5 wherein R_{VII-19} is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, $-\text{SR}_{VII-20}$, $-\text{OR}_{VII-21}$, and $\text{BR}_{VII-22}\text{CO}_2\text{R}_{VII-23}$, wherein

R_{VII-20} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aminoaryl, aminoheteroaryl, aminoheterocyclyl, alkylheteroaryl amino, arylheteroaryl amino,

10 R_{VII-21} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl,


R_{VII-22} is selected from the group consisting of alkylene or arylene, and

R_{VII-23} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;




15

wherein R_{VII-24} is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, aralkyl, aralkenyl, and aralkynyl;






20

wherein R_{VII-25} is heterocyclidenyl;




wherein R_{VII-26} and R_{VII-27} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;


-178-



- wherein $\text{R}_{\text{VII-28}}$ and $\text{R}_{\text{VII-29}}$ are independently selected from the group
 5 consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;





- wherein $\text{R}_{\text{VII-30}}$ and $\text{R}_{\text{VII-31}}$ are independently alkoxy, alkenoxy, alkynoxy,
 aryloxy, heteroaryloxy, and heterocyclioxy; and



10


- wherein $\text{R}_{\text{VII-32}}$ and $\text{R}_{\text{VII-33}}$ are independently selected from the group
 consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and
 heterocyclyl;




15

- wherein $\text{R}_{\text{VII-36}}$ is selected from the group consisting of alkyl, alkenyl, aryl,
 heteroaryl and heterocyclyl;

-179-



wherein $\text{R}_{\text{VII-37}}$ and $\text{R}_{\text{VII-38}}$ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;




5

wherein $\text{R}_{\text{VII-39}}$ is selected from the group consisting of hydrogen, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio and heterocyclylthio, and

10 $\text{R}_{\text{VII-40}}$ is selected from the group consisting of haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, haloheterocyclyl, cycloalkyl, cycloalkenyl, heterocyclalkoxy, heterocyclalkenoxy, heterocyclalkynoxy, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio and heterocyclylthio;




wherein $\text{R}_{\text{VII-41}}$ is heterocyclidienyl;



15

wherein $\text{R}_{\text{VII-42}}$ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl, and

20 $\text{R}_{\text{VII-43}}$ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, and haloheterocyclyl;



wherein $\text{R}_{\text{VII-44}}$ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;



25

-180-

- N = C = O;


- N₃;- SR_{VII-45}

- wherein R_{VII-45} is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, haloheterocyclyl, heterocyclyl, cycloalkylalkyl, cycloalkenylalkyl, aralkyl, heteroarylalkyl, heterocyclalkyl, cycloalkylalkenyl, cycloalkenylalkenyl, aralkenyl, heteroarylalkenyl, heterocyclalkenyl, alkylthioalkyl, alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, heteroarylthioalkyl, heterocyclthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl, arylthioalkenyl, heteroarylthioalkenyl, heterocyclthioalkenyl, aminocarbonylalkyl, aminocarbonylalkenyl, aminocarbonylalkynyl, aminocarbonylaryl, aminocarbonylheteroaryl, and aminocarbonylheterocyclyl,

-SR_{VII-46}, and -CH₂R_{VII-47},


- wherein R_{VII-46} is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, and

R_{VII-47} is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl; and



- wherein R_{VII-48} is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, and


R_{VII-49} is selected from the group consisting of alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclloxy, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl and haloheterocyclyl;




25

wherein R_{VII-50} is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy and heterocyclloxy;

-181-



wherein $\text{R}_{\text{VII-51}}$ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl and haloheterocyclyl; and



5


wherein $\text{R}_{\text{VII-53}}$ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;

provided that when $\text{R}_{\text{VII-5}}$ is selected from the group consisting of heterocyclylalkyl and heterocyclylalkenyl, the heterocyclyl radical of the corresponding heterocyclylalkyl or heterocyclylalkenyl is other than δ -lactone; and

provided that when $\text{R}_{\text{VII-4}}$ is aryl, heteroaryl or heterocyclyl, and one of $\text{R}_{\text{VII-2}}$ and $\text{R}_{\text{VII-6}}$ is trifluoromethyl, then the other of $\text{R}_{\text{VII-2}}$ and $\text{R}_{\text{VII-6}}$ is difluoromethyl;

(8) a substituted pyridine having the Formula VIII

10



Formula VIII

15 or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof, in which

A_{VIII} stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or

20 alkoxy with up to 7 carbon atoms each, or by a group of the formula

$-\text{NR}_{\text{VIII-1}}\text{R}_{\text{VIII-2}}$, wherein

$\text{R}_{\text{VIII-1}}$ and $\text{R}_{\text{VIII-2}}$ are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms,

D_{VIII} stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is substituted by hydroxy,

E_{VIII} and L_{VIII} are either identical or different and stand for straight-chain or branched alkyl with up to 8 carbon atoms, which is optionally substituted by
 5 cycloalkyl with 3 to 8 carbon atoms, or stands for cycloalkyl with 3 to 8 carbon atoms, or

E_{VIII} has the above-mentioned meaning and

L_{VIII} in this case stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy,
 10 trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula



R_{VIII-3} and R_{VIII-4} are identical or different and have the meaning given above for R_{VIII-1} and R_{VIII-2}, or


15 E_{VIII} stands for straight-chain or branched alkyl with up to 8 carbon atoms, or stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula



R_{VIII-5} and R_{VIII-6} are identical or different and have the meaning given above for R_{VIII-1} and R_{VIII-2}, and

L_{VIII} in this case stands for straight-chain or branched alkoxy with up to 8 carbon atoms or for cycloalkyloxy with 3 to 8 carbon atoms,

25 T_{VIII} stands for a radical of the formula



R_{VIII-7} and R_{VIII-8} are identical or different and denote cycloalkyl with 3 to 8 carbon atoms, or aryl with 6 to 10 carbon atoms, or denote a 5- to 7-member aromatic, optionally benzo-condensed, heterocyclic compound with up to 3
 30 heteroatoms from the series S, N and/or O, which are optionally substituted up to 3 times in an identical manner or differently by trifluoromethyl, trifluoromethoxy, halogen, hydroxy, carboxyl, by straight-chain or branched alkyl, acyl, alkoxy, or alkoxycarbonyl with up to 6 carbon atoms each, or by phenyl, phenoxy, or

-183-

thiophenyl, which can in turn be substituted by halogen, trifluoromethyl, or trifluoromethoxy, and/or the rings are substituted by a group of the formula

$-NR_{VIII-11}R_{VIII-12}$, wherein

$R_{VIII-11}$ and $R_{VIII-12}$ are identical or different and have the meaning given above

5 for R_{VIII-1} and R_{VIII-2} ,

X_{VIII} denotes a straight or branched alkyl chain or alkenyl chain with 2 to 10 carbon atoms each, which are optionally substituted up to 2 times by hydroxy,

R_{VIII-9} denotes hydrogen, and


10 $R_{VIII-10}$ denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, mercapto, trifluoromethoxy, straight-chain or branched alkoxy with up to 5 carbon atoms, or a radical of the formula

$-NR_{VIII-13}R_{VIII-14}$, wherein

$R_{VIII-13}$ and $R_{VIII-14}$ are identical or different and have the meaning given above for R_{VIII-1} and R_{VIII-2} , or

15 R_{VIII-9} and $R_{VIII-10}$ form a carbonyl group together with the carbon atom;

(9) a substituted 1,2,4-triazole having the Formula IX



Formula IX

or a pharmaceutically acceptable salt or tautomer thereof;

20 wherein R_{IX-1} is selected from higher alkyl, higher alkenyl, higher alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyl, alkylthioalkyl, arylthioalkyl, and cycloalkylalkyl;

wherein R_{IX-2} is selected from aryl, heteroaryl, cycloalkyl, and cycloalkenyl, wherein


R_{IX-2} is optionally substituted at a substitutable position with one or more radicals independently selected from alkyl, haloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, 25 alkoxy, halo, aryloxy, aralkyloxy, aryl, aralkyl, aminosulfonyl, amino, monoalkylamino and dialkylamino; and

wherein R_{IX-3} is selected from hydrido, -SH and halo;

provided R_{IX-2} cannot be phenyl or 4-methylphenyl when R_{IX-1} is higher alkyl and when R_{IX-3} is BSH;

-184-

(10) a hetero-tetrahydroquinoline having the Formula X



Formula X

or a pharmaceutically acceptable salt, enantiomer, or stereoisomer or N-oxide of said compound;

5 in which


A_x represents cycloalkyl with 3 to 8 carbon atoms or a 5 to 7-membered, saturated, partially saturated or unsaturated, optionally benzo-condensed heterocyclic ring containing up to 3 heteroatoms from the series comprising S, N and/or O, that in case of a saturated heterocyclic ring is bonded to a nitrogen

10 function, optionally bridged over it, and in which the aromatic systems mentioned above are optionally substituted up to 5-times in an identical or different substituents in the form of halogen, nitro, hydroxy, trifluoromethyl, trifluoromethoxy or by a straight-chain or branched alkyl, acyl, hydroxyalkyl or alkoxy each having up to 7 carbon atoms or by a group of the formula $BNR_{x-3}R_{x-4}$,

15 in which



R_{x-3} and R_{x-4} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms,
or

A_x represents a radical of the formula




-185-

D_x represents an aryl having 6 to 10 carbon atoms, that is optionally substituted by phenyl, nitro, halogen, trifluormethyl or trifluoromethoxy, or it represents a radical of the formula



or



5 in which

R_{X-5} , R_{X-6} and R_{X-9} independently of one another denote cycloalkyl having 3 to 6 carbon atoms, or an aryl having 6 to 10 carbon atoms or a 5- to 7-membered aromatic, optionally benzo-condensed saturated or unsaturated, mono-, bi-, or tricyclic heterocyclic ring from the series consisting of S, N and/or O, in which the rings are substituted, optionally, in case of the nitrogen containing aromatic rings via the N function, with up to 5 identical or different substituents in the form of halogen, trifluoromethyl, nitro, hydroxy, cyano, carbonyl, trifluoromethoxy, straight chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy, or alkoxycarbonyl each having up to 6 carbon atoms, by aryl or trifluoromethyl-substituted aryl each having 6 to 10 carbon atoms or by an, optionally benzo-condensed, aromatic 5- to 7-membered heterocyclic ring having up to 3 heteroatoms from the series consisting of S, N, and/or O, and/or substituted by a group of the formula BOR_{X-10} , $-SR_{X-11}$, SO_2R_{X-12} or $BNR_{X-13}R_{X-14}$,

in which



20 R_{X-10} , R_{X-11} and R_{X-12} independently from each other denote aryl having 6 to 10 carbon atoms, which is in turn substituted with up to 2 identical or different substituents in the form of phenyl, halogen or a straight-chain or branched alkyl having up to 6 carbon atoms,

-186-

R_{X-13} and R_{X-14} are identical or different and have the meaning of R_{X-3} and R_{X-4} indicated above,

or

R_{X-5} and/or R_{X-6} denote a radical of the formula



5

or

R_{X-7} denotes hydrogen or halogen, and

R_{X-8} denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy or alkyl having up to 6 carbon atoms or a radical of the formula

10

$BNR_{X-15}R_{X-16}$,

in which

R_{X-15} and R_{X-16} are identical or different and have the meaning of R_{X-3} and R_{X-4} indicated above,

15

or

R_{X-7} and R_{X-8} together form a radical of the formula $=O$ or $=NR_{X-17}$,

in which

R_{X-17} denotes hydrogen or straight chain or branched alkyl, alkoxy or acyl having up to 6 carbon atoms,

20

L_X denotes a straight chain or branched alkylene or alkenylene chain having up to 8 carbon atoms, that are optionally substituted with up to 2 hydroxy groups,

T_X and X_X are identical or different and denote a straight chain or branched alkylene chain with up to 8 carbon atoms

or

25

T_X or X_X denotes a bond,


V_X represents an oxygen or sulfur atom or an BNR_{X-18} -group, in which

-187-

R_{X-18} denotes hydrogen or straight chain or branched alkyl with up to 6 carbon atoms or phenyl,

E_X represents cycloalkyl with 3 to 8 carbon atoms, or straight chain or branched alkyl with up to 8 carbon atoms, that is optionally substituted by cycloalkyl with 3 to 8 carbon atoms or hydroxy, or represents a phenyl, that is optionally substituted by halogen or trifluoromethyl,

R_{X-1} and R_{X-2} together form a straight-chain or branched alkylene chain with up to 7 carbon atoms, that must be substituted by carbonyl group and/or by a radical with the formula



in which a and b are identical or different and denote a number equaling 1, 2, or 3,

R_{X-19} denotes hydrogen, cycloalkyl with 3 up to 7 carbon atoms, straight chain or branched silylalkyl with up to 8 carbon atoms or straight chain or branched alkyl with up to 8 carbon atoms, that are optionally substituted by hydroxyl, straight chain or branched alkoxy with up to 6 carbon atoms or by phenyl, which in turn might be substituted by halogen, nitro, trifluoromethyl, trifluoromethoxy or by phenyl or by tetrazole-substituted phenyl, and alkyl, optionally be substituted by a group with the formula BOR_{X-22} , in which

R_{X-22} denotes a straight chain or branched acyl with up to 4 carbon atoms or benzyl, or



R_{X-19} denotes straight chain or branched acyl with up to 20 carbon atoms or benzoyl, that is optionally substituted by halogen, trifluoromethyl, nitro or trifluoromethoxy, or it denotes straight chain or branched fluoroacyl with up to 8 carbon atoms and 9 fluorine atoms,

R_{X-20} and R_{X-21} are identical or different and denote hydrogen, phenyl or straight chain or branched alkyl with up to 6 carbon atoms, or

R_{X-20} and R_{X-21} together form a 3- to 6- membered carbocyclic ring, and the carbocyclic rings formed are optionally substituted, optionally also geminally, with up to six identical or different substituents in the form of trifluoromethyl, hydroxy, nitrile,

-188-

halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy with 3 to 7 carbon atoms each, by straight chain or branched alkoxy carbonyl, alkoxy or alkylthio with up to 6 carbon atoms each or by straight chain or branched alkyl with up to 6 carbon atoms, which in turn is substituted with up to 2 identically or differently by hydroxyl, benzyloxy, trifluoromethyl, benzoyl, straight chain or branched alkoxy, oxyacyl or carbonyl with up to 4 carbon atoms each and/or phenyl, which may in turn be substituted with a halogen, trifluoromethyl or trifluoromethoxy, and/or the formed carbocyclic rings are optionally substituted, also geminally, with up to 5 identical or different substituents in the form of phenyl, benzoyl, thiophenyl or sulfonylbenzyl, which in turn are optionally substituted by halogen, trifluoromethyl, trifluoromethoxy or nitro, and/or optionally are substituted by a radical with the formula




in which

c denotes a number equaling 1, 2, 3, or 4,

d denotes a number equaling 0 or 1,

R_{X-23} and R_{X-24} are identical or different and denote hydrogen, cycloalkyl with 3 to 6 carbon atoms, straight chain or branched alkyl with up to 6 carbon atoms, benzyl or phenyl, that is optionally substituted with up to 2 identically or differently by halogen, trifluoromethyl, cyano, phenyl or nitro, and/or the formed carbocyclic rings are substituted optionally by a spiro-linked radical with the formula



in which

W_X denotes either an oxygen or a sulfur atom

Y_X and Y'_X together form a 2 to 6 membered straight chain or branched alkylene chain,

e denotes a number equaling 1, 2, 3, 4, 5, 6, or 7,

f denotes a number equaling 1 or 2,


R_{X-25} , R_{X-26} , R_{X-27} , R_{X-28} , R_{X-29} , R_{X-30} and R_{X-31} are identical or different and denote hydrogen, trifluoromethyl, phenyl, halogen or straight chain or branched alkyl or alkoxy with up to 6 carbon atoms each,

or

R_{X-25} and R_{X-26} or R_{X-27} and R_{X-28} respectively form together a straight chain or branched alkyl chain with up to 6 carbon atoms,

or

R_{X-25} and R_{X-26} or R_{X-27} and R_{X-28} each together form a radical with the formula



in which

W_X has the meaning given above,


g denotes a number equaling 1, 2, 3, 4, 5, 6, or 7,

R_{X-32} and R_{X-33} form together a 3- to 7- membered heterocycle, which contains an oxygen or sulfur atom or a group with the formula SO , SO_2 or $-NR_{X-34}$,

in which

R_{X-34} denotes hydrogen, phenyl, benzyl or straight or branched alkyl with up to 4 carbon atoms;

(11) a substituted tetrahydro naphthaline or an analogous compound having the Formula XI



Formula XI

or a stereoisomer, stereoisomeric mixture, or salt thereof, in which

A_{XI} stands for cycloalkyl with 3 to 8 carbon atoms, or stands for aryl with 6 to 10 carbon atoms, or stands for a 5- to 7-membered, saturated, partially unsaturated or unsaturated, possibly benzocondensated, heterocycle with up to 4 heteroatoms from the series S, N and/or O, where aryl and the heterocyclic ring systems mentioned above are

-190-


substituted up to 5-fold, identical or different, by cyano, halogen, nitro, carboxyl, hydroxy, trifluoromethyl, trifluoro-methoxy, or by straight-chain or branched alkyl, acyl, hydroxyalkyl, alkylthio, alkoxycarbonyl, oxyalkoxycarbonyl or alkoxy each with up to 7 carbon atoms, or by a group of the formula



in which

R_{X1-3} and R_{X1-4} are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms

D_{X1} stands for a radical of the formula



in which

R_{X1-5} , R_{X1-6} and R_{X1-9} , independent of each other, denote cycloalkyl with 3 to 6 carbon atoms, or denote aryl with 6 to 10 carbon atoms, or denote a 5- to 7-membered, possibly benzocondensated, saturated or unsaturated, mono-, bi- or tricyclic heterocycle with up to 4 heteroatoms of the series S, N and/or O, where the cycles are possibly substituted in the case of the nitrogen-containing rings also via the N-function up to 5-fold, identical or different, by halogen, trifluoromethyl, nitro, hydroxy, cyano, carboxyl, trifluoromethoxy, straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl with up to 6 carbon atoms each, by aryl or trifluoromethyl substituted aryl with 6 to 10 carbon atoms each, or by a possibly benzocondensated aromatic 5- to 7-membered heterocycle with up to 3 heteroatoms of the series S, N and/or O, and/or are substituted by a group of the formula



in which


R_{X1-10} , R_{X1-11} and R_{X1-12} , independent of each other, denote aryl with 6 to 10 carbon atoms, which itself is substituted up to 2-fold, identical or different, by phenyl, halogen, or by straight-chain or branched alkyl with up to 6 carbon atoms,

R_{X1-13} and R_{X1-14} are identical or different and have the meaning given above for R_{X1-3} and R_{X1-4} ,

or

R_{X1-5} and/or R_{X1-6} denote a radical of the formula

-191-



R_{X1-7} denotes hydrogen, halogen or methyl,

and

R_{X1-8} denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy or alkyl with up to 6 carbon atoms each, or a radical of the formula $-NR_{X1-15}R_{X1-16}$,

in which

R_{X1-15} and R_{X1-16} are identical or different and have the meaning given above for R_{X1-3} and R_{X1-4} ,

or

R_{X1-7} and R_{X1-8} together form a radical of the formula $=O$ or $=NR_{X1-17}$, in which

R_{X1-17} denotes hydrogen or straight-chain or branched alkyl, alkoxy or acyl with up to 6 carbon atoms each,

L_{X1} denotes a straight-chain or branched alkylene- or alkenylene chain with up to 8 carbon atoms each, which is possibly substituted up to 2-fold by hydroxy,

T_{X1} and X_{X1} are identical or different and denote a straight-chain or branched alkylene chain with up to 8 carbon atoms,

or

T_{X1} and X_{X1} denotes a bond,

V_{X1} stands for an oxygen- or sulfur atom or for an $-NR_{X1-18}$ group,


in which

R_{X1-18} denotes hydrogen or straight-chain or branched alkyl with up to 6 carbon atoms, or phenyl,

E_{X1} stands for cycloalkyl with 3 to 8 carbon atoms, or stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by cycloalkyl with 3 to 8 carbon atoms or hydroxy, or stands for phenyl, which is possibly substituted by halogen or trifluoromethyl,

R_{X1-1} and R_{X1-2} together form a straight-chain or branched alkylene chain with up to 7 carbon atoms, which must be substituted by a carbonyl group and/or by a radical of the formula

-192-



in which

a and b are identical or different and denote a number 1, 2 or 3

R_{X1-19} denotes hydrogen, cycloalkyl with 3 to 7 carbon atoms, straight-chain or branched silylalkyl with up to 8 carbon atoms, or straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by hydroxy, straight-chain or branched alkoxy with up to 6 carbon atoms, or by phenyl, which itself can be substituted by halogen, nitro, trifluoromethyl, trifluoromethoxy or by phenyl substituted by phenyl or tetrazol, and alkyl is possibly substituted by a group of the formula $-OR_{X1-22}$,

in which

R_{X1-22} denotes straight-chain or branched acyl with up to 4 carbon atoms, or benzyl,

or

R_{X1-19} denotes straight-chain or branched acyl with up to 20 carbon atoms or benzoyl, which is possibly substituted by halogen, trifluoromethyl, nitro or trifluoromethoxy, or denotes straight-chain or branched fluoroacyl with up to 8 carbon atoms and 9 fluorine atoms,


R_{X1-20} and R_{X1-21} are identical or different, denoting hydrogen, phenyl or straight-chain or branched alkyl with up to 6 carbon atoms,

or

R_{X1-20} and R_{X1-21} together form a 3- to 6-membered carbocycle; and, possibly also geminally, the alkylene chain formed by R_{X1-1} and R_{X1-2} , is possibly substituted up to 6-fold, identical or different, by trifluoromethyl, hydroxy, nitrile, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy with 3 to 7 carbon atoms each, by straight-chain or branched alkoxy carbonyl, alkoxy or alkoxythio with up to 6 carbon atoms each, or by straight-chain or branched alkyl with up to 6 carbon atoms, which itself is substituted up to 2-fold, identical or different, by hydroxyl, benzyloxy, trifluoromethyl, benzoyl, straight-chain or branched alkoxy, oxyacyl or carboxyl with up to 4 carbon atoms each, and/or phenyl- which itself can be substituted by halogen, trifluoromethyl or trifluoromethoxy, and/or the alkylene chain formed by R_{X1-1} and R_{X1-2} is substituted, also geminally, possibly up to 5-fold, identical or different, by phenyl, benzoyl, thiophenyl or

-193-

sulfobenzyl -which themselves are possibly substituted by halogen, trifluoromethyl, trifluoromethoxy or nitro, and/or the alkylene chain formed by R_{X1-1} and R_{X1-2} is possibly substituted by a radical of the formula




in which

c denotes a number 1, 2, 3 or 4,

d denotes a number 0 or 1,

R_{X1-23} and R_{X1-24} are identical or different and denote hydrogen, cycloalkyl with 3 to 6 carbon atoms, straight-chain or branched alkyl with up to 6 carbon atoms, benzyl or phenyl, which is possibly substituted up to 2-fold, identical or different, by halogen, trifluoromethyl, cyano, phenyl or nitro, and/or the alkylene chain formed by R_{X1-1} and R_{X1-2} is possibly substituted by a spiro-jointed radical of the formula



in which

W_{X1} denotes either an oxygen or a sulfur atom,

Y_{X1} and Y'_{X1} together form a 2- to 6-membered straight-chain or branched alkylene chain,

e is a number 1, 2, 3, 4, 5, 6 or 7,

f denotes a number 1 or 2,

R_{X1-25} , R_{X1-26} , R_{X1-27} , R_{X1-28} , R_{X1-29} , R_{X1-30} and R_{X1-31} are identical or different and denote hydrogen, trifluoromethyl, phenyl, halogen, or straight-chain or branched alkyl or alkoxy with up to 6 carbon atoms each,


or

R_{X1-25} and R_{X1-26} or R_{X1-27} and R_{X1-28} together form a straight-chain or branched alkyl chain with up to 6 carbon atoms,

or

R_{X1-25} and R_{X1-26} or R_{X1-27} and R_{X1-28} together form a radical of the formula

-194-



in which

W_{XI} has the meaning given above,


g is a number 1, 2, 3, 4, 5, 6 or 7,

R_{XI-32} and R_{XI-33} together form a 3- to 7-membered heterocycle that contains an oxygen- or sulfur atom or a group of the formula SO , SO_2 or $-NR_{XI-34}$,

in which

R_{XI-34} denotes hydrogen, phenyl, benzyl, or straight-chain or branched alkyl with up to 4 carbon atoms;

(12) a 2-aryl-substituted pyridine having the Formula (XII)



Formula XII

or pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds,

in which

A_{XII} and E_{XII} are identical or different and stand for aryl with 6 to 10 carbon atoms which is possibly substituted, up to 5-fold identical or different, by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, nitro or by straight-chain or branched alkyl, acyl, hydroxy alkyl or alkoxy with up to 7 carbon atoms each, or by a group of the formula $-NR_{XII-1}R_{XII-2}$,

where


R_{XII-1} and R_{XII-2} are identical or different and are meant to be hydrogen, phenyl or straight-chain or branched alkyl with up to 6 carbon atoms,

D_{XII} stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is substituted by hydroxy,

-195-

L_{XII} stands for cycloalkyl with 3 to 8 carbon atoms or for straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by cycloalkyl with 3 to 8 carbon atoms, or by hydroxy,

T_{XII} stands for a radical of the formula $R_{XII-3}-X_{XII}$ or



where

R_{XII-3} and R_{XII-4} are identical or different and are meant to be cycloalkyl with 3 to 8 carbon atoms, or aryl with 6 to 10 carbon atoms, or a 5- to 7-membered aromatic, possibly benzocondensated heterocycle with up to 3 heteroatoms from the series S, N and/or O, which are possibly substituted. up to 3-fold identical or different, by trifluoromethyl, trifluoromethoxy, halogen, hydroxy, carboxyl, nitro, by straight-chain or branched alkyl, acyl, alkoxy or alkoxycarbonyl with up to 6 carbon atoms each. or by phenyl, phenoxy or phenylthio which in turn can be substituted by halogen. trifluoromethyl or trifluoromethoxy, and/or where the cycles are possibly substituted by a group of the formula $-NR_{XII-7}R_{XII-8}$,

where

R_{XII-7} and R_{XII-8} are identical or different and have the meaning of R_{XII-1} and R_{XII-2} given above,

X_{XII} is a straight-chain or branched alkyl or alkenyl with 2 to 10 carbon atoms each, possibly substituted up to 2-fold by hydroxy or halogen,

R_{XII-5} stands for hydrogen,

and

R_{XII-6} means to be hydrogen, halogen, mercapto, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy with up to 5 carbon atoms, or a radical of the formula $BNR_{XII-9}R_{XII-10}$,


where

R_{XII-9} and R_{XII-10} are identical or different and have the meaning of R_{XII-1} and R_{XII-2} given above,

or

R_{XII-5} and R_{XII-6} , together with the carbon atom, form a carbonyl group; or
(13) a compound having the Formula (XIII)

-196-



Formula XIII

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, or solvate of said compounds, in which

R_{XIII} is a straight chain or branched C_{1-10} alkyl; straight chain or branched C_{2-10} alkenyl; halogenated C_{1-4} lower alkyl; C_{3-10} cycloalkyl that may be substituted; C_{5-8} cycloalkenyl that may be substituted; C_{3-10} cycloalkyl C_{1-10} alkyl that may be substituted; aryl that may be substituted; aralkyl that may be substituted; or a 5- or 6-membered heterocyclic group having 1 to 3 nitrogen atoms, oxygen atoms or sulfur atoms that may be substituted,

X_{XIII-1} , X_{XIII-2} , X_{XIII-3} , X_{XIII-4} may be the same or different and are a hydrogen atom; halogen atom; C_{1-4} lower alkyl; halogenated C_{1-4} lower alkyl; C_{1-4} lower alkoxy; cyano group; nitro group; acyl; or aryl, respectively;

Y_{XIII} is $-CO-$; or BSO_2- ; and

Z_{XIII} is a hydrogen atom; or mercapto protective group.

9. A composition as defined in claim 8, wherein said CETP inhibitor is selected from:

[2R,4S] 4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-dinitro-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(2,6-dichloro-pyridin-4-ylmethyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-methoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-ethoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2,2,2-trifluoro-ethylester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethoxy-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,
- [2R,4S] (3,5-bis-trifluoromethyl-benzyl)-(1-butyryl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
- [2R,4S] (3,5-bis-trifluoromethyl-benzyl)-(1-butyl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
- [2R,4S] (3,5-bis-trifluoromethyl-benzyl)-[1-(2-ethyl-butyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester, hydrochloride;
- [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-7-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2,6,7-trimethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester

[2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-diethyl-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-ethyl-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-2,3,4,6,7,8-hexahydro-cyclopenta[g]quinoline-1-carboxylic acid ethyl ester:

[6R, 8S] 8-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methyl-3,6,7,8-tetrahydro-1H-2-thia-5-aza-cyclopenta[b]naphthalene-5-carboxylic acid ethylester;

[6R, 8S] 8-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methyl-3,6,7,8-tetrahydro-2H-furo[2,3-g]quinoline-5-carboxylic acid ethyl ester:

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-3,4,6,8-tetrahydro-2H-furo[3,4-g]quinoline-1-carboxylic acid ethyl ester;

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-3,4,6,7,8,9-hexahydro-2H-benzo[g]quinoline-1-carboxylic acid propyl ester;

[7R,9S] 9-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-methyl-1,2,3,7,8,9-hexahydro-6-aza-cyclopenta[a]naphthalene-6-carboxylic acid ethyl ester;

[6S,8R] 6-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-8-methyl-1,2,3,6,7,8-hexahydro-9-aza-cyclopenta[a]naphthalene-9-carboxylic acid ethyl ester:

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-isopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-cyclopropyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.

[2S,4S] 2-cyclopropyl-4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;

- [2R,4R] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxy-ethyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester.
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;
- [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;
- [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2S,4S] 4-[1-(3,5-bis-trifluoromethyl-benzyl)-ureido]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

- [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;
- [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.
- 2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-3-(4-trifluoromethylbenzoyl)-4,6,7,8-tetrahydro-1H-quinolin-5-one;
- 2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-3-(4-trifluoromethylbenzoyl)-7,8-dihydro-6H-quinolin-5-one;
- [2-cyclopentyl-4-(4-fluorophenyl)-5-hydroxy-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanone;
- [5-(t-butyldimethylsilyloxy)-2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanone;
- [5-(t-butyldimethylsilyloxy)-2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanol;

-201-

5-(t-butyltrimethylsilyloxy)-2-cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-(4-trifluoromethylphenyl)-methyl]-7,7-dimethyl-5,6,7,8-tetrahydroquinoline;

2-cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-(4-trifluoromethylphenyl)-methyl]-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol;

dimethyl 5,5=dithiobis[2-difluoromethyl-4-(2-methylpropyl)-6-(trifluoromethyl)-3-pyridine-carboxylate]

2,4-dihydro-4-(3-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(2-fluorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(2-methylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(3-chlorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(2-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(3-methylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

4-cyclohexyl-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(3-pyridyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(2-ethoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(2,6-dimethylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(4-phenoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

4-(1,3-benzodioxol-5-yl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;

4-(2-chlorophenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(4-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-5-tridecyl-4-(3-trifluoromethylphenyl)-3H-1,2,4-triazole-3-thione;

2,4-dihydro-5-tridecyl-4-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione;

4-(3-chloro-4-methylphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;

2,4-dihydro-4-(2-methylthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;

4-(4-benzyloxyphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;

-202-

- 2,4-dihydro-4-(2-naphthyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-5-tridecyl-4-(4-trifluoromethylphenyl)-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(1-naphthyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(3-methylthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(4-methylthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(3,4-dimethoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(2,5-dimethoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(2-methoxy-5-chlorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 4-(4-aminosulfonylphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-5-dodecyl-4-(3-methoxyphenyl)-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(3-methoxyphenyl)-5-tetradecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-(3-methoxyphenyl)-5-undecyl-3H-1,2,4-triazole-3-thione;
- 2,4-dihydro-4-methoxyphenyl)-5-pentadecyl-3H-1,2,4-triazole-3-thione;
- 2-cyclopentyl-5-hydroxy-7,7-dimethyl-4-(3-thienyl)-3-(4-trifluoromethylbenzoyl)-5,6,7,8-tetrahydroquinoline;
- 2-cyclopentyl-3-[fluoro-(4-trifluoromethylphenyl)methyl]-5-hydroxy-7,7-dimethyl-4-(3-thienyl)-5,6,7,8-tetrahydroquinoline;
- 2-cyclopentyl-5-hydroxy-7,7-dimethyl-4-(3-thienyl)-3-(trifluoromethylbenzyl)-5,6,7,8-tetrahydroquinoline.
- 4,6-bis-(p-fluorophenyl)-2-isopropyl-3-[(p-trifluoromethylphenyl)-(fluoro)-methyl]-5-(1-hydroxyethyl)pyridine;
- 2,4-bis-(4-fluorophenyl)-6-isopropyl-5-[4-(trifluoromethylphenyl)-fluoromethyl]-3-hydroxymethyl)pyridine;
- 2,4-bis-(4-fluorophenyl)-6-isopropyl-5-[2-(3-trifluoromethylphenyl)vinyl]-3-hydroxymethyl)pyridine;

N,N'-(dithiodi-2,1-phenylene)bis[2,2-dimethyl-propanamide];
N,N'-(dithiodi-2,1-phenylene)bis[1-methyl-cyclohexanecarboxamide];
N,N'-(dithiodi-2,1-phenylene)bis[1-(3-methylbutyl)-cyclopentanecarboxamide];
N,N'-(dithiodi-2,1-phenylene)bis[1-(3-methylbutyl)-cyclohexanecarboxamide];
N,N'-(dithiodi-2,1-phenylene)bis[1-(2-ethylbutyl)-cyclohexanecarboxamide];
N,N'-(dithiodi-2,1-phenylene)bis-tricyclo[3.3.1.^{1^{3,7}}]decane-1-carboxamide;
propanethioic acid, 2-methyl-, S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] ester;
propanethioic acid, 2,2-dimethyl-, S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] ester; and
ethanethioic acid, S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] ester.

10. A composition comprising:

a compound which is [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; or a compound which is [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; or a compound which is [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
a cosolvent;
a high HLB surfactant;
a low HLB surfactant; and
optionally, a digestible oil.

11. A composition as claimed in claim 10, wherein

said cosolvent comprises triacetin or ethyl lactate;
said high HLB surfactant comprises polysorbate 80 or a polyethylene hydrogenated castor oil;
said low HLB surfactant comprises a mixture of mono- and diglycerides of capric and caprylic acids;

-204-

said digestible oil comprises a medium chain triglyceride, wherein each of the three hydrocarbon chains therein is C6-C12.

12. A composition as claimed in claim 11, which comprises, by weight:

- 5 -25% of said CETP inhibitor;
- 10-25% of said digestible oil;
- 20-35% of said cosolvent;
- 10-35% of said high HLB surfactant; and
- 10-35% of said low HLB surfactant;

13. A composition as claimed in claim 10, which comprises, by weight:

- 8-12% of [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
- 10-20% of said digestible oil;
- 25-35% of said cosolvent which is triacetin;
- 10-30% of said high HLB surfactant which is polysorbate 80; and
- 15-35% of said low HLB surfactant.

14. A composition as claimed in claim 10, which comprises, by weight:

- 8-25% of [2R, 4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- 10-25% of digestible oil;
- 20-35% of said cosolvent which comprises triacetin;
- 10-30% of said high HLB surfactant which comprises polysorbate 80; and
- 15-35% of said low HLB surfactant which comprises a mixture of medium chain mono- and di-glycerides.

15. A composition as claimed in claim 43, which comprises, by weight:

- 8-12% of [2R,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
- 10-20% of said digestible oil;
- 25-35% of said cosolvent which comprises triacetin;

-205-

10-30% of said high HLB surfactant which comprises a polyethylene (40) hydrogenated castor oil;

15-35% of said low HLB surfactant which comprises a mixture of medium chain mono- and di-glycerides.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 2003/000295 A3

(51) International Patent Classification⁷: **A61K 47/44**,
9/10, 9/107, 31/4706, 31/44, 31/4196, 31/47, 31/015,
31/41, A61P 3/06

(74) Agents: **LUMB, J., Trevor et al.**; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(21) International Application Number:
PCT/IB2002/001571

(22) International Filing Date: 3 May 2002 (03.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/300,028 21 June 2001 (21.06.2001) US

(71) Applicant (for all designated States except US): **PFIZER
PRODUCTS INC.** [US/US]; Eastern Point Road, Groton,
CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GUMKOWSKI,
Michael, Jon** [US/US]; Pfizer Global Research and
Development, Eastern Point Road, Groton, CT 06340
(US). **MURDANDE, Sharad, Balasaheb** [IN/US]; Pfizer
Global Research and Development, Eastern Point Road,
Groton, CT 06340 (US). **PERLMAN, Michael, Ellis**
[US/US]; Pfizer Global Research and Development, East-
ern Point Road, Groton, CT 06340 (US). **LOMBARDO,
Franco** [US/US]; Pfizer Global Research and Develop-
ment, Eastern Point Road, Groton, CT 06340 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
27 May 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS

(57) Abstract: CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise 1. a CETP inhibitor; 2. a cosolvent; 3. a surfactant having an HLB of 1 to 8; 4. a surfactant having an HLB of over 8 to 20; and 5. optionally, a digestible oil.



WO 2003/000295 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/01571

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/44 A61K9/10 A61K9/107 A61K31/4706 A61K31/44
A61K31/4196 A61K31/47 A61K31/015 A61K31/41 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 18723 A (MISCHKE DEBORAH A ; MONSANTO CO (US); PARNAS BARRY L (US); DURLEY R) 6 April 2000 (2000-04-06) cited in the application the whole document page 65, line 11 - line 34	8-10
X	WO 99 14204 A (SEARLE & CO ; SIKORSKI JAMES A (US)) 25 March 1999 (1999-03-25) cited in the application the whole document page 83, line 9 - page 84, line 7 -/-	8-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *S* document member of the same patent family

Date of the actual completion of the international search

3 February 2003

Date of mailing of the international search report

20/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Economou, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/01571

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 41237 A (CONNOLLY DANIEL T ;SCHILLING ROGER J (US); GLENN KEVIN C (US); LEE) 19 August 1999 (1999-08-19) cited in the application the whole document page 166, line 23 -page 167, line 20	8-10
Y	DE 197 41 399 A (BAYER AG) 25 March 1999 (1999-03-25) cited in the application the whole document	8-10
Y	EP 1 020 439 A (JAPAN TOBACCO INC) 19 July 2000 (2000-07-19) cited in the application the whole document	8-10
Y	WO 01 40190 A (APPLETON TROY ANTHONY ;PFIZER PROD INC (US); ALLEN DOUGLAS JOHN ME) 7 June 2001 (2001-06-07) cited in the application the whole document page 14, line 15 - line 22	8-10
Y	WO 00 17164 A (WESTER RONALD THURE ;PFIZER PROD INC (US); DENINNO MICHAEL PAUL (U) 30 March 2000 (2000-03-30) cited in the application the whole document page 78; examples 7,8	8-10
Y	EP 0 992 496 A (PFIZER PROD INC) 12 April 2000 (2000-04-12) cited in the application the whole document page 37; examples 7,8	8-10
Y	WO 00 17165 A (WESTER RONALD THURE ;PFIZER PROD INC (US); DENINNO MICHAEL PAUL (U) 30 March 2000 (2000-03-30) cited in the application the whole document page 79; examples 7,8	8-10
Y	US 5 993 858 A (CRISON JOHN R ET AL) 30 November 1999 (1999-11-30) cited in the application column 1, line 10 -column 4, line 55 column 5, line 1 - line 45 example 1 column 7, line 64 -column 8, line 4 claims 1-12	8-10

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-7; 8-15 (partially)

Present claims 1-7 relate to an extremely large number of possible compounds and products. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compositions comprising the compounds defined in claims 8-10 in combination with the surfactants mentioned in claims 5-6, since their definition by "high HLB" or "low HLB" is unclear.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/01571

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-7; 8-15 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/01571

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0018723	A	06-04-2000	AU 6161099 A CA 2345108 A1 EP 1115694 A1 JP 2002525350 T WO 0018723 A1	17-04-2000 06-04-2000 18-07-2001 13-08-2002 06-04-2000
WO 9914204	A	25-03-1999	AU 9297798 A WO 9914204 A1	05-04-1999 25-03-1999
WO 9941237	A	19-08-1999	AU 3285499 A WO 9941237 A1	30-08-1999 19-08-1999
DE 19741399	A	25-03-1999	DE 19741399 A1 AU 9537098 A WO 9915504 A1 EP 1017677 A1 JP 2001517655 T US 2002165252 A1 US 6291477 B1 US 2002042515 A1	25-03-1999 12-04-1999 01-04-1999 12-07-2000 09-10-2001 07-11-2002 18-09-2001 11-04-2002
EP 1020439	A	19-07-2000	JP 2894445 B2 JP 11049743 A AU 728979 B2 AU 5781898 A BR 9807222 A EP 1020439 A1 HU 0002483 A2 NO 993869 A NZ 337122 A SK 109599 A3 US 6426365 B1 CN 1252053 T WO 9835937 A1 JP 3290962 B2 JP 11222428 A RU 2188631 C2 ZA 9801119 A TR 9901932 T2	24-05-1999 23-02-1999 25-01-2001 08-09-1998 23-05-2000 19-07-2000 28-05-2001 23-09-1999 23-02-2001 16-05-2000 30-07-2002 03-05-2000 20-08-1998 10-06-2002 17-08-1999 10-09-2002 24-08-1998 21-06-2000
WO 0140190	A	07-06-2001	AU 1048801 A BR 0015836 A EP 1246804 A1 WO 0140190 A1 NO 20022558 A TR 200201446 T2	12-06-2001 06-08-2002 09-10-2002 07-06-2001 29-05-2002 21-11-2002
WO 0017164	A	30-03-2000	AU 752566 B2 AU 5440199 A BG 105428 A BR 9913810 A CA 2344350 A1 CN 1318058 T CZ 20010955 A3 EE 200100166 A EP 1114031 A1 HR 20010201 A1 HU 0103506 A2	19-09-2002 10-04-2000 31-01-2002 19-06-2001 30-03-2000 17-10-2001 12-12-2001 17-06-2002 11-07-2001 30-04-2002 28-01-2002

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/01571

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0017164 A		WO 0017164 A1	30-03-2000
		JP 2002526475 T	20-08-2002
		NO 20011350 A	09-05-2001
		NZ 509840 A	26-11-2002
		PL 347099 A1	25-03-2002
		SK 3542001 A3	04-06-2002
		TR 200100768 T2	23-07-2001
		US 6197786 B1	06-03-2001
EP 0992496 A	12-04-2000	BR 9904162 A	12-09-2000
		EP 0992496 A1	12-04-2000
		JP 2000095764 A	04-04-2000
		US 6147089 A	14-11-2000
		US 6310075 B1	30-10-2001
WO 0017165 A	30-03-2000	AU 747715 B2	23-05-2002
		AU 5440399 A	10-04-2000
		BG 105429 A	31-12-2001
		BR 9913855 A	24-07-2001
		CA 2344248 A1	30-03-2000
		CN 1318057 T	17-10-2001
		CZ 20010954 A3	12-12-2001
		EE 200100167 A	17-06-2002
		EP 1114032 A1	11-07-2001
		HR 20010200 A1	30-04-2002
		HU 0103512 A2	28-02-2002
		WO 0017165 A1	30-03-2000
		JP 2002526476 T	20-08-2002
		NO 20011349 A	14-05-2001
		NZ 509837 A	26-11-2002
		PL 346830 A1	25-02-2002
		SK 3532001 A3	03-12-2001
		TR 200100780 T2	23-07-2001
		US 6140343 A	31-10-2000
		US 6489478 B1	03-12-2002
US 5993858 A	30-11-1999	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.